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Alzheimer disease (AD) is characterized by a loss of cognitive function caused by the 
dysfunction and death of neurons and other cells in the brain. This cell injury is largely 
due to the toxic effects of aggregates of amyloid-beta (Aβ), which accumulates into 
dense plaques in the brain. Research in humans and in animals suggests that brain 
blood flow is reduced in AD by ~30%. Although it likely contributes to cognitive 
impairment and disease progression, no physiological explanation for this 
hypoperfusion has emerged. 
 
In part, studies of cerebral blood flow pathology have been limited by the inability to 
perform in vivo imaging of vascular function at cellular resolution. The focus of this 
thesis is to present the underlying cellular mechanism responsible for this 
hypoperfusion phenomena and Aβ clearance in AD mouse models.  Chronic cranial 
windows and in vivo two-photon excited fluorescence microscopy were used to study 
cerebrovascular blood flow. 
 
While no blood flow disruption in cortical arterioles or venules were observed, blood 
flow was found to be stalled in an average of 1.8% of cortical capillaries in mouse 
 models of AD, as compared to 0.25% in wild type controls. These capillary stalls 
appeared early in disease progression, before any amyloid deposition. We found that 
the majority of the occlusions were caused by leukocytes, which adhered tightly to the 
endothelium. Indeed, blocking neutrophil adhesion in AD mouse models led to the 
fraction of capillary stalls decrease by 70 %, causing brain blood flow to increase by 
~30% and cognitive function to improve.  
 
These data suggest a working model to explain the origin of hypoperfusion in AD: Aβ 
accumulation leads to increased production of ROS that stresses endothelial cells and 
leads to increases in inflammatory receptors on the vessel lumen. This vascular 
inflammation causes leukocytes to adhere and plug capillaries, resulting in decreases 
in perfusion. This blood flow deficit could contribute to dementia independently of the 
direct effects of Aβ and could also accelerate Aβ aggregation by decreasing clearance 
of Aβ monomers.  
 
This research provides for the first time an explanation for the long known 
phenomenon of reduced blood flow in Alzheimer’s disease, one which has an early 
and significant impact on the development of pathological phenotypes. Brief reviews 
of multi-photon microscopy (MPM) and Brain blood flow in AD are also presented. 
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1 
CHAPTER 1 
INTRODUCTION AND ORGANIZATION OF DISSERTATION 
 
Introduction 
Recently, reductions of volumetric blood flow have been identified as a common 
pathology in the majority of the dementias, including in Alzheimer’s disease (AD) 1,2. 
However, the exact causes of this cerebral blood flow deficit remain unclear, mainly due 
to the technical challenges presented in the study of cell dynamics in cerebral 
microvessels. Some of these challenges are the following: first, in order to study the cell 
dynamics in the brain microvessels during disease progression at physiological conditions 
it is necessary to perform the experiments in vivo. Also, while advances in neurovascular 
imaging techniques such as BOLD-fMRI, laser doppler flowmetry, and arterial spin 
labeling allow for measurements of homogenous global blood flow changes, 
quantification of flow changes in individual vessels as small as capillaries in vivo requires 
much higher spatial resolution. Two-photon excited fluorescence microscopy (2PEF) is 
an ideal tool to visualize changes in cerebral blood flow with cellular resolution and 
minimal invasiveness. By being able to observe vessel flow dynamics in vivo using 
2PEF, we may be able to better understand the mechanisms at work behind 
cerebrovascular pathology in AD. 
The work presented in this dissertation is focused on the cellular mechanism responsible 
for a new phenomena (capillary occlusions) that occurs in AD animal models and might 
explain the significant reduction of cerebral blood flow in AD and other dementias. The 
identification of this novel mechanism allowed us to manipulate the cell–cell interaction 
  
 
 
 
2 
and study the downstream effects of the occlusions in the cerebral microvessels. Our 
results of cerebral blood flow recovery and improvement in cognitive abilities in AD 
mouse models after reductions of these capillary stalls, suggest that the full elucidation of 
the cellular and molecular pathways that triggers this phenomena could open new 
window for alternative treatments in order to stop or ameliorate the progression of AD.   
 
Organization of Dissertation 
This thesis summarizes the techniques developed, results observed, and insights obtained 
over the last 6 years. This thesis is comprised of 10 chapters, including this introduction. 
The first two chapters provide background material, which provide context and serve as a 
reference for the rest of the thesis.  
Chapter 2: This chapter takes a look at the current state of AD and cerebral blood flow 
(CBF) impairment, including clinical outcomes, pathogenesis and genetics and pre-
clinical animal studies, with a spotlight on in vivo imaging and what it offers AD and 
vascular research.  
Chapter 3: This chapter provides an introduction to multi-photon microscopy, basic 
experimental techniques and the achievement of optical sectioning, as well as a more 
detailed look at the individual processes of 2-photon excited fluorescence (2PEF), 3-
photon excited fluorescence (3PEF) and second and third harmonic generation (SHG and 
THG, respectively).  
Chapters 4-7 are formatted papers, whether they are published as of yet or whether they 
contain work in progress, including supplementary files and information. 
Chapter 4: This chapter provides a re-formatted unpublished manuscript of our paper on 
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elucidation of the cellular mechanism responsible of hypoperfusion phenomena in AD.  
This chapter includes work on blood flow and the microvascular network of cortical 
region in AD, consisting of theoretical modeling, blood flow measurements, 
topographical mapping of the occlusion and Aβ, and the effects stalls release on CBF and 
cognitive behavior.  
Chapter 5: This chapter provides a re-formatted published manuscript of our paper on 
“Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic 
Distribution”. This chapter includes work on how the anatomical distribution of 
microbleeds in the human brain affect the concentrations of CSF beta-amyloid and CSF 
p-tau, and longitudinal cognitive decline. 
Chapter 6: This chapter provides a re-formatted published manuscript of our paper on 
“Use of Tethered Enzymes as a Platform Technology for Rapid Analyte Detection”. This 
chapter includes work on the design and construction of a new diagnostic platform 
(biosensor), which achieve rapid and sensitive detection of neuron-specific enolase 
(NSE), a clinically relevant biomarker for multiple diseases ranging from acute brain 
injuries to lung cancer. 
Chapter 7: This chapter discusses the development of a curriculum for high school 
science students. The curriculum centers around the concept of blood flow in the brain 
during normal and disease states. Two laboratory exercises are discussed which are 
analogous to flow in the brain. This chapter also includes an assessment of the curriculum 
from the students and a resulted manuscript.  
Chapter 8: This chapter summarizes what has been successfully completed in the results 
of this thesis. It also discusses impacts in the clinical setting and future project directions 
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for whomever picks this project up where I must inevitably leave off.  
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CHAPTER 2 
Alzheimer’s Disease: an Overview 
 
In this chapter, we review the current outlook on Alzheimer’s disease (AD) from a 
demographic, scientific and clinical perspective. This chapter is divided into three 
sections. In the first section, we review the current state of demographics of AD 
(prevalence and mortality). In the second section, we consider the changes in the cellular 
and molecular key components through the disease progression, and the different 
hypothesis that explains the pathogenesis and neuropathology of AD. Finally, we 
examine the clinical implications of the targeting these key cellular players and how the 
discovery of a new cellular mechanism provides a new target approach to ameliorate the 
disease progression. 
 
2.1 INTRODUCTION 
Alzheimer’s disease (AD) is the most common cause of dementia, a neurodegenerative 
disease that is characterized by the decline of memory and cognitive abilities [1,2]. The 
pathogenesis of AD is defined by soluble cerebral amyloid-β (Aβ) accumulation and 
aggregation into dense senile plaques throughout the brain, as well as neurofibrillary 
tangle formation within axon microtubules of individual neurons, composed of 
hyperphosphorylated tau protein [3]. Independently these two different pathways affect 
the normal state of the neuron cells and triggers the cognitive disabilities in AD patients. 
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In addition to these main proteins abnormalities, clinical and experimental evidence 
strongly suggests that AD and vascular pathology are interrelated, and that reduced brain 
blood flow may play a significant role in exacerbation of AD. In both humans and in 
mouse models of AD, disease progression has been accompanied by decreased cortical 
blood flow (CBF) and impaired blood flow responses during functional hyperemia [4,5]. 
Human patients [6,7] with, as well as mouse models [8,9] of, Alzheimer’s disease (AD) 
exhibit reductions in cortical CBF of ~20-30% early in disease development, and are 
therefore not due visible to accumulation of cerebral amyloid angiopathy [10]. However, 
the exact cause of this blood flow deficit in AD remains unclear. 
 
One difficultly in understanding reduced CBF in AD is the ability to measure 
physiological flow within microvessels in the brain. While advances in neurovascular 
imaging techniques such as BOLD-fMRI, laser doppler flowmetry, and arterial spin label 
MRI allow for measurements of homogenous global blood flow changes, quantification 
of flow changes in individual vessels as small as capillaries in vivo requires much higher 
spatial resolution. Two-photon excited fluorescence microscopy (2PEF) is an ideal tool to 
visualize changes in CBF with cellular resolution and minimal invasiveness. By being 
able to observe vessel flow dynamics in vivo using 2PEF, we may be able to better 
understand the mechanisms at work behind cerebrovascular pathology in AD.  
 
2.2 DEMOGRAPHICS OF ALZEIMER’S DISEASE 
2.2.1 Prevalence 
Longitudinal studies using the most recent census (2010) has estimated a population of 
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5.5 millions AD patients living in United States in 2017 [11].  Of this population 5.3 
million people represent the late-onset of AD (65 and older) and approximately 200,000 
individuals the younger-onset AD (under age 65), though there is greater uncertainty 
about the younger-onset estimate [12]. An approximation of the age distribution between 
the AD patients is shown in Fig.2.1. Based on this census 1 in 10 people age 65 and older 
(10%) developed Alzheimer’s dementia, but AD begins many years before the onset of 
dementia. Due to the nature of the disease Alzheimer’s dementia is under-diagnosed and 
underreported, a large portion of Americans with Alzheimer’s may not know they have it. 
However, if AD could be accurately detected before dementia develops, the number of 
people reported to have AD expand to include more than just people who have been 
diagnosed with fully Alzheimer’s dementia.  
 
Figure 2.1 Age of People with Alzheimer’s Dementia in the United States, 2017. 
Percentages do not total 100 because of rounding. Created from data from Hebert et al. 11 
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On the other hand, due to medical advances, as well as social and environmental 
conditions the life expectancy is expected to grow dramatically13. One of the largest 
segments of the American population, “the baby boom generation,” have begun to reach 
age 65 and older, in which risk for Alzheimer’s is more prominent. By 2030, it is 
projected that 74 million Americans (65 and older) will make up over 20 % of the total 
population (up from 14 percent in 2012) [13]. As the number of older Americans grows 
rapidly, so too will the numbers of new and existing cases of Alzheimer’s dementia, as 
shown in Fig. 2.2 [A1,11].  
Based on the 2000 and 2010 census and the predictions for 2050: 
• 454,000 new cases of Alzheimer’s dementia were identified, just in 2010. The 
projection of AD population by 2030 is around 615,000 (a 35 percent increase), and 
by 2050, 959,000 (a 110 percent increase from 2010) [14].   
• In 2017, the number of people age 65 and older with Alzheimer’s dementia is 5.3 
millions, and is estimated to increase 35 percent by 2025 reaching an estimated 
population of 7.1 million of AD patients [A2,11]. 
• By 2050, the number of people age 65 and older with Alzheimer’s dementia may 
nearly triple, from 5.3 million to a projected 13.8 million, barring the development of 
medical breakthroughs to prevent or cure AD [A1,11]. Previous estimates based on 
high-range projections of population growth provided by the U.S. Census suggest that 
this number may be as high as 16 million [A3, 15]. 
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Figure 2.2 Projected Number of People Age 65 and Older (Total and by Age Group) 
in the U.S. Population with Alzheimer’s Dementia, 2010 to 2050. Created from data 
from Hebert et al [11]. 
 
2.2.2 Mortality and Morbidity 
As the population of the United States ages, Alzheimer’s is becoming a more common 
cause of death, and of the top 10 leading causes of death, it is the only one that cannot be 
prevented, cured, or even slowed.  It is difficult to determine how many deaths are caused 
by AD each year because of non-standardized medical documentation. AD patients who 
die due to these acute conditions may not be counted among the number of people who 
died from AD according to the World Health Organization definition, even though AD 
may well have caused the acute condition listed on the death certificate. Although deaths 
from other major causes have decreased significantly, official records indicate that deaths 
from AD have increased significantly [16].  
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Between 2000 and 2014, deaths from AD as recorded on death certificates increased 89 
percent, while deaths from the number one cause of death (heart disease) decreased 14 
percent (Fig. 2.3) [16]. The increase in the number of death certificates listing 
Alzheimer’s as the underlying cause of death reflects both changes in patterns of 
reporting deaths on death certificates over time as well as an increase in the actual 
number of deaths attributable to AD.  
 
 
 
Figure 2.3 Percentages changes in selected causes of death (all ages) between 2000 
and 2014. Created from data from the national center for health statistics [16]. 
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A1. Projected number of people with Alzheimer’s dementia: This figure comes from the CHAP study [11]. 
Other projections are somewhat lower (see, for example, Brookmeyer et al. [17]) because they relied on 
more conservative methods for counting people who currently have Alzheimer’s dementia.  
A2. Projected number of people age 65 and older with Alzheimer’s dementia in 2025: The number 7.1 
million is based on a linear extrapolation from the projections of prevalence of Alzheimer’s for the years 
2020 (5.8 million) and 2030 (8.4 million) from CHAP data [11].  
A3. Previous high and low projections of Alzheimer’s dementia prevalence in 2050: High and low 
prevalence projections for 2050 from the U.S. Census were not available for the most recent analysis of 
CHAP data [11]. The previous high and low projections indicate that the projected number of Americans 
with Alzheimer’s in 2050 age 65 and older will range from 11 to 16 million [14].  
 
2.3 PATHOGENESIS AND NEUROPATHOLOGY 
2.3.1 The amyloid cascade model 
The core hypothesis of the amyloid cascade model, which forms the backbone of the 
current understanding of the pathogenesis of AD, is that accumulation of β-amyloid is an 
early event leading to neuro-degeneration [18]. 
 
APP is a cell surface receptor that is expressed in many cell types, in particular in 
neuronal synapses, as a part of normal metabolism. Although its primary function 
remains unclear, amyloid precursor protein (APP) is believed to be implicated in synaptic 
formation and repair, signaling, and cell adhesion [19]. Several isoforms of the cleaved 
APP gene existing ranging in length between 365 and 770 amino acids exist, some of 
which appear more closely associated with the pathogenesis of AD than others [20].  
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As depicted in Fig. 2.4, APP is cleaved by α-secretase and beta-site amyloid precursor 
protein–cleaving enzyme 1 (BACE-1), a β-secretase, both of which release a soluble 
extracellular fragment (sAPP α and sAPP β). Cleavage by β-secretase leaves the Aβ 
region attached to the C-terminus fragment (α-CTF), while α-secretase cleavage takes 
place within the Aβ region, thereby preventing release of the full-length Aβ polypeptide. 
The α-CTF and β-CTF are subsequently cleaved by a ϒ-secretase in the transmembrane 
region releasing, respectively, either a harmless p3 fragment or the Aβ polypeptide [21]. 
 
Based on the chemical composition of the peptide the Aβ is able to self-aggregates into 
multiple coexisting physical forms. One form consists of oligomers (2 to 6 peptides), 
which coalesce into intermediate assemblies [22,23] (Fig. 2.4). Also the β-amyloid 
peptides can self-ensemble into fibrils, organized in β-pleated sheets to form the insoluble 
fibers of advanced amyloid plaques. 
  
 
 
 
13 
 
Figure 2.4 Processing of the Amyloid Precursor Protein. In Panel A, cleavage by α-
secretase interior to the β-amyloid peptide (Aβ) sequence initiates nonamyloidogenic 
processing. The amyloid precursor protein (sAPPα) ectodomain is released, leaving 
behind an 83-residue carboxy-terminal fragment. C83 is then digested by γ-secretase, 
liberating extracellular p3 and the amyloid intracellular domain (AICD). Amyloidogenic 
processing is initiated by β-secretase beta-site amyloid precursor protein–cleaving 
enzyme 1 (BACE-1), releasing a shortened sAPPα. The retained C99 is also a γ-secretase 
substrate, generating Aβ and AICD. γ-Secretase cleavage occurs within the cell 
membrane in a unique process termed “regulated intramembranous proteolysis.” sAPPα 
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and sAPPβ are secreted APP fragments after α-secretase and β-secretase cleavages, 
respectively. AICD is a short tail (approximately 50 amino acids) that is released into the 
cytoplasm after progressive ε-to-γ cleavages by γ-secretase. AICD is targeted to the 
nucleus, signaling transcription activation. Lipid rafts are tightly packed membrane 
microenvironments enriched in sphingomylelin, cholesterol, and 
glycophosphatidylinositol (GPI)–anchored proteins. Soluble Aβ is prone to aggregation. 
In Panel B, left inset, protofibrils (upper) and annular or pore like profiles (lower) are 
intermediate aggregates. In the right inset, self-association of 2 to 14 Aβ monomers into 
oligomers is dependent on concentration (left immunoblot). In the right immunoblot, 
oligomerization is promoted by oxidizing conditions (lane 2) and divalent metal 
conditions (lane 3).  
 
Despite the fact that the amyloid plaques are the main hallmark of AD, the most 
neurotoxic form of the Aβ is the soluble oligomers, monomers and intermediate amyloids 
[24]. In vitro studies have been shown, that in brain slices preparations, dimers and 
trimers of Aβ are toxic to synapses [25,26]. In Human and mouse models of AD, the 
severity of the cognitive impairments correlates with levels of oligomers and monomers 
in the brain, not the total Aβ burden [24,27]. 
 
In order to reduce the Aβ burden, some enzymes and peptides have been tested as 
potential therapeutic targets. The proteases neprilysin and insulin-degrading enzyme was 
one of the first therapeutic for AD, based on their enzymatic activity on regulate steady-
state levels of Aβ. Neprilysin-deficient knockout mice show both Alzheimer's-like 
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behavioral impairment and amyloid-beta deposition in the brain [28,29] providing strong 
evidence for the protein's association with the Alzheimer's disease process. In AD mouse 
models, deletion of insulin-degrading enzyme reduces Aβ degradation by more than 50% 
[30].  Conversely, overexpression of neprilysin or insulin-degrading enzyme prevents 
plaque formation [31]. However, prevention or reduction of plaques formation is not 
correlated with improvements on cognition.  
 
On the other hand, clinical trials of a γ-secretase inhibitor [32], aggregation blockers, 
vaccination with Aβ, and monoclonal antibodies against various Aβ epitopes are in 
progress. The antibodies targeting the Aβ induce or trigger phagocytosis by microglia, or 
enhance clearance of Aβ, or both [33]. Vaccination in a phase 2 trial (NCT00021723) 
[34]  resulted in encephalitis [35], and follow-up of immunized patients showed no 
cognitive or survival benefit despite diminution of plaques [36]. A phase 2 trial of passive 
immunization resulted in vasogenic cerebral edema in some patients (NCT00112073). 
Phase 3 trials of two monoclonal antibodies against Aβ (bapineuzumab and solanezumab) 
and of 10% intravenous immune globulin are under way (NCT00818662).  
 
2.3.2 The Tau model 
Neurofibrillary tangles, is considered the second hallmark of AD. They are filamentous 
inclusions of abnormally phosphorylated tau protein, which in their normal state binds to 
the microtubules and promotes their assembly and stability, facilitating vesicle transport. 
This hyper-phosphorylated anomaly occurs in AD and other neurodegenerative disorders 
termed tauopathies [37]. The major component of the tangles is an abnormally hyper-
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phosphorylated and aggregated form of tau. Hyper-phosphorylated tau is insoluble, lacks 
affinity for microtubules, and self-associates into paired helical filament structures (Fig. 
2.5).  In contrast to amyloid plaques, the number of neurofibrillary tangles is a pathologic 
marker of the severity of AD. 
 
Figure 2.5 Tau Structure and Function. Four repeat sequences (R1-R4) make up the 
microtubule-binding domain (MBD) of tau. Normal phosphorylation of tau occurs on 
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serine (S; inset, above horizontal bar) and threonine (T; inset, below horizontal bar) 
residues, numbered according to their position in the full tau sequence. LWhenFfollowed 
by proline (P), these amino acids are phosphorylated by glycogen synthase kinase 3 
(GSK-3β), cyclin-dependent kinase (cdk5) and its activator subunit p25, or mitogen-
activated protein kinase (MAPK). Nonproline-directed kinases — Akt, Fyn,  protein 
kinase A (PKA), calcium–calmodulin protein kinase 2 (CaMKII), and microtubule 
affinity-regulating kinase (MARK) — are also shown. KXGS (denoting lysine, an 
unknown or other amino acid, glycine, and serine) is a target motif. Hyperphosphorylated 
sites specific to paired helical filament tau in Alzheimer’s disease tend to flank the MBD. 
Tau binding promotes microtubule assembly and stability. Excessive kinase, reduced 
phosphatase activities, or both cause hyperphosphorylated tau to detach and self-
aggregate and microtubules to destabilize.  
 
Like amyloid plaques, insoluble helical filament of tau may be inert, since increase on 
neuronal death is independent of the burden of neurofibrillary tangles [38]. Nevertheless 
the oligomers, intermediate aggregates of abnormal tau molecules are considered as the 
cytotoxic [39] component, which influence significantly on impairment of cognition 
[40,41]. Experimental evidence in mouse models of AD suggests that Aβ accumulation 
precedes and drives tau aggregation [42]. However, the elevated levels of phosphotau 
amino acids T181, T231, and total tau in the cerebrospinal fluid together, which 
constitute a biomarker, test with good accuracy for predicting incipient AD in patients 
with mild cognitive impairment [43]. 
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Given the difficulties presented in order to validate a potential therapy against Aβ with 
significant improvement in cognition, new therapies against phosphorylated tau are under 
trial phases. Some new agents with significant potential to reduce the neurofibrillary 
tangle are small-molecule inhibitors of β-amyloid (e.g., scylloinositol) (NCT00568776) 
and tau oxidation and aggregation (e.g., methylene blue) (NCT00568776) [44]. A more 
general agent that also show promise as therapeutic is poly-phenolic extracts from grape 
seeds (e.g., resveratrol), which stimulate aging-suppressor genes [45]. 
 
2.3.3 The vascular model 
The core hypothesis of the vascular model gives a new insight into the current 
understanding of the pathogenesis of AD.  This hypothesis postulates that vascular 
abnormalities are considered early events, suggesting that pathology starts with 
hypoperfusion, or decreased blood flow to the brain. This, in turn, leads to a crisis among 
glia and neurons, eventually culminating in Aβ accumulation, neurofibrillary tangles 
formation, neurodegeneration and cognitive impairment [46]. 
 
In addition to disruption of the vascular network present in AD, local and systemic 
inflammation triggers the cycle of protein aggregation and oxidative stress in the brain, 
leading to strokes and white-matter lesions, which contribute to cognitive decline. 
Ischemic components affect 60 to 90% of patients with AD, with major infarctions 
representing 30% of vascular lesions in autopsy cases. Conversely, 30% of putative cases 
of vascular dementia also present pathological features of AD. Despite the fact that pure 
cases of vascular dementia are recognized clinically via imaging [47,48], most cases of 
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dementia are in fact mixed. The most common pathological changes include cerebral 
amyloid angiopathy (CAA), [49] affecting more than 90% of patients with AD, capillary 
abnormalities, disruption of the blood–brain barrier [50]. All this pathological changes 
explain the local reduction of brain blood flow, nevertheless none of them explain the 
global hypoperfusion presented in AD patients [51,52].   
 
Another main component of the vascular hypothesis is that the accumulation of Aβ is due 
to disruptions of the Aβ clearance pathways due to loss of function of the vascular unit.  
The main sources of vascular Aβ and CAA are neurons, myocytes and the Aβ on 
circulation. Ex vivo experiments have been shown that vascular AB could contribute to 
blood flow reduction by inducing vasoconstriction [53], cytotocixity to the endothelium 
[54] and smooth muscle cells [55], conferring a predisposition to microhemorages. The 
“neurovascular uncoupling” hypothesis proposes that deregulation of Aβ transport across 
the capillary blood–brain barrier is caused by the imbalanced expression of low-density 
lipoprotein receptor–related proteins and receptors for advanced glycation end products, 
which mediate Aβ efflux and influx, respectively [56] (Fig. 2.6).  
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Figure 2.6 Inflammation and Mechanisms of Aβ Clearance. β-amyloid peptide (Aβ) is 
formed within intracellular compartments (the endoplasmic reticulum, Golgi apparatus, 
and endosomes) or it can enter multiple cell types through the low-density lipoprotein 
receptor–related protein. The ubiquitous apolipoprotein E (APOE) and α2- 
macroglobulins (α2M) are chaperones in this process and in the genesis of extracellular 
plaques. Microglia directly engulf Aβ through phagocytosis. Astrocytes also participate 
in Aβ clearance through receptor-mediated internalization and facilitation of its transfer 
out of the central nervous system and into the circulation. Microglia and astrocytes are 
recruited and stimulated in Alzheimer’s disease to release proinflammatory cytokines and 
  
 
 
 
21 
acute-phase reactants. Receptors for advanced glycation end products (RAGE) molecules 
transduce extra- cellular Aβ toxic and inflammatory effects and mediate influx of 
vascular Aβ. The inflammatory milieu provokes neuritic changes and break- down of the 
vascular blood–brain barrier. In addition to cell-mediated reactions, Aβ clearance occurs 
through enzymatic proteolysis, mainly through neprilysin (Nep) and insulin-degrading 
enzyme (IDE). Aβ oligomers block proteasome function, facilitating the buildup of 
intracellular tau and accumulation of Aβ into “aggresomes.” APP denotes amyloid 
precursor protein, MMP matrix metalloproteinase, MOTC microtubule-organizing center, 
and MVB multivesicular body.  
 
2.3.4 A new key component to the vascular model 
The previous model presented, could explain the local hypoperfusion phenomena but not 
the global blood flow reduction presented in AD patients and mouse models. In order to 
explain the local and global perfusion, we propose a new model based on the obstruction 
of small capillaries.  In this model we considered the interaction of the circulatory system 
(mostly leukocytes), the cerebral vascular unit, and the influence of inflammation 
presented in AD brains. 
 
Cerebral vascular Unit 
Neuronal and brain vascular network are characterized by their complexity on 
specialization, structural and functionality hierarchy and constant metabolic demands.  
The importance of the vascular network in the brain reside on the fact that even though 
the brain represents 20-25% of the metabolic demand in the entire body, the brain has a 
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limited capacity to store energy [57]. To highlight this point, small alterations in the brain 
vascular network affecting blood supply have significant metabolic consequences [58] 
resulting in different brain pathologies [59].  
 
In order to regulate the constant supply of oxygen and nutrients at different levels of 
metabolic demands, the vascular network is able to perform two different mechanisms: 
autoregulation and hyperemia. Autoregulation is the mechanism that regulates the supply 
of oxygen and nutrients through changes in cerebral vascular tone. Autoregulation is the 
mechanism that protects the cerebral blood flow (CBF) in physiological situations, such 
as exercise, and in pathological conditions, such as cardiogenic shock [60]. On the other 
hand, hyperemia is the mechanism that regulates CBF locally, ensuring that the supply of 
oxygen and nutrients matches the changes in activity of specific brain regions [61]. The 
hyperemia mechanism is activated, for example, in physiological situations, such as 
reading, calculating, or any other mental exercise [62].  
 
The changes in cerebral blood supply to match the metabolic demands in controlled by a 
group of cells of both vascular and neural origin, called the neurovascular unit (NVU). 
The NVU comprises vascular cells (that is, endothelium, pericytes, vascular smooth 
muscle cells), glial cells (that is, astrocytes, microglia, and oliogodendroglia) and neurons 
(Fig. 2.7) [63].  
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Figure 2.7 Organization of the capillary neurovascular unit. (A) Rings of smooth 
muscle encircle arterioles, while pericytes send processes along and around capillaries, 
without fully covering the vessel. (B) Pericytes are located outside the endothelial cells 
and are separated from them and the parenchyma by a layer of basal lamina. In the 
parenchyma, astrocyte end-feet and neuronal terminals are closely associated with the 
capillary.  
 
Each of these cell components are intimately and reciprocally linked to each other, 
establishing an anatomical and functional unit, which results in a highly efficient system 
to regulate CBF. From these components, the endothelial cells are connected by tight and 
adherens junctions which acts as filters that regulate the transport of oxygen, nutrients 
and metabolic residues from in and out of the blood brain barrier.  
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Importantly, another critical role for endothelial cells is regulating leukocyte adhesion 
and eventual infiltration into the tissues during inflammation. Adhesion is a well-
characterized response, which leads to activation of the endothelium as well as eventual 
extravasation of immune cells [64]. Usually endothelial cells change their phenotypes 
based on the stimuli, where the inflammation cascade driven by pathogens or cytokines 
leads to their active phenotype. In their active phenotype, the endothelial cells express 
numerous adhesive molecules including the selectins, ICAM, VCAM, chemoattractant 
molecules, and cytokines (MCP-1, IL-lp\ IL-8, and TGF-p) [65-67]. These molecules act 
to attract and provide anchor sites for leukocytes recruitment, adhesion and extravasation.  
 
Chronic stimulation of the endothelial cells leads to endothelial dysfunction [68,69]. It is 
likely that endothelial dysfunction is a common pathology in AD due to the constitutive 
and systemic inflammation presented in the brain. This state of dysfunction induces a 
proinflammatory state, which promotes the activation and migration of leukocytes. 
Chronic endothelial dysfunction can lead to vasoconstriction, decreased blood flow and 
weakening of the vessels [68,69]. 
 
Leukocytes  
Leukocytes are the cells of the immune system, which help, protect the body from foreign 
invaders as well as respond to injury and infectious diseases. There are several types of 
immune cells. The most relevant for our discussion are: blood-derived monocytes, blood-
derived neutrophils, tissue-derived macrophages and microglia. Monocytes are 
circulating leukocytes, which function primarily as phagocytes, cytokines production and 
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antigen presenting cells. Neutrophils are the most abundant circulating leukocytes, which 
function primarily as phagocytes, degranulation (release of anti-microbial agents) and 
generation of neutrophil extracellular traps (NET’s). Macrophages are monocytes which 
have migrated into the tissues and become tissue resident phagocytic cells. Microglia is a 
glial cell, which is considered the resident macrophage in the Central Nervous System 
(CNS), which function primarily as phagocytes, scavengers, cytokines producers, antigen 
presenting cells, and a promoter of tissue repair.  
 
Predominantly, monocytes, neutrophils, macrophage and microglia are key cell types 
involved in the development and progression of atherosclerosis, vascular dementia and 
AD, respectively. Based on specific stimulations, monocytes, neutrophils, macrophages, 
and microglia can go through multiple changes to adopt a active phenotype. Activated 
cells alter expression of a variety of genes, including cell adhesion molecules, cytokines, 
chemokines and co-stimulatory molecules [70,71]. Monocytes, neutrophils, macrophages, 
and microglia utilize these proteins to increase their adhesion and migration ability, 
restructure their cytoskeleton to assist in phagocytosis and migration, and to stimulate 
surrounding cells via secretion of chemokines [72].   
 
The hypothesis that brain hypoperfusion in AD is due to leukocyte plugging in capillaries 
and that this reduced blood flow contributes significantly to the cognitive impact of the 
disease is both novel and supported by our recent results (see chapter 4). Taken together, 
our data suggest a working model to explain the origin and consequences of brain 
hypoperfusion in AD: Aβ monomers accumulation leads to increased expression of 
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inflammatory receptors on the vessel lumen. This vascular inflammation causes 
leukocytes (mostly neutrophils) to adhere and block blood flow in capillaries, resulting in 
decreases in brain perfusion. This blood flow deficit directly contributes to cognitive 
dysfunction and also accelerates Aβ aggregation by decreasing clearance of Aβ 
monomers.  
 
Because one stalled capillary causes decreased flow in several downstream vessels, the 
impact on total brain blood flow is significant. We found that these stalls were caused by 
adhered neutrophils and when we blocked this adhesion, the capillary stalls got released, 
leading to an immediate ~30% increase in cortical CBF. Hypoperfusion likely contributes 
to cognitive deficits in AD patients and recent work has shown that flow reductions 
increase the rate of amyloid beta (Aβ) deposition [73-76], suggesting a positive feedback 
mechanism between Aβ aggregation and brain blood flow decreases, with each impacting 
neural function [77]. In addition, inflammation is a persistent and well-recognized feature 
of AD. A significant contributor to this inflammation is increased reactive oxygen species 
(ROS) induced by brain exposure to Aβ monomers aggregates. These ROS cause a loss 
of cerebrovascular flow regulation [78,79] and result in an increase in inflammatory 
adhesion receptors on endothelial cells [80-82]. We suggest that Aβ-induced endothelial 
ROS could drive the vascular inflammation that likely underlies leukocyte plugging of 
capillaries.  
 
In addition, there is a mutually reinforcing cascade of injury where AD pathophysiology 
drives vascular dysfunction and vice versa (Fig. 2.8). Indeed, microvascular strokes [73] 
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and brain hypoperfusion [74,83,84] have been shown to increase the rate of Aβ 
deposition. This vicious cycle of damage suggests a need to treat vascular dysfunction as 
well as Aβ aggregation and toxicity in AD patients. Reducing the blood flow deficit in 
AD could directly improve cognition and slow AD progression, but first the cause of this 
hypoperfusion must be identified. Our data in AD mouse models suggest that leukocyte 
plugging of brain capillaries, likely caused by increased vascular inflammation, could 
account for the decreased brain blood flow in AD.  
 
 
 
Figure 2.8 Brain hypoperfusion in the progression of AD and the role of leukocyte 
plugging of brain capillaries. (left) In sporadic AD, decreased clearance of Aβ with age 
(and other risk factors) is thought to lead to an increase in Aβ oligomers in the brain, 
which, through a variety of mechanisms, leads to neural dysfunction. Our data suggests 
that the brain hypoperfusion present in AD is also be caused by Aβ oligomer toxicity. 
This hypoperfusion likely contributes directly to neural dysfunction and also decreases 
clearance of Aβ from the brain, forming a positive feedback loop that may drive disease 
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progression. (right) We propose that Aβ oligomers lead to increased inflammation in 
capillary endothelial cells. Leukocytes then adhere to these inflamed capillary segments, 
blocking flow and reducing overall brain blood perfusion.  
 
2.4 CONCLUSIONS AND CLINICAL IMPLICATIONS  
Current treatment strategies for AD are focused on ameliorating the progression of the 
disease, maintain cognitive ability and reduce the phenotypic behavior related to the 
disease. However, there are no known treatments to prevent or cure AD. As some major 
key components for AD are still unknown, targeted treatments that effectively combat the 
development of the disease have proven to be elusive (Aβ amyloids and Tau vaccines).  
 
The major limitation in recent efforts to treat the disease is the lack of preclinical 
detection. There is an urgent need to identify cellular, molecular, and functional 
phenotypes associated with defined stages of the disease progression. Clinically, many 
types of AD-related dementias (i.e., frontotemporal, vascular, mixed, and Lewy-body 
dementias) in addition to normal aging exhibit both amyloid accumulation and vascular 
dysfunction.  Though amyloid changes occur during preclinical stages of AD, measures 
of amyloid (CSF levels of Aβ42 and Pittsburgh compound B PET) and tau do not appear 
to be sensitive enough to predict the early onset of cognitive impairment and AD clinical 
diagnosis. Elucidating the precise mechanism through which vascular insults influence 
AD development would be beneficial and might help identify new biomarkers associated 
with preclinical stages of the disease in addition to identify novel biologic targets for drug 
development and aid in patient-directed treatment efforts.  
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CHAPTER 3 
NONLINEAR OPTICAL MICROSCOPY 
 
In this introductory chapter we discuss the use of nonlinear optics for visualization and 
manipulation of biological systems. An overview of two- and three- photon microscopy 
(2PM and 3PM, respectively) and its advantages for in vivo work are presented. We then 
consider the processes of second and third harmonic generation (SHG and THG, 
respectively), and how these techniques share a common platform but a different 
mechanism than 2PM. Finally, we round out the chapter with a discussion of the 
significance of non-linear optics imaging and the description of our 2PM experimental 
setup.  
 
The advantages of nonlinear optical techniques such as 2PM and 3PM allowed me to 
perform in vivo imaging in the mouse cortex and hippocampus and investigate and 
characterized a new cellular phenomena in Alzheimer’s mouse model (Chapter 4) and 
record neuronal in hippocampus region (Chapter 6).  
 
In vivo imaging is critical for understanding systems networks, tissue structure and 
function, cellular dynamics, etc. as it occurs within an intact organism. Recent advances 
in non-linear optical imaging such as two-photon excited fluorescence microscopy (2PM) 
and three-photon microscopy (3PM) allow us to study the progression of diseases in 
complex biological systems as the brain, the heart, the spinal cord, etc. during in vivo 
experiments [1,2]. 2PM provides the best optical system to perform in vivo imaging at 
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subcellular level within 1 mm volume inside the brain without causing damage to the 
surrounding tissue [3,4]. However, the maximum imaging depth for 2PM is limited by 
the signal-to-background ratio (SBR). On the other hand, 3PM is an improvement over 
two-photon imaging because the SBR is orders of magnitude higher within the mouse 
brain [2]. In this chapter we provide an overview of 2PM and 3PM, second and third 
harmonic generation processes, the use of non-linear microscopy for in vivo imaging and 
the experimental setup. The imaging techniques discussed in this chapter are used 
primarily in Chapters 4 and 6.  
 
3.1 Two-Photon Excited Fluorescence 
2PM was first demonstrated by Denk, Strickler, and Webb in 1990 and revolutionized the 
field of tissue imaging in vivo, becoming the most widely used multiphoton imaging 
modality [5]. The non-linear nature of 2-photon absorption required the simultaneous 
interaction (10-16 s) between two-photons and the fluorophore in a determined focal 
region in order to reach the higher energy state [6] (Fig. 3.1).  Because the generated 
fluorescence signal is quadratically dependent on the light intensity, fluorescence is 
generated only at the focal volume of a pulsed femtosecond laser, where the photon 
density is the highest and is able to drive nonlinear absorption of photons [7]. This 
provides intrinsic optical sectioning, in where scattered excitation light cannot effectively 
generate fluorescence (Fig 3.2). Based on this principle, any emission signal can be 
attributed to the location of the laser focus. Therefore, the laser focus is the scanned in 
three dimensional raster fashion creating an image volume generated voxel-by-voxel.   
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Figure 3.1 Jablonski diagram showing the interaction of multiple infrared photons 
with the electronic and vibrational energy levels of a molecule.  
(A) Schematic of the linear excitation of a fluorescent molecule. In this case, one photon 
is absorbed and the fluorescent molecule is driven to an excited state. The molecule then 
relaxes and loses energy in the form of an emitted photon. (B) In two-photon excitation 
fluorescence (2PEF), the molecule absorbs two infrared photons that promote it to the 
excited electronic state. After relaxation to a lower vibrational level, the molecule emits a 
lower energy (red-shifted) photon.  
 
hv1 hv2
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Figure 3.2 Localization of Excitation by Two-Photon Excitation. 
(a) Single-photon excitation of fluorescein by focused 488-nm light. (b) Two-photon 
excitation using focused femtosecond pulses of 960-nm light.  Reprinted by permission 
from Nature Publishing Group: Nature Biotechnology, Zipfel,W.R., Williams R.M., and 
Webb W.W. Nonlinear magic: multiphoton microscopy in the biosciences, 21, 1369 – 
1377, Copyright 2003. [7] 
 
3.2 Three-Photon Microscopy (3PM) 
The first demonstration of 3PM was in the 1990s, with the purpose of extend the spectral 
range of the excitation source (e.g., access the transition band from 230 to 300 nm using a 
mode-locked Titanium:Sapphire laser) [8-10] . One of the main advantages of 3PM is the 
significant improvement in the overall excitation localization [8]. The fluorescence of 
2PEF falls off as ~ 1/z2 while in the 3PM falls off as ~ 1/z4
 
(where z is the distance away 
from the focal plane). Therefore, improves the SBR by orders of magnitude when 
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compared to 2PEF (Fig 3.3) [2]. In conclusion, 3PM is an improve of the 2PM system, by 
reducing the SBR allowing us to penetrate deeper in to the scattered sample.  
 
 
Figure 3.3 Comparing SBRs in 2PM and 3PM. Calculated SBRs of 2PM and 3PM at 
NA=. The effective attenuation lengths are 285 µm and 400 µm for excitation at 1,280nm 
and 1,7000 nm, respectively. Reprinted by permission from Nature Publishing Group: 
Nature Photonics, Horton, N.G., et al. In vivo three-photon microscopy of subcortical 
structures within an intact mouse brain, 7, 205-209, Copyright 2013. [2] 
 
3.3 Harmonic Generation 
Another properties from the nonlinear imaging systems include second and third 
harmonic generation (SHG and THG), which produce detectable signals without the 
introduction of fluorescence dyes. During this process the molecules are not excited to a 
higher energy state by the absorption of photons.  Instead, photons with the same 
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frequency are combined once they interact with the sample, generating new photons with 
twice energy, twice the frequency and half the wavelength on the initial photons [11,12] 
(Fig. 3.4). In order to generate SHG signal the molecules should maintain two physical 
properties: lack of inversion symmetry and be regularly oriented. One such structure is 
collage, which is present in most load-bearing tissue. This modality has been used for 
studies of the cornea, lamina cribrosa sclerae, or extracellular matrix, which consist 
primarily of collagen [13-15].  
Unlike SHG, in order to generate the THG signal the molecules does not require the need 
for lack of inversion symmetry. Instead the THG is generated at the interface between 
materials of different excitability. THG microscopy has been used for studies of the 
myelin sheets, cell embryos, cardiomyocytes and   lipids bodies in plants, where the lipid 
layer are separated by water [16-21]. 
 
 
Figure 3.4 Jablonski diagram showing the interaction of multiple infrared photons 
with the electronic and vibrational energy levels of a molecule. (A) In second 
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harmonic generation (SHG), two infrared photons are instantaneously upconverted to a 
single photon of twice the energy. (B) In third harmonic generation (THG), three infrared 
photons are instantaneously upconverted to a single photon of thrice the energy.  
 
3.4 The significance of Non-Linear Optical Imaging 
Over the last two decades laser scanning microscopy (NLSM) or multi-photon 
microscopy (MPM) has become the most popular optical imaging modality to perform in 
vivo experiments, based on its advantages for three-dimensional imaging. In particular, 
2PM and 3PM excitation excels at imaging of living cells, especially within scatter 
tissues such as brain, spinal cord, heart, whole organs, and even entire animals. They are 
a number of advantages that MPM offers in comparison with the usual one photon 
microscopy for conduct in vivo experiments. First, the near-infrared excitation light 
employed in MPM suffer less scattering by the sample when compared with the UV or 
blue-green light used in one-photon imaging system. Biological tissue is considered as 
non-uniform medium having multiple indexes of refraction.  Whereby, longer scattering 
length allows reaching deeper imaging volume, before the path of signal photons from 
the sample toward the detector get disrupted. The narrow localization of MPM to the 
illumination focal point is the basis for the technique's most significant advantages over 
linear microscopy. In confocal microscopy, confocality is achieves with the 
implementation of a pinhole aperture, which reject the out-of focus light. However, under 
deep volumes scattering of the emitted photons is inevitable, resulting in significant loss 
of signal at the pinhole aperture. By contrast, MPM only excites the sample at the focal 
plane, and since no background fluorescence is produced, providing an optical sectioning 
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without the needs of spatial filters [22]. A third factor is based on the nature of MPM 
which eliminate the out-of-focus absorption reducing the photo-bleaching and photo-
damage of the sample, given that the conditions for absorption are not met outside of the 
focal plane in comparison with linear microscopy which illuminates the sample with a 
double inverted cone of light. 
 
3.5 2PM Experimental Setup 
The overall microscope can be broken down into excitation optics, detection optics, and 
detection electronics. Each of these categories can be broken down further into 
components. Below we address the important components. The microscope design for the 
3PM is presented in Chapter 6. This section was adapted from Steve Tilley honor thesis. 
Laser  
In order to achieve the intensity necessary for 2-photon absorption, we need relatively 
high peak intensity laser (Fig 3.5, a). In order to maintain a relatively low average power 
so as not to damage our sample, a pulse laser is used. We use the Chameleon from 
Coherent. With this laser, it is exceptionally easy to change excitation wavelength, which 
is non-trivial on older lasers.  
Beam expanding telescope  
This is a simple telescope used to expand the beam of the laser (Fig 3.5, b-c). The beam 
is expanded so that 80% of the power is clipped on the scan mirrors. This ensures that the 
objective is being properly filled without clipping too much light.  
Power Control  
The excitation laser power is controlled using a half wave plate and a beamsplitter cube23 
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(Fid 3.5, d-e). The half wave plate can be rotated to change the polarization of the laser 
light. The beamsplitter cube reflects light of one polarization and transmits light of an 
orthogonal polarization. Therefore, rotating the beamsplitter cube changes the fraction of 
the light that is transmitted through the cube, and thus the power of the excitation light 
that reaches the sample. The half wave plate is mounted on a rotatable mount from 
Newport, which is rotated using a servo [23].  
Scan Mirrors  
The laser must be aligned so the beam hits the scan mirrors straight and level (Fig 3.5, f). 
The control boards for the scan mirrors were mounted in an aluminum box and wired to a 
power supply. The control boards take an input voltage and convert it to a mirror 
position. To prevent the mirrors from overheating, they were mounted on a block that 
was constantly cooled with water. The scan mirrors we used were from Cambridge 
Technology (6215HM40B).  
Scan and Tube Lens  
The purpose of the scan and tube lens is to image the scan mirrors on to the back aperture 
of the objective (Fig 3.5, g-h). This ensures that the angle of light caused by the mirrors 
directly maps to the angle entering the objective, without causing the beam location on 
the back aperture to shift. The scan and tube lenses have two other functions: they expand 
the beam to alter the fraction of the back aperture that is filled, and they alter the ratio of 
the angle of light at the scan mirror to the angle of light at the back aperture. The focal 
lengths of the scan and tube lenses are 75 and 300 mm, respectively.  
Detection Optics  
The basic detection setup (Fig 3.6). A primary dichroic, with a cutoff wavelength of 705 
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nm, splits the emitted light from the excitation light, and is the first optic after the 
objective (Fig 3.6, b). A 2 inches lens with a focal length of 200 mm is then used to limit 
the spreading of the light from the optical axis (Fig 3.6, c). This allows there to be enough 
room to add the dichroics (Fig 3.6, d-e) before the condenser focuses the light onto the 
PMT. The condenser is a 3 pieces compound lens, made from 75 mm diameter optics. 
The first is a spherical lens with focal length of 75 mm (Fig 3.6, f), the second is an 
asphere with a focal length of 60 mm (Fig 3.6, g), and the third is a flat piece of glass, 
which serves to delay the refraction at the glass/air interface by an inch (Fig 3.6, h). In 
front of the PMT is a bandpass filter (Fig 3.6, i) to select the wavelength of that channel.  
Preamplifier  
The purpose of the preamplifier is to convert the current signal coming from the PMT to 
a voltage signal, while also amplifying and low pass filtering the signal. The circuit used 
was designed in the Kleinfeld Lab [23]. For this microscope, the circuit was placed on 
custom printed circuit boards. This allowed for easier construction, and should allow for 
easier maintenance in the future.  
Stage  
We used the following stages.  
X/Y: Newport ILS100CC  
Z: Newport GTS30V  
In our microscopes, image translation was achieved by moving the sample, not the 
objective. These stages allow for a resolution of 0.5 µm in X/Y and 0.05 µm in Z.  
Data acquisition board  
All of our microscopes use the National Instruments PCI 6110 data acquisition board. 
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This board acquires all four analog imputs, controls the two analog outputs for the scan 
mirrors, controls the power control with a counter [23] and controls the shutter with a 
digital I/O port.  
Power Box  
The power box takes inputs from a power supply and routes it to the preamplifiers and 
PMTs. The power to the preamplifiers is just passed through, as both take ±15 volts. The 
PMTs, on the other hand, take an input of 15 volts, ground, and gain, where gain is 
between 0 and 0.9 volt. The PMTs output a reference voltage of 1.2 volts. A variable 
voltage divider using a potentiometer (pot) is used to drop these 1.2 volts down to 
anywhere between 0 and 0.9 volts by adjusting the pot. The system was designed so that 
dangerous voltages (>1) could not be reached. The 15 volts to the PMT is controlled by a 
switch, which illuminates when power is being supplied, so that a user can easily tell 
when the PMTs are on. This is important to help minimize the risk of someone exposing 
a powered PMT to excessive light.  
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Figure 3.5 Representative schematic of microscope from above.  
 
 
 
Figure 3.6 ZEMAX ray trace of optics design.  
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CHAPTER 4 
CAPILLARY OCCLUSIONS REDUCE CORTICAL BLOOD FLOW AND 
IMPAIR MEMORY IN ALZHEIMER’S MOUSE MODELS 
 
4.1 ABSTRACT 
Cerebral blood flow (CBF) is reduced in Alzheimer’s disease (AD) patients and related 
mouse models, but the underlying mechanisms and the resulting impacts on cognitive 
function and AD pathogenesis remain poorly understood. In the APP/PS1 mouse model 
of AD we found that an increased number of cortical capillaries were stalled as compared 
to wild type animals, largely due to leukocytes that adhered in capillary segments and 
blocked blood flow. Administration of antibodies against the neutrophil marker Ly6G 
reduced the number of stalled capillaries, leading to an immediate increase in CBF and to 
rapidly improved performance in spatial and working memory tasks. Increasing CBF by 
preventing the leukocyte adhesion that plugs capillaries may provide a novel strategy for 
improving cognition in AD. 
  
4.2 MAIN TEXT 
Patients with Alzheimer’s disease (AD) (1-3) and mice expressing mutated forms of 
amyloid precursor protein (APP) (4-6) exhibit cortical cerebral blood flow (cCBF) 
reductions of ~25% early in disease development. Cognitive function was impaired by 
CBF reductions of ~20% in healthy humans (7) and wild type (wt) mice (8), suggesting 
that the decreased CBF in AD likely contributes to cognitive dysfunction. To investigate 
cortical hypoperfusion in AD, we used in vivo two-photon excited fluorescence (2PEF) 
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microscopy to image the cortical vasculature in APP/PS1 mice (9) (Fig. 4.1A) and looked 
for occluded vessels (Fig. 4.1B). We observed no obstructions in arterioles or venules, 
but APP/PS1 mice had a 4-fold elevation in the number of capillaries with stalled blood 
flow as compared to age- and sex-matched, wt littermates (Fig. 4.1C, movie S1 and S2). 
The number of stalled capillaries was elevated by 12 weeks of age in APP/PS1 mice, and 
remained elevated throughout disease progression (Fig. 4.1D). Flowing and stalled 
capillaries (Fig. 4.1E) had about the same distance distribution relative to the nearest 
penetrating arteriole (Fig. 4.1F) or ascending venule (Fig. 4.1G). The incidence of 
capillary stalling did not increase with Aβ plaque density (fig. 4.S1), and was the same in 
awake and anesthetized animals (movie 3 and S4; fig. 4.S2). Capillary stalling was 
similarly elevated in TgCRND8 mice, a different mouse model of APP overexpression 
(fig. 4.S3) (10).  
 
Because each occluded capillary decreases blood flow in downstream vessels (11), a 
small number of stalled capillaries could have an outsized impact on CBF. We simulated 
blood flow in vascular networks from a 1 mm3 volume of mouse parietal cortex (Fig. 
4.1H) (12), a 6 mm3 volume of human cortex (Fig. 4.1I) (13), and a synthetic periodic 
network of order three (fig. 4.S4) using a non-linear model of microvascular blood flow 
(14) (see Supplementary Text). cCBF decreased linearly with an increasing fraction of 
stalled capillaries, with the same slope and without any threshold effect, across all three 
networks (Fig. 4.1J), suggesting that capillary stalling may impact CBF in humans and 
mice similarly. These simulations predicted a ~5 % deficit in cCBF due to 2% of 
capillaries stalled.   
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Using labeling strategies to distinguish leukocytes, platelets, and RBCs (Fig. 4.2A), we 
found the majority of stalled capillary segments contained a leukocyte (Fig. 4.2B). 
Stalled capillaries had a modestly smaller average diameter than flowing capillaries (Fig. 
4.2C), but no difference in the density of nearby Aβ deposits (Fig. 4.2D). Most plugged 
capillaries were transiently stalled with a half-life of less than 5 min, while one-third 
remained stalled for 15 min and 10% began flowing and then re-stalled within 15 min 
(Fig. 4.2E; fig. 4.S5). We also observed that some capillary segments alternated between 
flowing and stalled in repeated imaging sessions over weeks (Fig. 4.2F). The same 
capillaries were stalled across multiple imaging sessions about ten times as frequently as 
predicted by a model that assumed each capillary had an equal probability of being 
stalled at any time point (Fig. 4.2G). Taken together, these data suggest that the capillary 
stalls were caused by leukocytes adhering in a distinct subset of capillary segments.  
 
To determine the class of leukocyte causing the capillary stalls, we injected fluorescently-
labeled antibodies against Ly6G (α-Ly6G; 4 mg/kg animal weight), a neutrophil surface 
marker, and serendipitously found that this reduced the number of stalled capillaries 
within 10 min (Fig. 4.3A and fig. 4.S6). Isotype control (Iso-Ctr) antibodies did not 
impact capillary stalling. The rapid resolution of the capillary stalls suggests that α-Ly6G 
interfered with leukocyte adhesion. Median volumetric blood flow in penetrating 
arterioles, measured using 2PEF (Fig. 4.3B), increased by 26% in young (3-4 months) 
and 32% in aged (11-14 months) APP/PS1 mice one hour after α-Ly6G administration 
(Fig. 4.3C). This increase in blood flow was due to an increase in RBC speed and not an 
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increase in vessel diameter (fig. 4.S7). Penetrating arterioles with lower baseline flow 
tended to show larger flow increases (fig. 4.S8). Iso-Ctr antibodies did not change blood 
flow in APP/PS1 mice, nor did α-Ly6G in wt animals (Fig. 4.3C). Further, capillary 
stalling decreased and penetrating arteriole flow increased one day after administration of 
antibodies against LFA-1, which depleted circulating leukocytes (fig. 4.S9). Across all 
antibody and control treatments, penetrating arteriole flows increased (decreased) when 
the number of stalled capillaries decreased (increased) (fig. 4.S10). We also used arterial 
spin labeled MRI (ASL-MRI) to measure cCBF in 7-9-month old animals (Fig 4.3D). At 
baseline, average cCBF in APP/PS1 mice was 17% lower than in wt animals (Fig. 4.3E). 
cCBF increased by 13% in APP/PS1 mice at ~5 hr after α-Ly6G administration, 
recovering about two-thirds of the deficit relative to wt animals, but was unchanged in 
APP/PS1 mice given Iso-Ctr antibodies or wt mice given α-Ly6G (Fig. 4.3E). Thus, 
administration of α-Ly6G led to a rapid increase in cCBF in APP/PS1 mice that exceeded 
the flow improvement predicted by our simulations after elimination of capillary stalls. 
We next tested whether α-Ly6G administration improves cognitive function in APP/PS1 
mice (Fig. 4.4A). In the object replacement (OR) test of spatial short-term memory (Fig. 
4.4B), a single dose of α-Ly6G in ~11-month old APP/PS1 mice improved performance 
to the level of wt animals at 3 and 24 hours after administration (Fig. 4.4C; fig. 4.S11). 
APP/PS1 mice treated with Iso-Ctr antibodies showed no change, nor did wt animals with 
α-Ly6G (Fig. 4C). Similarly, α-Ly6G improved performance of APP/PS1 mice in the Y-
maze test of working memory (Fig. 4.4D; fig. 4.S12). We detected no improvement in 
sensory-motor function (balance beam walk, fig. 4.S13) and a trend toward reduced 
depression- and anxiety-like behavior (forced swim, fig. 4.S14) in APP/PS1 mice with α-
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Ly6G. We continued to treat these animals with α-Ly6G every three days for a month, 
resulting in depletion of neutrophils (fig. 4.S15). After this regimen, APP/PS1 mice 
exhibited short-term memory performance that matched wt animals in OR (Fig. 4.4C), Y-
maze (Fig. 4.4D), and novel object recognition (NOR) (Fig. 4.4E; fig. 4.S16). We saw no 
improvement in sensory-motor function (fig. 4.S13) and a trend toward decreased 
depression- and anxiety-like behavior (fig. 4.S14).  
  
Because one of the clearance pathways for Aβ is through the vasculature (15) we 
assessed whether improving cCBF with α-Ly6G decreases the concentration of Aβ 
monomers and aggregates. Using enzyme-linked immunosorbent assays (ELISAs) of 
brain extracts from the animals that received one month of antibody treatment, we found 
that α-Ly6G reduced the concentration of Aβ1-40 compared to Iso-Ctr antibodies (Fig. 
4.4F), while the concentration of Aβ1-42 (Fig. 4.4F) and aggregates of Aβ (fig. 4.S17D) 
remained unchanged. We saw no difference in the number and density of Aβ plaques 
between α-Ly6G and Iso-Ctr treated animals (fig. 4.S17).  
 
Brain blood flow reductions occur early in disease development for both AD patients (1, 
16) and for mouse models that express mutant APP (4-6). Proposed mechanisms for this 
hypoperfusion include constriction of brain arterioles (17), loss of vascular density (18), 
and changes in neural activity patterns (19) or in neurovascular coupling (20, 21). Our 
data reveal that neutrophil adhesion to the capillary endothelium may be previously-
unrecognized mechanism for the flow reduction. Capillary obstructions, often linked to 
tissue inflammation, have been observed in a variety of organ systems (typically at higher 
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incidence than observed here) and contribute to pathology (22-28). Indeed, Aβ-induced 
vascular inflammation (29, 30) is a likely cause of the capillary stalling we observed. The 
rapid resolution of the capillary stalls after α-Ly6G treatment suggests the stalls are 
caused by receptor-mediated interactions of neutrophils with the capillary endothelium 
(31). Our observation that some capillary segments were more likely to stall suggests that 
the vascular inflammation is not uniform. Increased leukocyte adherence likely causes 
not only stalls, but also slowed flow in some capillary segments, which was not taken 
into account in our simulations and likely contributes the model’s underestimation of the 
increase in CBF after α-Ly6G administration. However, the simulations predicted a 
similar sensitivity of brain blood flow to capillary stalling in humans and mice, 
suggesting that, if capillary stalling occurs in AD patients, significant blood flow 
improvements could be achieved. Spatial and working memory improved after increasing 
blood flow in APP/PS1 mice on a time scale that was too fast for significant neuronal 
plasticity or synaptic remodeling, suggesting that a mismatch between neuronal energy 
metabolism and delivery of energy substrates through blood flow contributes to the 
cognitive deficit. We, and others (32), have also observed improved cognitive function 
after extended treatment with antibodies that deplete neutrophils. The previous study used 
different AD mouse models (3xTg and 5xFAD) and different antibodies (α-GR-1, α-
LFA-1) than used here and suggested that inhibition of neutrophil trafficking into the 
brain contributed to the cognitive benefits (32). We have shown that such neutrophil 
depletion also increases brain blood flow, which may also have contributed to the 
cognitive improvements in this previous work. Improving CBF by interfering with 
neutrophil adhesion may be a novel therapeutic approach for AD.  
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4.3 RESULTS  
 
Fig. 4.1 2PEF imaging of mouse cortical vasculature revealed a higher fraction of 
plugged capillaries in APP/PS1 mice, which simulations predicted would decrease 
cCBF. (A) Rendering of 2PEF image stack of cortical vasculature (red; Texas Red 
dextran) and amyloid deposits (white; methoxy-X04). (B) Individual brain capillaries 
were scored as flowing or stalled based on the motion of unlabeled blood cells (black) 
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within the fluorescently labeled blood plasma (red). (C) Fraction of capillaries with 
stalled blood flow in APP/PS1 and wt mice; (D) same data as a function of age. One 
outlier not shown: APP/PS1, 42 weeks, 4.4% stalled. (E) Tracing of the vascular network 
in panel A, with stalled capillaries indicated in brown. (F) and (G) Histograms showing 
the topological location of flowing and stalled capillaries relative to the nearest 
penetrating arteriole and ascending venule, respectively. (H) and (I) Spatial maps of 
simulated blood flow changes caused by stalling of 2% of capillaries (indicated by purple 
spheres) in an mouse cortical vascular network (H, from (33)), and a human network (I, 
from (13)) (J) Normalized cortical perfusion as a function of the fraction of capillaries 
that were occluded, expressed as a fraction of the perfusion with no occlusions, in mouse, 
human, and synthetic networks.  
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Fig. 4.2 Characterization of the cause, location, and dynamics of capillary occlusions 
in APP/PS1 mice. (A) 2PEF images of capillaries stalled by a leukocyte (LEU), RBCs, 
and platelet aggregates (PLT), or found empty of blood cells (EMT), distinguished by 
fluorescent labels (red: Texas Red-labeled blood plasma; green: rhodamine 6G-labeled 
leukocytes and platelets; blue: Hoechst-labeled leukocyte nuclei). (B) Fraction of stalled 
capillaries stalled by LEU, RBC, PLT, or EMT. (C) Histogram of the diameter of flowing 
and stalled capillaries (Averages: 5.8±0.05 µm (stalled), 6.3±1.1 µm (flowing); 
p<0.0001). (D) Violin plot of the density of amyloid deposits within tubes of different 
radii that followed the capillary centerline for flowing and stalled capillary segments. (E) 
Fraction of stalled capillaries that remained stalled (red), resumed flowing (green), or 
resumed flowing and then re-stalled (blue) over 15 minutes. (F) 2PEF images of the same 
capillary alternately stalled (arrows) and flowing (white: methoxy-X04). (G) Cumulative 
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probability of an initially stalled capillary to be observed stalled again at any subsequent 
imaging time point, showing both real observations and predictions from a model that 
assumed each capillary had an equal probability of stalling at each time point.  
 
 
 
Fig. 4.3 Administration of antibodies against Ly6G reduced the number of stalled 
capillaries and increased cCBF in APP/PS1 mice. (A) Number of capillaries with 
stalled blood flow ~1 hr after α-Ly6G or Iso-Ctr antibody administration shown as a 
fraction of the number of stalled capillaries at baseline. (B) Projection of 2PEF image 
stack of brain surface vasculature, with surface (red lines) and penetrating (red dots) 
arterioles identified. For each penetrating arteriole, volumetric blood flow is indicated at 
baseline (left) and after α-Ly6G administration (right), along with the percentage of 
baseline flow. (C) Volumetric blood flow in penetrating arterioles measured 60-90 min 
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after α-Ly6G or Iso-Ctr antibody administration in young and old APP/PS1 mice and wt 
control animals shown as a fraction of baseline arteriole flow. (D) CBF map measured 
using ASL-MRI at baseline and ~5 hr after administration of α-Ly6G or Iso-Ctr 
antibodies in APP/PS1 and wt mice. (E) cCBF measurements (ASL-MRI, inset indicates 
ROI on T2 MRI image) at baseline and ~5 hr after administration of α-Ly6G or Iso-Ctr 
antibodies in APP/PS1 and wt mice.  
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Fig. 4.4 Administration of α-Ly6G improved short-term memory and decreased the 
concentration of Aβ1-40 in APP/PS1 mice. (A) Experimental timeline for behavioral 
studies. (B) Tracking of mouse nose location from video recording during training and 
trial phases of OR task taken 3-5 hr after administration of α-Ly6G or Iso-Ctr antibodies 
in APP/PS1 mice. (C) Preference score in OR task and (D) spontaneous alternation in Y-
maze task for APP/PS1 and wt mice at baseline and at 3 hr and 24 hr after a single 
administration of α-Ly6G or Iso-Ctr antibodies, and after 4 weeks of treatment every 
three days. (E) Preference score in NOR task for APP/PS1 and wt mice at baseline and 
after 4 weeks of treatment every three days. (F) ELISA measurements of Aβ1-40 (left) 
and Aβ1-42 (right) monomer concentrations after 4 weeks of treatment every three days.  
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4.5 MATERIALS AND METHODS 
4.5.1 Animals and surgical preparation   
All animal procedures were approved by the Cornell Institutional Animal Care and Use 
Committee and were performed under the guidance of the Cornell Center for Animal 
Resources and Education. We used adult transgenic mice (B6.Cg-Tg (APPswe, 
PSEN1dE9) 85Dbo/J) as a mouse model of AD (34) and littermate wild-type mice 
(C57BL/6) as controls (APP/PS1: RRID:MMRRC_034832-JAX, The Jackson 
Laboratory). Animals were of both sexes and ranged in age from 12 to 100 weeks.  
 
For cranial window implantation, mice were anesthetized under 3% isoflurane on a 
custom-built stereotactic surgery frame and then maintained on ~1.5% isoflurane in 
100% oxygen. Once unresponsive to a toe pinch, mice were given 0.05 mg per 100 g of 
mouse weight of glycopyrrolate (Baxter Inc.) or 0.005 mg/100 g of atropine (54925-063-
10, Med-Pharmex Inc.) to prevent lung secretions, 0.025 mg/100 g of dexamethasone 
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(07-808-8194, Phoenix Pharm Inc.) to reduce post-surgical inflammation, and 0.5 mg/100 
g of ketoprofen (Zoetis Inc.) to reduce post-surgical inflammation and provide post-
surgical analgesia. Glycopyrrolate and ketoprofen were injected intramuscularly, while 
atropine and dexamethasone were injected subcutaneously. Bupivacaine (0.1 ml, 0.125%) 
(Hospira Inc.) was subcutaneously administered at the incision site to provide a local 
nerve block. Animals were provided 1 ml per 100 g of mouse weight of 5% (w/v) glucose 
in normal saline subcutaneously every hour during the procedure. We used a 
thermometer and feedback-controlled heating blanket (40-90-8D DC, FHC) to maintain 
body temperature at 37 °C.  The head was shaved and washed 3 times with alternating 
70% (v/v) ethanol and iodine solutions (AgriLabs). A 6-mm diameter craniotomy was 
performed over the cerebral cortex using a high-speed drill (HP4-917-21, Fordom) using 
bits with diameters of 1.4, 0.9, 0.7, and 0.5 mm (Fine Science Tools) for different steps in 
the craniotomy procedure. The craniotomy was then covered with a sterile 8-mm 
diameter glass coverslip (11986309, Thermo Scientific), glued onto the remaining skull 
with cyanoacrylate adhesive (Loctite) and dental cement (Co-Oral-Ite Dental). All 
procedures were done using sterile technique.  
 
Once the craniotomy was completed, mice were returned to their cages and given 
injections of 0.025 mg/100 g of dexamethasone and 0.5 mg/100 g of ketoprofen 
subcutaneously 1 and 2 days after surgery, and all cages were placed over a heating pad 
during this period. Animals were given at least two weeks to recover from cranial 
window implantation before experimentation to minimize inflammation from the surgical 
procedure. 
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Cranial window implantations were also performed in TgCRND8 mice (10). These 
animals were housed at The Rockefeller University’s Comparative Biosciences Center 
and treated in accordance with IACUC-approved protocols. The window implantation 
followed the same protocol as described above, except that mice were anaesthetized 
using avertin (50 mg/100 g, intraperitoneal) and were given atropine (0.004 mg/100 g).  
 
4.5.2 In vivo two-photon microscopy 
During imaging sessions, mice were anesthetized with 3% isoflurane, placed on a custom 
stereotactic frame, and were given glycopyrrolate or atropine and glucose as described 
above. During imaging, anesthesia was maintained with ~1.5% isoflurane in 100% 
oxygen, with small adjustments to the isoflurane made to maintain the respiratory rate at 
~1 Hz. The mouse was kept at 37 °C with a feedback-controlled heating pad (40-90-8D 
DC, FHC). 
 
To fluorescently label the microvasculature, Texas Red dextran (40 µl, 2.5%, MW = 
70,000 kDA, Thermo Fisher Scientific) in saline was injected retro-orbitally just prior to 
imaging. In some animals, amyloid beta (Aβ) deposits were labeled using methoxy-X04 
(35). In early experiments using methoxy-X04 obtained directly from Prof. Klunk at the 
University of Pittsburgh, we retro-orbitally injected 40 µL of 1 mg/ml methoxy-X04 in 
0.9% saline (adjusted to pH 12 with 0.1 N NaOH) just prior to imaging. In later 
experiments using methoxy-X04 available commercially from Tocris, we 
intraperitoneally injected methoxy-X04 (dissolved in DMSO at 100 mM) one day prior to 
imaging at a dose of 1 mg/100 g. We observed no obvious differences in the amyloid 
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labeling between these two administration approaches. In some animals, leukocytes and 
blood platelets were labeled with a retro-orbital injection of Rhodamine 6G (0.1 ml, 1 
mg/ml in 0.9% saline, Acros Organics, Pure) (27). Leukocytes were distinguished from 
blood platelets with a retro-orbital injection of Hoechst 33342 (50 µl, 4.8 mg/ml in 0.9% 
saline, Thermo Fisher Scientific). Texas Red (and methoxy-X04, when given retro-
orbitally) were dosed in a single syringe, while Rhodamine 6G and Hoechst were dosed 
together in a second syringe.  
 
Three-dimensional images of the cortical vasculature and measurement of red blood cell 
flow speeds in specific vessels were obtained via a custom-built two-photon excited 
fluorescence (2PEF) microscope. Imaging was done using 830-nm, 75-fs pulses from a 
Ti:Sapphire laser oscillator (MIRA HP pumped by a Verdi-V18 or Vision S, Coherent) 
and 900-nm, 75-fs pulses from a second Ti:Sapphire laser oscillator (Vision S, Coherent). 
Lasers were scanned by galvonometric scanners (1 frame/s) and focused into the sample 
using a 20× water-immersion objective lens for high-resolution imaging (numerical 
aperture (NA) = 1.0, Carl Zeiss Microscopy; or NA = 0.95, Olympus), or a 4× objective 
for mapping of the cortical surface vasculature (NA = 0.28, Olympus). The emitted 
fluorescence was detected on either a two-channel detection system or, for later data sets, 
on an upgraded four-channel detection system. On the two-channel system, the 
fluorescence was split by a 600-nm long pass dichroic and two successive image stacks 
were acquired first with 645/45 nm (center wavelength/bandwidth) and 575/25 nm 
bandpass filters to image Texas Red and Rhodamine 6G, respectively, and then with 
645/65 nm and 460/50 nm filters to image Texas Red and both methoxy-X04 and 
  
 
 
 
71 
Hoescht (on the same channel), all under 830-nm excitation. On the four-channel system, 
a secondary long-pass dichroic at 520 nm was followed by tertiary long-pass dichroics at 
458 nm and one at either 562 or 605 nm. Emission was detected on four photomultiplier 
tubes through the following emission filters: 417/60 nm for Hoechst, 494/41 nm for 
methoxy-X04, 550/49 nm for Rhodamine 6G, and 641/75 nm for Texas Red. Laser 
excitation was 830 nm except when trying to image deep cortical tissue in animals where 
only Texas Red was present in which case 900-nm excitation was used. Laser scanning 
and data acquisition was controlled by ScanImage software (36). To visualize the cortical 
vasculature, stacks of images spaced by 1 µm axially were taken to a cortical depth of 
300-500 µm.  
 
For TgCRND8 mice, imaging was performed using a Fluoview 1000MPE two-photon 
laser scanning microscope (Olympus) equipped with a SpectraPhysics MaiTai DeepSee 
laser and a 25x/1.05 NA objective at The Rockefeller University Bio-Imaging Resource 
Center. 
 
4.5.3 Awake imaging 
A subset of mice was imaged with 2PEF without anesthesia. During the craniotomy 
surgery, a 3D-printed skull-attached mounting frame was secured on top of the cranial 
window to allow for head fixation during anesthesia-free imaging. The 3D-printed frame 
was flanked by 4 screws (TX000-1-1/2 self tapping screws, Small Parts Inc., Miami 
Lakes, FL) inserted into the skull. The screws and appropriate parts of the frame were 
glued to the skull using Loctite and dental cement to firmly attach the mounting frame.  
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We adapted and modified the awake imaging system from Dombeck et al. (37), in which 
a large (8 inch diameter) Styrofoam ball (Floracraft) was levitated using a thin cushion of 
air between the ball and a custom made (3D printed) casting containing eight 0.25 inch 
diameter air jets, arranged symmetrically. The air pressure was adjusted to just float the 
ball when the mouse was on top of it.  
 
We trained mice to remain in a calm state during awake, head-fixed imaging. During the 
first training session, mice were handled, with the room lights on, by a trainer wearing 
gloves for ~10 min or until the mice routinely ran from hand to hand. The mice were then 
transferred to the ball and allowed to move freely for ~10 min with the room lights on 
while the handler rotated the ball to keep the mice centered near the top. The second 
training session consisted of again allowing the mice to move freely on the ball for ~10–
15 min, again with the room lights on. The third training session began by head 
restraining the mice on the ball in complete darkness for ~15–20 min. Typically it would 
take 5–10 min for the mouse to learn to balance and then begin to walk or run. Mice were 
then head-fixed and placed on the ball during imaging under the microscope. Awake 
imaging lasted less than 30 min. Following awake imaging, mice were anesthetized as 
described above and imaging was repeated over the same cortical area to compare 
capillary physiology between the awake and anesthetized states. 
 
4.5.4 Quantification of capillary network topology and capillary segment stalling 
The 2PEF images of vascular networks were manually traced in three-dimensions to 
create a vectorized skeleton that represents the cortical vasculature using custom-written 
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tracing software. The researchers producing these tracings were blinded to the genotype 
of the animal and any treatment it had received. Volumes of these image stacks where 
vessels could not be readily identified and traced were excluded from all analysis. These 
regions were typically deep and near the edges of the imaged volume, or occasionally 
directly underneath a large surface vessel. Vessel segments were classified as surface and 
penetrating arterioles, capillaries, or ascending and surface venules. All vessels smaller 
than 10 µm in diameter were classed as capillaries. Large surface arterioles were 
distinguished from large surface venules based on morphology (arterioles were smaller 
diameter, had smoother walls and less tortuosity, and tended to branch more 
symmetrically and in Y-shape junctions as compared to venules). Other arterioles or 
venules were classed by tracing their connectivity to these readily identifiable large 
vessels.  
 
Each capillary segment in these images was then manually classed as either flowing or 
stalled based on the motion of RBCs during the entire time each capillary was visible in 
the 3D image stack. The Texas Red dextran labels the blood plasma, but not the blood 
cells, so RBCs and other blood cells show up as dark patches in the vessel lumen. The 
motion of these dark patches indicates flowing blood cells. Each capillary segment was 
visible in a minimum of ~5 successive frames in the 3D image stack, or for ~5 s 
(capillaries not oriented parallel to the cortical surface were observed for significantly 
more frames). We scored a capillary segment as stalled if we did not see motion of the 
RBCs and other cells in the capillary segment over this observation time. This manual 
scoring of capillaries as flowing or stalled was performed with the researcher blinded to 
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the genotype and treatment status of the animal. In addition, this scoring was performed 
using only the image data visible on the Texas Red imaging channel. All animals had at 
least 800 capillary segments scored as flowing or stalled.  
 
Using the traced vascular network, the topologically shortest path from each flowing or stalled 
capillary to the nearest penetrating arteriole and ascending venule was calculated using Dijkstra's 
algorithm (38). 
 
4.5.5 Distinguishing causes of capillary stalls 
In some animals, once capillary stalls were identified we used the additional fluorescent 
labels to determine what was blocking blood flow in the capillary segment. Stalled 
capillary segments with a cell-shaped object labeled with both Rhodamine 6G and 
Hoechst present were scored as being caused by a leukocyte. Stalled segments with 
punctate objects labeled with Rhodamine 6G alone were scored as being caused by 
platelet aggregates. Stalled capillary segments with only RBCs present were classed as 
RBC stalls (note that some stalls with leukocytes or platelets present also had RBCs 
present — these were scored as being caused by the leukoctye or platelet aggregate). A 
small fraction of capillaries had no moving blood cells in them at all. Because we define 
flowing vessels by the motion of blood cells, these vessels with no cells present at all 
were also scored as stalled and classed as “empty,” although it is likely there was plasma 
flow in these vessel segments.  
 
We assessed if the diameter of flowing and stalled capillaries was different, on average. 
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To reduce the salt and pepper noise in the vascular images, we filtered using a 3D 5 x 5 x 
5 pixel Gaussian filter. We then corrected for unevenness in the image intensity by 
filtering the image (85 x 85 pixel sized mean filter) and subtracting this from the 
Gaussian filtered image. The resulting image was binarized using Otsu’s method (39). 
Finally, objects smaller than 1000 voxels were eliminated, where voxels were considered 
part of the same connected object whenever they shared at least a corner. We then used 
this binarized image to correct the manual tracing of the vasculature by shifting the 
centerline so it was equidistant from the vessel boundaries (done within a 10-µm 
neighborhood to avoid confusion between neighboring capillaries). Every 5 µm along the 
centerline of each capillary segment, we estimated the vessel radius by finding the closest 
distance from the centerline to the vessel boundary. Measurements of less than 2 µm or 
more than 10 µm were excluded as they likely reflected imaging artifacts, and we 
averaged across all measurements for each capillary segment.  
 
4.5.6 Amyloid plaque segmentation and density analysis 
2PEF images of methoxy-X04 labeled amyloid plaques were filtered and binarized. 
Briefly, we first reduced the background signal in a line-by-line fashion by subtracting 
the median of each line. Salt and pepper image noise was reduced using the adaptive 
Wiener method with a 3 x 3 pixel kernel (40). The image was then binarized using a manually-
determined threshold (99% of the intensity distribution), and smoothed with a 3 x 3 pixel median 
filter.  Objects smaller than 25 voxels were then removed, with object connectivity here defined 
as voxels sharing a face. The volume fraction of amyloid either globally or in a tube that follows 
the centerline of each capillary segment was then calculated from this binarized image. The tube 
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volume was generated by swaying a sphere with a specified radius along the centerline of 
the capillary segment from one end to the other. 
 
4.5.7 Kinetics of capillary stalling  
To determine the short-term fate of capillaries that stalled, we repeatedly imaged the 
same capillary bed at baseline and at 5, 10, and 15 min later in APP/PS1 mice (n= 6 
animals), and tracked the fate of all the capillaries that were stalled at baseline. If a vessel 
was observed as stalled at all subsequent imaging time points, it was scored as remaining 
stalled, and if flow had resumed the stall was scored to have resolved. If the originally 
stalled capillary resumed flow, then re-stalled at a later time point that was scored as re-
stalled. In some animals, we further determined the cause of capillary stalls at each of 
these time points.  
 
To evaluate the longer-term fate of capillaries that were stalled, we imaged APP/PS1 
mice (n= 5 animals) at baseline and then 1, 3, 7, and 14 days later and determined what 
fraction of the capillaries stalled at baseline were stalled at any subsequent imaging 
session.  
 
We estimated how frequently we would observe capillaries stalled at baseline to be 
stalled at any subsequent imaging session assuming that no stalls lasted long enough to 
stay stalled between imaging sessions and that each capillary segment was equally likely 
to stall. With this model, the cumulative probability, Pc, of the capillaries stalled at 
baseline to be stalled at any subsequent imaging session is: 
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𝑃! = 1− (1− 𝑟)!  Eq. 1,  
where r is the fraction of capillaries with stalled blood flow and N is the number of 
observations after the baseline imaging.  
 
4.5.8 Administration of antibodies against Ly6G and impact on neutrophil 
population 
We treated APP/PS1 mice (n = 9, 12-25 weeks old) with intraperitoneal injections of 
monoclonal antibodies against lymphocyte antigen 6 complex, locus G (Ly6G) (α-Ly6G, 
clone 1A8, 4 mg/kg, BD Biosciences) or an isotype control antibody (n = 6, Rat IgG2a, κ, 
4 mg/kg, BD Biosciences). The same cortical capillary bed was imaged in anesthetized 
mice immediately before and at 30-60 min and 60-90 min after treatment. Quantification 
of stalled capillaries was performed blinded to imaging time and treatment type.  
 
To determine the impact of α-Ly6G on neutrophil number, we used flow cytometry to 
determine neutrophil counts 24 hr after a single treatment (4 mg/kg) and after one month 
of treatment every three days (2 mg/kg).  
 
Mouse blood was collected from the submandibular vein and mixed with 1x RBC lysis 
buffer (00-4300-54, ThermoFisher Scientific). After incubation at room temperature for 
10 min, the sample was centrifuged at 500 g for 5 min and the supernatant was removed. 
The cell pellet was re-suspended in 500 uL of Hank’s balanced salt solution (HBSS) 
supplemented with 1% bovine serum albumin (BSA) and centrifuged again; this washing 
procedure was repeated 3 times. Following isolation, neutrophils were re-suspended at a 
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density of 107 cells per ml in HBSS supplemented with 1% BSA. The cell samples were 
labeled at room temperature for 45 min with the following anti-mouse antibodies: anti-
CD45 (560695, BD Bioscience), anti-CD11b (557686, BD Bioscience) and anti-Ly6G 
(551460, BD Bioscience). After washing the samples with HBSS, the remaining 
leukocytes were analyzed by flow cytometry using a Guava easyCyte Flow Cytometer 
(EMD Millipore Corporation). Data were analyzed using FlowJo software (FlowJo LLC). 
The neutrophil population was identified based on the side and forward scatter and later 
gated for CD45high and CD115low and finally gated as CD11bhigh and Ly6Ghigh using 
FlowJo. 
 
4.5.9 Measurement of volumetric blood flow in penetrating arterioles 
To quantify blood flow in cortical penetrating arterioles, we measured the vessel diameter 
from image stacks and the centerline RBC flow speed from line-scan measurements, as 
described in Santisakultarm T.P. et al. (41). The volumetric blood flow, F, was calculated 
as:   𝐹 = !"!!!  Eq. 2,  
where v is the time-averaged centerline RBC speed and r is the vessel radius. To correlate 
the impact of the number of capillaries stalled on penetrating arteriole blood flow, we 
imaged the same capillaries and measured blood flow in the same six to eight penetrating 
arterioles in both young APP/PS1 and wt mice (ages 3-4 months) and older APP/PS1 
mice (age 11-14 months) treated with antibodies against Ly6G or with isotype control 
antibodies. Images to determine capillary stalling and line scans to determine penetrating 
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arteriole blood flow speed were taken at baseline and at 30-60 and 60-90 min after 
treatment. All analysis was conducted blinded to the animal genotype, age, treatment, and 
imaging time point.  
 
4.5.10 Measurement of global blood flow using ASL-MRI 
Imaging was performed on a 7.0 Tesla small animal MRI system with 450 mT/m gradient 
amplitude and a 4500 T/m/s slew rate (Biospec 70/30, Bruker). The animals were 
anesthetized with isoflurane in oxygen and immobilized in the MRI using a nose cone 
and bite ring. A volume coil was used for transmission and a surface coil for reception. 
We imaged APP/PS1 and wt mice (age 7-9 months) at baseline. About 48 hrs later, 
animals were given an intraperiotenial injection of α-Ly6G or isotype control antibodies 
(4 mg/kg) and a second set of images were acquired between 2-6 hr after injection. 
 
Anatomical images were acquired to find a coronal slice at a location approximately 1 
mm caudal to Bregma (42). This position was used for subsequent ASL imaging, which 
was based on a FAIR-RARE pulse sequence that labeled the inflowing blood by global 
inversion of the equilibrium magnetization (43). In this method, inversion recovery data 
from the imaging slice are acquired after selective inversion of the slice and after 
inversion of both the slice and the surrounding tissue. The difference of the apparent R1 
relaxation rate images then yields a measure of the CBF (44). Three averages of one axial 
slice were acquired with a field of view of 15 × 15 mm, spatial resolution of 0.23 × 0.23 
× 2 mm3, echo time TE of 5.36 ms, effective TE of 26.84 ms, repeat time TR of 10 s, and 
a RARE factor of 36. This resulted in a total scan time for the CBF images of about 25 
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min. Turbo-RARE anatomical images were acquired with the following parameters: 10 
averages of 14 slices with the same field-of-view and orientation as the ASL images, 
resolution = 0.078 × 0.078 × 1 mm3, TE = 48 ms, TR = 2000 ms, and a RARE factor of 
10. The total scan time was 6:20 min. 
 
For computation of CBF, the Bruker ASL perfusion processing macro was used. It uses 
the model and includes steps to mask out the background and ventricles (44). The masked 
CBF images were exported to Analyze format on the MRI console. We then used the 
anatomical image to create a mask that outlined the entire cortical region, excluding the 
sinus, and averaged the CBF measurement across this region for each animal at each 
imaging time point. Analysis of ASL-MRI data was conducted blinded to animal 
genotype and treatment.  
 
4.5.11 Extraction of network topology and vessel diameters from mouse anatomical 
dataset 
One large postmortem dataset from the vibrissa primary sensory (vS1) cortex in mouse 
previously obtained by Tsai et al. (12) and Blinder et al. (33), was used for this study (~1 
mm3 and ~15,000 vessel segments). In brief, this dataset was obtained by filling the 
vessels with a fluorescent indicator, extracting the brain and imaging with 2PEF from the 
pial surface to near the bottom of cortex. In this dataset, penetrating arterioles and 
ascending venules that reached the pial surface were identified by following their 
connections to a large cerebral arteriole or venule. We further labeled subsurface vessels 
in three classes: arterioles, capillaries, and venules. Starting with the surface and 
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penetrating arterioles (venules) were defined by iteratively seeking all vessels with 
diameter above 6 µm connected to any previously labeled arteriole (venule). All 
remaining vessels were labeled as capillaries. The diameter threshold was manually 
chosen as the smallest integer diameter value which resulted in arteriolar and venular 
trees that exhibited no loops, in contrast to the very looped capillary network.  
 
Due to post-mortem shrinkage, vessel diameters in this mouse dataset were smaller than 
those measured in-vivo, so required rescaling (12, 41, 46). As blood flow is highly 
dependent on vessel diameters, two successive corrections were applied. First, a 
monotonically increasing function, which tends to one at large diameters, was applied to 
all vessels diameters:  𝑑 = 𝑑! + 𝐴 cos tan!! !!! ,      𝐴 > 0,      𝐵 > !!𝐴 sin tan!! !!       Eq. 3 
where d is the corrected diameter and d0 is the diameter extracted from the image stack. A 
and B are constrained parameters calculated so that the corrected vessel diameter 
distribution matched in vivo measurements from two photon microscopy (12), as shown 
in Fig. 4.S18. This function ensures that the hierarchy of diameters in the network is 
preserved and the larger vessels are not rescaled. For the network represented in Fig. 
4.1H, A=1.4 and B=10.3, so that the diameter threshold for capillary vessels becomes 7.2 
µm. A second depth-dependent correction was then applied to the diameter of arterioles 
and venules: 𝑑 = 𝑑! 𝑎𝑧 + 𝑏      Eq. 4 
where z is the depth below the cortical surface and a and b are parameters determined so 
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that the diameters of the trunks of the penetrating arterioles and ascending venules 
matched in-vivo measurements (46). For the network represented in Fig. 4.1H, these 
parameters were a=-0.0014 µm-1 (-9.36e-4 µm-1) and b=2.54 (2.02) for arterioles 
(venules).  
 
4.5.12 Extraction of network topology and vessel diameters from human anatomical 
dataset 
The dataset used was previously obtained by Cassot et al. (47) and Lauwers et al. (13) 
from thick sections (300 µm) of a human brain injected with India ink from the Duvernoy 
collection (48). The brain came from a 60-year old female who died from an abdominal 
lymphoma with no known vascular or cerebral disease. It corresponds to a large volume 
(6.4 mm3 of cerebral cortex) extending across 20.8 mm2 along the lateral part of the 
collateral sulcus (fisiform gyrus) extracted from Section S2 in Lauwers et al. (13), and 
includes a total of 27,340 vessel segments. The mean radius and length of each segment 
were rescaled by a factor of 1.1 to account for the shrinkage of the anatomical 
preparation. The main vascular trunks were identified manually and divided into 
arterioles and venules according to their morphological features, following Duvernoy's 
classification (48, 49). Following Lauwers et al. (13) and Lorthois et al. (14) as in the 
mouse data sets, arterioles (venules) were defined by iteratively seeking all vessels with 
diameter above 9.9 µm connected to any previously identified arteriole (venule), so that 
no loops were present. All remaining vessels were classified as capillaries. 
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4.5.13 Synthetic network generation  
The synthetic periodic network of order three (i.e. three edges per node) was generated to 
match the mouse network parameters. A 1-mm3 vascular network was constructed by 
replication of a simple periodic network (fig. 4.S4). Capillary diameters and lengths were 
uniform and were set to the averages for the mouse network. A single penetrating 
arteriole and ascending venule (with diameters set to the averages from the mouse 
network) served as inlet/outlet. The distance between the inlet and outlet corresponded to 
the average distance between penetrating arterioles and ascending venules from the 
mouse dataset. 
 
4.5.14 Blood flow simulations 
The methodology for simulating blood flow in these intra-cortical vascular networks has 
been presented in detail in Lorthois et al. (14). Briefly, the network was represented by a 
graph in which edges represent vessel segments between branches that are characterized 
by an average diameter and length. We used a one-dimensional (analogous to electric 
circuit models) nonlinear network model that was slightly modified from Pries et al. (50) 
to handle large networks for the flow simulations. Using an iterative procedure, the 
model takes into account the complex rheological properties of blood flow in the 
microcirculation (Fåhræus, Fåhræus-Lindqvist, and phase separation effects). These 
effects are modeled using empirical descriptions (51, 52) deduced from experiments in 
rats. The model was used to calculate the flow and hematocrit in each vessel and the 
pressure at each intersection of vessels. For the human dataset, the parameters for the 
empirical descriptions of the Fåhræus, Fåhræus -Lindqvist and phase separation effects 
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were re-scaled in order to account for the difference in characteristic size between human 
and rat RBCs, as proposed by Lorthois et al. (14) and Roman et al. (27). This simulation 
approach has no free parameters. 
 
Boundary conditions: Physiologically realistic pressure drops of 60 mmHg, as measured 
in rats (54) and estimated in humans (14), were imposed between all arteriolar and 
venular trunks feeding and draining the computational volume, while a no-flow condition 
was imposed on deeper arteriolar or venular vessels that intersected the lateral boundaries 
of the simulated volume. A constant discharge hematocrit of 0.45, corresponding to a 
typical value of the systemic hematocrit, was also imposed in arteriolar trunks. Moreover, 
a pseudo-periodic boundary condition was applied to all capillaries at the lateral 
boundaries, as illustrated in fig. 4.S19. Fictitious vessels were created that link capillaries 
intersecting opposing faces in a semi random fashion. A grid was created on the two 
faces and refined until, for a given cell, each capillary on one face was matched with at 
most 2 capillaries on the opposing face, allowing the creation of fictitious bifurcations. 
Once the optimal grid was found, the closest neighboring vessels from the opposing faces 
were connected together. The length of the resulting fictitious vessels was set to 50 µm 
and their diameters to the average diameters of the connected capillaries. This pseudo-
periodic boundary condition is similar in spirit but simpler and more computationally 
effective than the one recently introduced by Schmid et al. (55). Finally, a no-flow 
boundary condition was applied to all vessels intersecting the bottom face of the domain. 
We also compared the results with no-flow boundary conditions for all capillaries at the 
lateral boundaries.  
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Simulating stalls: In order to study the influence of capillary stalling on cerebral blood 
flow, a given proportion of capillaries in each network was randomly occluded. To 
simulate occlusion, the radius of the selected vessels was divided by 100. This resulted in 
a large increase of the hemodynamic resistance, of order 108, and a similar decrease of 
the computed flow through these vessels. At least five repetitions were performed for 
each proportion of stalled capillaries and each set of conditions considered. On the mouse 
data, 1000 simulations in total were run on a 32-core Intel(R) Xeon E5-2680 v2 @ 3.3 
GHz for a total computational time of ~170 hours. For human data set, about 100 
simulations were run on the same machine for a total computational time of ~50 hours. 
 
4.5.15 Behavior experiments 
All experiments were performed under red light in an isolated room. The position of the 
mouse’s nose was automatically traced by Viewer III software (Biobserve, Bonn, 
Germany). In addition to the automatic results obtained by Viewer III software, a blinded 
experimenter independently scored mouse behavior manually. Animals were taken into 
the behavior room one-hour prior to the experiment. Behavioral analysis was conducted 
at baseline and at 3 and 24 h after injection with α-Ly6G or isotype control antibodies (IP 
4 mg/kg). Animals were then treated every three days for four weeks (IP 2 mg/kg) and 
behavior experiments were repeated. The OR, Y-maze, balance beam walk, and forced 
swim tests were performed at all time points. The NOR task was performed only at 
baseline and the 4-week time point to avoid animals becoming accustomed to the objects. 
Animals were ~11 months of age at the start of the experiment (APP/PS1, α-Ly6G n=11; 
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APP/PS1 Iso-Ctl, n=9; wt α-Ly6G, n=10; and wt Iso-Ctl, n=10).  
 
Object replacement test: The object replacement (OR) task evaluated spatial memory 
performance. All objects were validated in a separate cohort of mice to ensure that no 
intrinsic preference or aversion was observed and animals explored all objects similarly. 
Exploration time for the objects was defined as any time when there was physical contact 
with an object (whisking, sniffing, rearing on or touching the object) or when the animal 
was oriented toward the object and the head was within 2 cm of the object. In trial 1, 
mice were allowed to explore two identical objects for 10 min in the arena and then 
returned to their home cage for 60 min. Mice were then returned to the testing arena for 
3 min with one object moved to a novel location (trial 2). Care was taken to ensure that 
the change of placement alters both the intrinsic relationship between objects (e.g. a 
rotation of the moved object) and the position relative to internal visual cues (e.g. new 
location in the arena; one wall of testing arena had a pattern). In addition to using the 
tracking software to determine the object exploration times, the time spent at each object 
was manually scored by an independent experimenter who was blinded to the genotype 
and treatment. The preference score (%) for OR tasks was calculated as ([exploration 
time of the novel object]/[exploration time of both objects]) × 100 from the data in trial 2. 
Automated tracking and manual scoring yielded similar results across groups, so we 
report the automated tracking results.  
 
Y-Maze: The Y-Maze task was used to measure working memory by quantifying 
spontaneous alternation between arms of the maze. The Y-maze consisted of three arms 
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at 120° and was made of light grey plastic. Each arm was 6-cm wide and 36-cm long, and 
had 12.5-cm high walls. The maze was cleaned with 70% ethanol after each mouse. A 
mouse was placed in the Y-maze and allowed to explore for 6 min. Mouse behavior was 
monitored, recorded, and analyzed using the Viewer software. A mouse was considered 
to have entered an arm if the whole body (except for the tail) entered the arm and to have 
exited if the whole body (except for the tail) exited the arm. If an animal consecutively 
entered three different arms, it was counted as an alternating trial. Because the maximum 
number of triads is the total number of arm entries minus 2, the spontaneous alternation 
score was calculated as (the number of alternating triads)/(the total number of arm entries 
− 2). 
 
Forced swim test: The forced swim test measured depression-like behavior. Mice were 
individually placed in a 4-L glass beaker filled with 2.5 L of 25°C water. Mice were 
allowed to adjust for 1 min and then were evaluated for 6 min. An experimenter blind to 
the genotype and treatment analyzed the videotaped behavior and scored the immobility 
time, defined by the absence of active, escape-oriented behaviors such as swimming, 
jumping, rearing, sniffing or diving. 
 
Balance beam walk: The balance beam walk measured motor coordination and balance 
by scoring the ability of the mice to traverse a graded series of narrow beams to reach an 
enclosed safety platform. The beams consisted of long strips of wood (80 cm) with round 
cross section of 12- and 6-mm diameter. The beams were placed horizontally, 40 cm 
above the floor, with one end mounted on a narrow support and the other end attached to 
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an enclosed platform. Bright light illuminated the end of the beam where the mice started. 
Mice received three consecutive trials on each of the round beams, in each case 
progressing from the widest to the narrowest beam (15 min between each trial). Mice 
were allowed up to 60 s to traverse each beam. The time to traverse each beam and the 
number of times either hind paw slipped off each beam were recorded for each trial. 
Analysis of each measure was based on the mean score across all trials for that mouse at 
that time point. Experimenters were blinded to the genotype and the treatment of the 
mice.  
 
Novel object recognition test: The novel object recognition (NOR) task measures 
recognition memory and is based on rodents’ innate preference for exploring novel 
objects. This test was conducted only in the animals at baseline and after 4 weeks of 
treatment. The testing approach was identical to the OR task, but with a novel object 
placed at the location of one of the initial objects in trial 2. 
 
4.5.16 ELISA  
After the conclusion of the behavior experiments, the APP/PS1 animals that had received 
α-Ly6G or isotype control antibodies every 3 days for a month were sacrificed by lethal 
injection of pentobarbital (5 mg/100 g). Brains were quickly extracted and divided along 
the centerline. One half was immersed in 4% paraformaldehyde in phosphate buffered 
saline (PBS) for later histological analysis and the other half was snap frozen in liquid 
nitrogen.  
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The frozen APP/PS1 mouse hemi-brains (Iso-Ctr: n=6, 11.5-12.5 months old; α-Ly6G: 
n=7, 11.5-12.5 months old) were weighed and homogenized in 1 ml PBS containing 
complete protease inhibitor (Roche Applied Science) and 1 mM AEBSF (Sigma) using a 
Dounce homogenizer. The homogenates were then sonicated and centrifuged at 14,000 g 
for 30 min at 4° C. The supernatant (PBS-soluble fraction) was removed and stored at 
−80° C. The pellet was re-dissolved in 0.5 ml 70% formic acid, sonicated, and 
centrifuged at 14,000 g for 30 min at 4° C, and the supernatant was removed and 
neutralized using 1M Tris buffer at pH 11. Protein concentration was measured in the 
PBS soluble fraction and the formic acid soluble fraction using the Pierce BCA Protein 
Assay (Thermo Fischer Scientific). The PBS soluble fraction extracts were diluted 1:5. 
Formic acid extracts were diluted 1:1 after neutralization. These brain extracts were 
analyzed by sandwich ELISA for Aβ1-40, Aβ1-42, and Aβ aggregates using commercial 
ELISA kits and following the manufacturer’s protocol (Aβ1-40: KHB3481; Aβ1-42: 
KHB3441; Aβ aggregates: KHB3491, Thermo Fisher Scientific). The Aβ concentration 
was calculated by comparing the sample absorbance with the absorbance of known 
concentrations of synthetic Aβ1–40 and Aβ1–42 standards on the same plate. Data was 
acquired with a Synergy HT plate reader (Biotek) and analyzed using Gen5 software 
(BioTek) and Prism (Graphpad).  
 
4.5.17 Histopathology 
Immunohistochemistry was performed on the brains of mice chronically treated every 
third day for 4 weeks with either α-Ly6G antibody or isotype control (Iso-Ctr n=5, α-
Ly6G n=4).  A single paraformaldehyde-fixed hemisphere of each brain was cut into 40 
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µm thick sagittal sections. 
 
Every sixth section from each mouse was stained with 1% Thioflavin-S (T1892, Sigma) 
for 10 min at room temperature and washed twice with 80% ethanol for 2 min. The 
sections were mounted using Fluoroshield with DAPI (F6057, Sigma). Images were 
taken using confocal microscopy (Zeiss Examiner.D1 AXIO). For each image, the 
background was subtracted using the ImageJ background subtraction plugin (Rolling ball 
with 7 µm radius). Images were then manually thresholded, using the same threshold for 
all sections from a given mouse. Appropriate thresholds varied mouse to mouse and were 
set to ensure that the smallest Thioflavin-S labeled objects that morphologically appeared 
to be an amyloid plaque remained above threshold. Cortical and hippocampal regions of 
interest were defined in each section anatomically, and the fraction of pixels above 
threshold was determined across all sections for these regions of interest. All image 
processing was done blinded to treatment group. As a second measure of amyloid 
deposition, we manually counting the number of Thioflavin-S positive amyloid plaques 
in the cortex and hippocampus, again across all sections and while blinded to the 
treatment group. All sections were stained and imaged in parallel. Artifacts such as 
bubbles were eliminated from analysis by manually excluding these regions. 
  
4.5.18 Statistical analysis 
Boxplots were created using Prism7 (GraphPad). The box extends between the values for 
the 25th and 75th percentile of the data. The whiskers extend 1.5 times the difference 
between the value of the 75th and 25th percentile of the data from the top and bottom of 
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the box. Values lying outside the whiskers were defined as outliers and the mean was 
computed excluding these outliers. The median is indicated with a black horizontal line 
inside the box, while the mean is indicated with a red horizontal line. Violin plots were 
created using the statistical software package, R (56).  
 
Data in all groups was tested for normality using D’Agostino-Pearson omnibus normality 
test. Parametric statistics were used only if the data in all groups in the comparison were 
normally distributed. The statistical significance of differences between multiple groups 
was determined using one-way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison correction for normally distributed data, and using Kruskal-Wallis 
one-way ANOVA followed by Dunn’s multiple comparison correction for data with a 
non-normal distribution. Statistical comparisons between two groups were performed 
using the Student’s t test or paired t test for normally distributed data, or using the Mann-
Whitney test or Wilcoxon matched-pairs test for data with a non-normal distribution. P-
values smaller than 0.05 were considered statistically significant. All statistical analysis 
was performed using Prism7 (GraphPad). 
 
We use a standardized set of significance indicators across all figures in this manuscript. 
For comparisons between groups: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. For 
matched comparisons before and after treatment: +p<0.05, ++p<0.01. Supplementary 
Table 1 provides details of the groups compared, animal and capillary numbers, statistical 
tests, and explanatory notes for individual panels in the main figures. This information is 
included in the caption of supplementary figures.  
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4.6 SUPPLEMENTARY TEXT ON NUMERICAL SIMULATIONS OF 
CEREBRAL BLOOD FLOW CHANGES INDUCE BY CAPILLARY 
OCCLUSIONS 
In previous work, we studied how the occlusion of a single cortical capillary influenced 
blood flow in downstream vessels (11) and found strong reductions in blood flow (10% 
of baseline value 1 branch downstream; 25% at 2 branches; 50% at 3 and 4 branches), 
suggesting that even the small fraction of occluded capillaries we observed in APP/PS1 
mice could cause a significant decrease in overall brain blood flow. To test this idea, we 
simulated blood flow in anatomically accurate blood vessel networks from mice and 
humans and examined how flow changed when we occluded a random selection of 
capillaries.  
 
4.6.1 Validation of simulations by comparison to in vivo measurements in mouse 
As described in the Materials and Methods above, our simulations resulted in calculated 
values for flow (Fig. 4.S20A), pressure (fig. 4.S20B), and hematocrit (fig. 4.S20C) in 
each vessel segment in the volume. We validated the simulation by comparing in vivo 
measurements of blood flow at different levels in the microvascular hierarchy acquired 
by 2PEF from the top 300 µm of mouse cortex (data from Santisakultarm, et al. (41)) 
with the simulation predictions. The simulation results are highly dependent on the 
boundary conditions imposed on capillaries at the lateral edges of the simulation volume. 
The calculated velocity distribution using pseudo-periodic boundary conditions in 
capillaries up to 300 µm in depth and using the vessel diameter corrections described 
above matches the experimental distribution well (fig. 4.S20D). For comparison, the 
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velocity distribution calculated using diameters from the raw datasets (without correction 
for the difference in vessel size between in vivo and post mortem measurements) and that 
calculated using a no-flow boundary condition both led to an order of magnitude 
underestimation of capillary flow speeds (fig. 4.S20D). Our new pseudo-periodic 
boundary condition, together with the correction of vessel diameters, led to a velocity 
distribution that approaches the distribution of experimental velocities. The experimental 
distribution has a sharper peak, which might be due to experimental bias associated with 
the limited number of vessels in which these measurements have been performed (147 in 
vivo measurements vs. 3,400 capillaries in the simulations). The simulated speeds in 
penetrating arterioles and ascending venules as a function of their diameters also closely 
matched experimental results from Santisakultarm, et al. (41) and from Taylor, et al. (46) 
(fig. 4.S20E).  
 
4.6.2 Numerical simulation of cerebral blood flow reductions caused by capillary 
occlusions:  
The effect of occlusions in capillaries was investigated by randomly selecting a given 
proportion of capillaries and reducing their flow by imposing a 100-fold reduction in 
diameter (fig. 4.S21A, Fig. 4.1H). To quantify the effects of the occlusions, we calculated 
the normalized cortical perfusion as the summed flow in the penetrating arterioles feeding 
the region, normalized by the value calculated with no capillary occlusions (Fig. 4.1J). 
While the magnitude of this summed flow is highly dependent on the boundary 
conditions, the decrease in flow due to capillary occlusions was much less sensitive to the 
choice of boundary conditions (fig. 4.S21B). For the mouse network shown in Figs. 4.1H 
  
 
 
 
94 
and S20A with pseudo-periodic boundary conditions and diameter correction, we found a 
linear decrease in the normalized perfusion with a slope S=-2.3±0.2 %baseline 
perfusion/% capillaries stalled (mean±SD) (Fig. 4.1J). This linear behavior was very 
robust to variations in the parameters chosen for the computations, with slopes equal to -
2.2±0.1 (-2.1±0.2) with no-flow boundary conditions and diameter correction (no 
diameter correction). In order to evaluate the influence of boundary conditions with 
regard to the size of the simulated volume, 300 µm-thick sub-volumes of the mouse 
anatomical datasets were randomly extracted. The decrease in blood flow with increasing 
numbers of stalled capillaries was slightly larger when 300 µm-thick sub-volumes of the 
datasets were used (-2.6±0.4 and -2.9±0.5 with the pseudo-periodic boundary condition 
and the no-flow boundary condition, respectively), as compared to the full ~1 mm-thick 
volume. In Fig. 4.1J, only computations on the maximum simulation volume with the 
corrected diameters and pseudo-periodic boundary conditions are presented. 
 
The simulations in the human network using pseudo-periodic boundary conditions 
yielded a slope of S=-2.3±0.6, very similar to the mouse results. This linear decrease was 
also observed in synthetic periodic networks of order three (i.e. three edges per node; S=-
2.9, Fig. 4.1J).  
 
4.6.3 Limitations and methodological considerations 
 The human dataset used in the simulations was only 300 µm thick, raising concerns 
about the influence of boundary conditions. The broad agreement between simulation 
results in mouse datasets with 1-mm and 300-µm thickness reduces this concern. The 
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simulations predicted a similar CBF increase across mouse and human vascular networks 
when stalls were reduced, suggesting that the blood flow improvements we observed in 
APP/PS1 mice may be achievable in humans.  
 
The simulations predicted a smaller impact of capillary stalling on CBF than we observed 
experimentally. One possible explanation is that the simulations used vascular networks 
from wt mice, while AD mouse models have different vascular densities and topologies 
(57) that may influence the sensitivity of CBF to capillary stalls. In addition, increased 
leukocyte adhesion in APP/PS1 mice may lead not only to complete stalls, but also to 
slowed flow in some capillaries that is not captured in the simulations.  
 
We also observed differences in the 2PEF and ASL-MRI measurements of blood flow 
increase after alpha-Ly6G administration that may be due to the limited sampling of 
penetrating arterioles at one anatomical location with 2PEF and to taking ASL-MRI data 
several hours later after treatment than 2PEF. In addition, the correlation between ASL-
MRI values and arteriole flow may not be exact due to technical limitations in mouse 
ASL-MRI. 
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4.7 SUPPLEMENTARY FIGURES 
 
 
Fig. 4.S1. The fraction of capillaries with stalled blood flow did not increase with 
increasing cortical amyloid plaque density in APP/PS1 mice. Fraction of capillaries 
with stalled blood flow as a function of the cortical volume fraction that was labeled by 
methoxy-X04.  Mice ranged from 50 to 64 weeks of age.  
 
 
 
Fig. 4.S2. Plot of the fraction of capillaries with stalled blood flow in mice imaged 
while anesthetized and awake. Lines connecting data points indicate data from the same 
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animal. Animals were first trained to remain calm while head fixed and standing on a 
spherical treadmill. On the day of imaging, animals were briefly anesthetized to enable 
retro-orbital injection of Texas-Red dextran, and were then allowed to wake up. We 
imaged these animals first while awake and then while anesthetized under 1.5% 
isoflurane, with both imaging sessions occurring on the same day (n = 6 mice, no 
significant difference by Wilcoxon test).  
 
 
 
Fig. 4.S3. 2PEF imaging of cortical vasculature reveals a higher fraction of stalled 
capillaries in TgCRND8 mice as compared to wt mice.  Fraction of capillaries with 
stalled blood flow in TgCRND8 and age-matched wild type littermates (TgCRND8: 3 
mice, 3,028 capillaries; wild type: 4 mice, ~4,062 capillaries; p=0.06, Mann-Whitney). 
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Fig. 4.S4. Synthetic capillary network of order three. Capillaries are indicated in 
green, while red and blue indicate the single feeding arteriole and draining venule, 
respectively. 
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Fig. 4.S5. Characterization of capillary stall dynamics in APP/PS1 mice. (A) 
Repeated 2PEF imaging over 15 min of capillaries that were stalled at the baseline 
measurement and (top) remained stalled, (middle) began flowing and then re-stalled and 
(bottom) resolved and remained flowing. Blood plasma labeled with Texas-Red dextran 
(red) and leukocytes labeled with Rhodamine 6G (green). (B) Characterization of the fate 
of individual capillaries observed as being stalled across four image stacks taken at 
baseline and 5, 10, and 15 min later. Each row represents an individual capillary and the 
color of the box for each capillary at each time point indicates the status: flowing (grey), 
stalled with a leukocyte present (cyan), stalled with platelet aggregates present (green), 
and stalled with only RBCs (red).  
 
 
0 min 5 min 10 min 15 min
C
on
tin
uo
sl
y 
st
al
le
d
R
e-
st
al
le
d
R
es
ol
ve
d
20 um
0 min 5 min 10 min 15 min
A B
  
 
 
 
100 
 
Fig. 4.S6. Number of stalled capillaries in APP/PS1 mice dropped rapidly after α-
Ly6G administration. 2PEF image stacks were taken repeatedly over an hour after α-
Ly6G or isotype control antibody injection and the number of stalled capillaries 
determined at each time point (α-Ly6G: n=6 mice; Iso-Ctr: n=4; each mouse imaged 2 to 
6 times over the hour). 
 
 
Fig. 4.S7. Administration of antibodies against Ly6G increased the RBC flow speed 
but did not alter the diameter of cortical penetrating arterioles in APP/PS1 mice. 
(A) RBC flow speed and (B) vessel diameter after α-Ly6G or isotype control antibody 
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administration in young (3-4 months) and old (11-14 months) APP/PS1 mice and wt 
control animals shown as a fraction of baseline (young wt α-Ly6G: 5 mice, 30 arterioles; 
young APP/PS1 Iso-Ctr: 5 mice, 32 arterioles; young APP/PS1 α-Ly6G: 5 mice, 33 
arterioles; old APP/PS1 Iso-Ctr: 3 mice, 18 arterioles; old APP/PS1 α-Ly6G: 3 mice, 22 
arterioles; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, Kruskal-Wallis one-way 
ANOVA with post-hoc pair-wise comparisons using Dunn’s multiple comparison test).  
 
 
 
Fig. 4.S8. Penetrating arterioles with slower initial flow tended to increase flow 
speed more after α-Ly6G injection in APP/PS1 mice. Plot of penetrating arteriole flow 
after α-Ly6G antibody administration in young (3-4 months) and old (11-14 months) 
APP/PS1 mice shown as a fraction of baseline flow. Same data as shown in Fig. 3C.  
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Fig. 4.S9. Treating APP/PS1 mice with α-LFA-1 reduced the number of stalled 
capillaries and improved arterial blood flow after 24 hours. (A) Flow cytometry 
scatter plots for APP/PS1 mice 24 hours after injection of isotype control antibodies (left) 
or with antibodies against Lymphocyte Functional Antigen 1 (α-LFA-1; M17/4 clone, 
BD Biosciences; 4 mg/kg, retro-orbital injection). Circles depict the gate used to identify 
leukocytes. (B) Leukocyte concentration in the blood 24 hours after treatment with α-
LFA-1 or isotype control antibodies in APP/PS1 and wt mice. Leukocytes counts in the 
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gating area were decreased by 84% after α-LFA-1 as compared to the isotype control in 
APP/PS1 mice (Iso-Ctr in wt: 8 mice, Iso-Ctr in APP/PS1: 9 mice, α-LFA-1 in APP/PS1: 
7 mice; *p<0.05, ***p<0.001, Kruskal-Wallis one-way ANOVA with post-hoc pair-wise 
comparisons using Dunn’s multiple comparison test). (C and D) Fraction of capillaries 
with stalled blood flow as a function of time after a single retro-orbital treatment with 
0.9% saline (C) or α-LFA-1 antibodies (D) in APP/PS1 mice (saline: n = 6 mice; α-LFA-
1: n = 7 mice, 4 mg/kg). We observed a transient increase in the number of capillaries 
with stalled blood flow at about 1 hr after treatment in both groups. There was a 
significant decrease in the fraction of stalled capillaries 24 hours after injection in the α-
LFA-1 group. Images were collected over the same capillary bed on each imaging day, 
and the fraction of capillaries stalled was determined for each time point, with the 
analysis performed blinded to treatment day and treatment type. (E) Number of stalled 
capillaries, expressed as a fraction of the baseline number, 24 hrs after administration of 
α-LFA-1 or saline. α-LFA-1 reduced capillary stalls by 65% as compared to the saline 
control. (n = 6 mice per treatment group. **p<0.01, Mann-Whitney test). (F) Fraction of 
baseline arteriole flow in penetrating arterioles from APP/PS1 mice 24 hours after α-
LFA-1 or saline treatment. Each point represents a single arteriole in one mouse. The 
blood flow was increased after α-LFA-1 treatment by 29% compared with saline controls 
(APP/PS1 α-LFA1: 4 mice, 11 arterioles; APP/PS1 saline: 4 mice, 12 arterioles; *p<0.05, 
Mann- Whitney test).  
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Fig. 4.S10. Brain penetrating arteriole blood flow negatively correlates with the 
number of capillaries stalled in underlying capillary beds in APP/PS1 mice. To 
correlate the effect of capillary stalling on penetrating arteriole blood flow, we imaged 
the same capillaries and measured blood flow in the same penetrating arterioles in 
APP/PS1 mice multiple times before and after administration of saline, α-LFA-1, α-
Ly6G, and isotype control antibodies. For saline and α-LFA-1 animals, there were 
measurements at multiple time points over two weeks (data in Fig. S9). For α-Ly6G and 
isotype control animals there were measurements only at baseline and ~1 hr after 
administration (data in Fig. 3C and Figs. S7 and S8). For each penetrating arteriole at 
each imaged time point, we plotted the volumetric flow, expressed as a fraction of the 
baseline volumetric flow, as a function of the number of capillaries stalled at that time 
point, expressed as a fraction of the baseline number of capillaries stalled (APP/PS1 α-
LFA1: 4 mice, 11 arterioles; APP/PS1 saline: 4 mice, 12 arterioles; APP/PS1 α-Ly6G: 3 
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mice, 22 arterioles; APP/PS1 Iso-Ctr: 3 mice, 18 arterioles). These data confirm the 
sensitive dependence of penetrating arteriole blood flow on the fraction of capillaries 
with stalled flow across several different manipulations that led to either increases or 
decreases in the fraction of capillaries that are stalled. The linear regression is defined by: 
Y = -0.47 X + 1.6 (R2 = 0.2, goodness of fit test; 95% confidence interval on slope: -0.65 
– -0.29). 
 
 
Fig. 4.S11. Time spent at the replaced object in wild type controls and APP/PS1 
animals treated with α-Ly6G or isotype control antibodies. Time spent at the replaced 
object measured over 6 minutes for APP/PS1 and wt mice at baseline and at 3h and 24h 
after a single administration of α-Ly6G or isotype control antibodies, and after 4 weeks of 
treatment every three days (APP/PS1 Iso-Ctr: 10 mice; APP/PS1 α-Ly6G: 10 mice; wt 
Iso-Ctr: 11 mice; wt α-Ly6G: 11 mice; no significant differences among groups as 
determined by Kruskal-Wallis one-way ANOVA). 
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Fig. 4.S12. Number of arm entries in the Y-maze for wild type controls and 
APP/PS1 animals treated with α-Ly6G or isotype control antibodies. Number of arm 
entries in the Y-maze measured for 6 minutes for APP/PS1 and wt mice at baseline and at 
3h and 24h after a single administration of α-Ly6G or isotype control antibodies, and 
after 4 weeks of treatment every three days (APP/PS1 Iso-Ctr: 10 mice; APP/PS1 α-
Ly6G: 10 mice; wt Iso-Ctr: 11 mice; wt α-Ly6G: 11 mice; no significant differences 
among groups as determined by Kruskal-Wallis one-way ANOVA). 
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Fig. 4.S13. Balance beam walk (BBW) to measure motor coordination in wildtype 
controls and APP/PS1 animals treated with α-Ly6G or isotype control antibodies. 
(A and B) BBW time to cross on a 6- and 12-mm diameter beam, respectively, for 
APP/PS1 and wild type mice at baseline and at 3h and 24h after a single administration of 
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α-Ly6G or isotype control antibodies, and after 4 weeks of treatment every three days. 
APP/PS1 mice showed a modest trend toward taking more time to cross the 6-mm 
diameter beam as compared to wt controls. (C and D). Number of slips on the BBW for a 
6- and 12-mm diameter beam, respectively, for APP/PS1 and wild type mice at baseline 
and at 3h and 24h after a single administration of α-Ly6G or isotype control antibodies, 
and after 4 weeks of treatment every three days. For both beam diameters, APP/PS1 mice 
showed significantly more slips while crossing the beam as compared to wt animals, 
suggesting a motor deficit in the APP/PS1 mice. All animal groups showed a reduction in 
the number of slips with subsequent trials, suggesting improved motor coordination with 
practice. This improvement did not appear different between α-Ly6G and isotype control 
treated APP/PS1 mice, suggesting that increases in brain blood flow did not influence the 
motor learning underlying the reduction in the number of slips (APP/PS1 Iso-Ctr: 10 
mice; APP/PS1 α-Ly6G: 10 mice; wt Iso-Ctr: 11 mice; wt α-Ly6G: 11 mice; * p < 0.05, 
*** p < 0.001, Kruskal-Wallis one-way ANOVA with post-hoc pair-wise comparisons 
using Dunn’s multiple comparison test) 
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Fig. 4.S14. Depression-like behavior measured as immobility time in a forced swim 
test for wild type controls and APP/PS1 animals treated with α-Ly6G or isotype 
control antibodies. Immobility time in forced swim test measured over 6 minutes for 
APP/PS1 and wt mice at baseline and at 3h and 24h after a single administration of α-
Ly6G or isotype control antibodies, and after 4 weeks of treatment every three days 
(APP/PS1 Iso-Ctr: 10 mice; APP/PS1 α-Ly6G: 10 mice; wt Iso-Ctr: 11 mice; wt α-Ly6G: 
11 mice; * p < 0.05, Kruskal-Wallis one-way ANOVA with post-hoc pair-wise 
comparisons using Dunn’s multiple comparison test; p=0.06 comparison between 
baseline and 3h for APP/PS1 α-Ly6G, Wilcoxon matched-pairs signed rank test relative 
to baseline).  
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Fig. 4.S15. Treatment with α-Ly6G leads to neutrophil depletion in both APP/PS1 
and wildtype control mice. (A) Representative flow cytometry data for blood drawn 
from APP/PS1 mice 24 hours after treatment with isotype control antibodies (top row) 
and α-Ly6G (bottom row). Left column shows forward and side scattering from entire 
population of blood cells (after lysing and removing red blood cells). The second column 
shows the gate on CD45+ cells, indicating leukocytes. The third column shows 
expression of CD11b (high for monocytes and neutrophils) and Ly6G (high for 
neutrophils) for the CD45+ cells. Cells with high expression levels of both CD11b and 
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Ly6G were considered to be neutrophils (right column). (B) Neutrophil counts for 
APP/PS1 and wt mice 24 hr after treatment with α-Ly6G or isotype control antibodies 
(left) and after 4 weeks of treatment every three days (right) (24 hr data: wt Iso-Ctr: n=9 
mice; wt Ly6G: n=4; APP/PS1 Iso-Ctr: n=6; APP/PS1 Ly6G: n=7; 4 week data: wt Iso-
Ctr: n=3; wt Ly6G: n=7; APP/PS1 Iso-Ctr: n=3; APP/PS1 Ly6G: n=3; *p<0.05, 
**p<0.01, Mann-Whitney comparison between Iso-Ctr and Ly6G treated animals).  
 
 
Fig. 4.S16. Representative map of animal location and time spent at the novel object 
in wild type controls and APP/PS1 animals treated with α-Ly6G or isotype control 
antibodies. (A) Tracking of mouse nose location from video recording during training 
and trial phases of novel object recognition task taken 4 weeks after administration of α-
Ly6G or isotype control antibodies every three days in APP/PS1 mice. (B) Time spent at 
the novel object (APP/PS1 Iso-Ctr: 10 mice; APP/PS1 α-Ly6G: 10 mice; wt Iso-Ctr: 11 
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mice; wt α-Ly6G: 11 mice; no significant differences among groups as determined by 
Kruskal-Wallis one-way ANOVA).  
 
 
Fig. 4.S17. Amyloid plaque density and concentration of amyloid-beta oligomers 
were not changed in 11-month-old APP/PS1 animals treated with α-Ly6G every 
three days for a month. (A) Thioflavin-S staining of amyloid plaques in representative 
cortical sections (upper 2 panels) and hippocampal sections (lower 2 panels) for APP/PS1 
mice treated with isotype control antibodies (left panels) or α-Ly6G (right panels). (B) 
Number of amyloid plaques in the cortex (left) and hippocampus (right) for APP/PS1 
mice after one month of treatment (Iso-Ctr: 5 mice; α-Ly6G: 3 mice). (C) Percentage of 
tissue section positive for Thioflavin-S in the cortex (left) and hippocampus (right) (Iso-
Ctr: 6 mice; α-Ly6G: 3 mice). (D) ELISA measurements of Aβ aggregate concentrations 
after 4 weeks of treatment with α-Ly6G or isotype control antibodies every three days 
(Iso-Ctr: 7 mice; α-Ly6G: 6 mice).  
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Fig. 4.S18. Histogram of mouse capillary diameters from in vivo measurements and 
post-mortem vascular casts. The diameter correction described in Eq. 3 closely aligned 
the post mortem diameters to the in vivo data. 
 
 
 
Fig. 4.S19. Illustration of the pseudo-periodic boundary conditions. Vessels 
categorized as arterioles are labeled in red, venules in blue, and capillaries in green.  
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Fig. 4.S20. Validation of simulations. Spatial distribution of simulated blood flow (A), 
pressure (B), and hematocrit (C) in each vessel in the mouse vascular network. (D) 
Comparison of red blood cell velocities in capillaries in the top 300-µm of mouse cortex 
from experimental, in vivo measurements (red line), simulations with pseudo-periodic 
boundary conditions with corrected diameters (blue line), and no-flow boundary 
conditions without corrected diameters (black line). (E) Relationship between red blood 
cell speed and vessel diameter in arterioles and venules in calculations (solid red and blue 
dots) and experimental measurements (grey points).  
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Fig. 4.S21. Calculated blood flow decreases due to capillary stalls was robust with 
respect to simulation parameters. (A) Pressure changes in mouse cortical vessel 
network due to randomly placed occlusions in 2% of capillaries. The corresponding flow 
changes are shown in Fig. 1J. (B) Calculated flow changes due to the occlusion of 
varying proportions of the capillaries using the full mouse dataset (1000 µm) or truncated 
datasets (1000x300 µm) with periodic or no flow boundary conditions, and with or 
without corrected vessel diameters. Error bars represent SD across n independent 
simulations (whole domain: n=5; 300 µm slices: n=5 for each of 3 slices). 
 
4.8 SUPLEMENTARY TABLE 
Table S1: Group sizes, statistical tests, and notes for main Figure panels.  
Figure 
panel 
Groups compared Statistical tests and Notes 
 
1C, D APP/PS1: 28 mice, 
~22,400 capillaries 
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Mann-Whitney, ****p<0.0001 
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~9,600 capillaries 10-week window and the shaded areas represent 95% 
confidence intervals. 
1F APP/PS1: 7 mice 
Stalled: n ~ 120 
Flowing: n = ~ 8,700 
 
1G APP/PS1: 7 mice 
Stalled: n ~ 120 
Flowing: n = ~ 8,600 
 
1J  Error bars represent SD across for five independent 
simulations.  
2B APP/PS1: 10 mice,  
235 stalled capillaries 
Error bars represent 95% confidence intervals. 
2C Stalled: n = 116 
Flowing: n = 8,431 
Mann-Whitney, ****p<0.0001 
2D APP/PS1:  7 mice 
Stalled: n ~ 120 
Flowing: n ~ 9,000 
 
2E APP/PS1: 3 mice,  
31 capillaries 
 
2G APP/PS1:  4 mice,  
49 stalled capillaries 
followed from first 
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imaging session 
3A α-Ly6G: 6 mice, 
~4,800 capillaries 
Iso-Ctr: 6 mice, 
~4,800 capillaries 
Mann-Whitney, **p<0.01 
3C young APP/PS1 Iso-
Ctr: 5 mice, 32 
arterioles 
old APP/PS1 Iso-Ctr: 
3 mice, 18 arterioles 
young wt α-Ly6G: 5 
mice, 30 arterioles 
young APP/PS1 α-
Ly6G: 5 mice, 33 
arterioles 
old APP/PS1 α-
Ly6G:     3 mice, 22 
arterioles 
Kruskal-Wallis one-way ANOVA with post-hoc using 
Dunn’s multiple comparison correction, **p<0.01 and 
***p<0.001 
3E wt α-Ly6G: 10 mice 
APP/PS1 α-Ly6G: 10 
mice 
APP/PS1 Iso-Ctr: 10 
Ordinary one-way ANOVA with post hoc using 
Tukey’s multiple comparison correction to compare 
across groups, *p<0.05 
Paired t-test to compare baseline and after treatment 
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mice within a group, ++p<0.01 
Each data point indicates a single mouse and lines 
connecting baseline and after measurements indicate 
the same animal. 
4C, D, 
E 
APP/PS1 Iso-Ctr: 10 
mice  
APP/PS1 α-Ly6G: 10 
mice  
wt α-Ly6G: 11 mice 
wt Iso-Ctr: 11 mice 
Kruskal-Wallis one-way ANOVA with post-hoc using 
Dunn’s multiple comparison correction to compare 
across groups, *p<0.05 and **p<0.01 
Wilcoxon matched-pairs signed rank test relative to 
the baseline measurement to compare baseline and 
after treatment within a group, +p<0.05 and ++p<0.01 
4F Iso-Ctr: 6 mice
  
α-Ly6G: 7 mice 
Mann-Whitney 
**p <0.01 
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CHAPTER 5 
CEREBRAL MICROBLEEDS, CSF P-TAU, AND COGNITIVE DECLINE: 
SIGNIFICANCE OF ANATOMIC DISTRIBUTION 
 
This chapter presents an extensive analysis of the correlation between the anatomical 
location of brain microbleeds vs. CSF beta-amyloid, CSF p-tau, and longitudinal 
cognitive decline. My contribution to this manuscript was primarily in the acquisition, 
curation and initial analysis of the data obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) (adni.loni.usc.edu), drafting of the first version of the 
manuscript, and contributing to the intellectual development of the study, while Gloria 
Chiang and others completed the final data analysis and final version of the manuscript. 
While I am not the first author on this work and thus consider it a secondary contribution, 
I include the full manuscript for clarity and completeness.  
 
This work is published in American Journal of Neuroradiology. The citation is:  
Chiang GC, Cruz Hernandez JC, Kantarci K, Jack CR Jr, Weiner MW (2015) Cerebral 
microbleeds, CSF p-Tau, and cognitive decline: significance of anatomic distribution. 
AJNR Am J Neuroradiol 36:1635–41. doi:10.3174/ajnr.A4351  
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5.1 ABSTRACT 
Background and Purpose—Cerebral microbleeds are associated with aging, 
hypertension, and Alzheimer’s disease. Microbleeds in a lobar distribution are believed to 
reflect underlying amyloid angiopathy, whereas microbleeds in the deep gray matter and 
infratentorial brain are commonly seen with hypertension. However, it is unknown how 
microbleeds in either distribution are related to Alzheimer’s pathogenesis. The purpose of 
this analysis was to test whether lobar and deep gray/infratentorial microbleeds 
demonstrate differential associations with CSF beta-amyloid, CSF p-tau, and longitudinal 
cognitive decline.  
Materials and Methods—626 subjects - 151 cognitively normal, 389 with mild 
cognitive impairment, and 86 with Alzheimer’s disease - from the Alzheimer’s Disease 
Neuroimaging Initiative who had 3 Tesla MRI scans and a lumbar puncture were 
included in the analysis. The number and location of microbleeds were visually assessed. 
Associations between lobar or deep gray/infratentorial microbleeds with levels of CSF 
beta-amyloid, abnormal CSF p-tau, and longitudinal cognitive decline were assessed 
using ordinary least squares, logistic, and mixed- effects regression models, adjusting for 
covariates.  
Results—Having three or more lobar microbleeds are associated with lower levels of 
CSF beta- amyloid (p=0.001). Adjusting for CSF beta-amyloid, lobar microbleeds are 
independently associated with a higher likelihood of having an abnormal CSF p-tau level 
(p=0.004). Lobar microbleeds are associated with accelerated longitudinal cognitive 
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decline (p=0.007). Deep gray/ infratentorial microbleeds demonstrated no significant 
associations.  
Conclusion—Microbleed distribution demonstrated different associations with amyloid, 
tau, and cognition. Lobar and deep gray/infratentorial microbleeds should be considered 
separately with regards to Alzheimer’s disease pathogenesis.  
 
5.2 INTRODUCTION 
Cerebral microbleeds are common findings on gradient-echo (GRE) and susceptibility- 
weighted magnetic resonance imaging (MRI) sequences, typically associated with aging, 
hypertension, and Alzheimer’s disease (AD). Approximately 36% of people over the age 
of 80 have microbleeds, compared to only 7% of people who are 45–50 years old [1]. 
Hypertensive individuals are four times more likely than the general population to have 
microbleeds [2], particularly in association with other signs of small vessel disease, such 
as white matter hyperintensities and lacunar infarcts [3,4]. People with mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD) have microbleeds with a reported 
prevalence of 20– 43% in MCI and 18–32% in AD, compared to 0–19% in cognitively 
normal individuals [5]. In the setting of AD, microbleeds are associated with global brain 
amyloidosis, seen with increased uptake on positron emission tomography (PET) scans 
using 18F-florbetapir (PiB) [6] and decreased levels of CSF beta-amyloid [5].  
 
The anatomical distribution of microbleeds is believed to reflect their underlying 
pathology. Microbleeds located in the deep gray matter and infratentorial brain are 
typically seen in hypertensive individuals [2,7] and correspond to foci of hemosiderin 
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leakage from abnormal small blood vessels [8]. Conversely, microbleeds in the setting of 
aging and AD are typically lobar, at the cortico-subcortical junction [2,7] and correspond 
to beta-amyloid deposition along vessel walls [9], also known as amyloid angiopathy. 
However, it remains unclear whether microbleeds, either from hypertension or amyloid 
angiopathy, relate to tau pathology or cognitive changes leading to Alzheimer’s 
pathogenesis [10], independent of global brain amyloidosis.  
 
The purpose of our analysis was to determine whether the distribution of microbleeds, 
either lobar or deep gray/infratentorial, may have differential associations with 
downstream events in Alzheimer’s pathogenesis. Specifically, using data from the 
multicenter Alzheimer’s Disease Neuroimaging Initiative (ADNI) (adni.loni.usc.edu) 
[11], we tested the hypotheses that lobar microbleeds (1) are associated with brain 
amyloidosis, reflected by lower levels of CSF beta-amyloid, (2) predict the presence of 
tau pathology, adjusting for overall brain amyloidosis, and (3) predict greater longitudinal 
cognitive decline. 
 
5.3 RESULTS 
5.3.1 Subjects Characteristics 
Subject characteristics are presented in Table 5.1. Four hundred and seven of the 626 
(65%) subjects had no microbleeds, whereas 219 (35%) had at least 1 microbleed. Of the 
219 subjects with microbleeds, 192 (87%) had at least 1 lobar microbleed and 27 (12%) 
had only deep gray/infratentorial microbleeds. As expected, subjects with microbleeds 
were older in age (p<0.001) [1]. In addition, those with lobar microbleeds, either alone or 
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in combination with deep gray/infratentorial microbleeds, had a greater proportion of 
APOE4 carriers (p=0.03), which has also been previously described [1].  
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5.3.2 Having 3 or more lobar microbleeds are associated with levels of CSF Abeta, 
whereas deep gray/infratentorial microbleeds are not  
Adjusting for covariates, having at least 1 lobar microbleed was associated with greater 
brain amyloidosis, reflected by lower CSF Abeta, although this association did not reach 
statistical significance (coeff=−0.04, p=0.08). However, accounting for increasing 
numbers of microbleeds, having three (coeff=−0.30, p=0.001) or more than three 
(coeff=−0.18, p=0.001) lobar microbleeds was also associated with lower levels of CSF 
Abeta (Table 5.2). Deep gray/infratentorial microbleeds were not associated with CSF 
Abeta (p=0.60), and increasing numbers of deep gray/infratentorial microbleeds also 
were not associated with CSF Abeta (p=0.27–0.99).  
 
Table 5.2 Regression model demonstrating association between lobar microbleeds 
and CSF beta-amyloid (log- transformed)  
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Table 2
Regression model demonstrating association between lobar microbleeds and CSF beta-amyloid (log-
transformed)
CSF Abeta (log-transformed) Coefficient [95% CI] p-value
1 lobar microbleed −0.005 [−0.057, 0.047] 0.86
2 lobar microbleeds −0.029 [−0.12, 0.057] 0.51
3 lobar microbleeds −0.30 [−0.48, −0.12] 0.001
More than 3 lobar microbleeds −0.18 [−0.29, −0.071] 0.001
Age −0.007 [−0.0099, −0.0042] <0.001
Male gender −0.013 [−0.056, −0.030] 0.55
Years of education 0.004 [−0.0044, 0.012] 0.38
APOE4 −0.23 [−0.28, −0.19] <0.001
APOE2 0.059 [−0.022, 0.14] 0.15
MCI −0.078 [−0.13, −0.028] 0.002
AD −0.26 [−0.33, −0.19] <0.001
AJNR Am J Neuroradiol. Author manuscript; available in PMC 2016 September 01.
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5.3.3 Lobar microbleeds are associated with a higher likelihood of having an 
abnormal CSF p- tau level, independent of CSF Abeta. Deep gray/infratentorial 
microbleeds are not associated with abnormal CSF p-tau levels  
Using logistic regression, adjusting for the CSF Abeta level, having at least 1 lobar 
microbleed was associated with more than double the odds of having an abnormal CSF p-
tau level (p=0.004). On the other hand, having deep gray/infratentorial microbleeds was 
not associated with abnormal CSF p-tau levels (p=0.97). Unlike with CSF Abeta, no 
dose- response relationship was visualized; having one lobar microbleed was most 
associated with an abnormal CSF p-tau level, with an odds ratio of 2.8 (p=0.001) (Table 
5.3).  
 
Table 5.3 Regression model demonstrating association between lobar microbleeds 
and likelihood of abnormal CSF phosphorylated tau  
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Table 3
Regression model demo str ting association b tween lobar micr s and likelihood of abnormal CSF 
phosphorylated tau
Abnormal CSF p-tau Odds ratio [95% CI] p-value
1 lobar microbleed 2.82 [1.52, 5.24] 0.001
2 lobar microbleeds 1.24 [0.51, 3.01] 0.63
3 lobar microbleeds 0.37 [0.081, 1.73] 0.21
More than 3 microbleeds 3.19 [0.40, 25.60] 0.27
Abnormal CSF Abeta 3.40 [2.16, 5.34] <0.001
Age 1.01 [0.99, 1.04] 0.33
Male gender 0.93 [0.61, 1.42] 0.74
Years of education 0.98 [0.90, 1.06] 0.56
APOE4 2.34 [1.42, 3.84] 0.001
APOE2 1.02 [0.52, 2.02] 0.95
MCI 1.05 [0.67, 1.67] 0.83
AD 3.5 [1.15, 10.70] 0.03
AJNR Am J Neuroradiol. Author manuscript; available in PMC 2016 September 01.
  
 
 
 
132 
 
 
5.3.4 Lobar microbleeds are associated with accelerated longitudinal cognitive 
decline  
Using a linear mixed-effects model and adjusting for covariates, including CSF Abeta 
level and diagnostic group, having at least 1 lobar microbleed was significantly 
associated with accelerated longitudinal change in ADAS scores (p=0.007) of 1.4 points 
per year compared to 0.8 points per year for those without lobar microbleeds. 
Furthermore, having more than 3 lobar microbleeds was significantly associated with an 
increase of 2.3 points per year (p<0.001) (Table 5.4). Deep gray/infratentorial 
microbleeds were not associated with change in ADAS scores (p=0.31).  
 
Table 5.4 Mixed effects regression model demonstrating association between lobar 
microbleeds and longitudinal change in ADAS  
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Table 4
Mixed effects regression model demonstrating association between lobar microbleeds and longitudinal change 
in ADAS
Annual change in ADAS [95% CI] p-value
No lobar microbleeds 0.78 [0.52, 1.03] <0.001
1 lobar microbleed 1.35 [0.91, 1.78] 0.025
2 lobar microbleeds 0.36 [−0.61, 1.33] 0.41
3 lobar microbleeds 0.50 [−2.07, 3.06] 0.83
More than 3 lobar microbleeds 2.34 [1.51, 3.18] <0.001
AJNR Am J Neuroradiol. Author manuscript; available in PMC 2016 September 01.
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5.4 DISCUSSION 
The major findings of our analysis are: (1) having 3 or more lobar microbleeds are 
associated with global brain amyloidosis, whereas deep gray/infratentorial microbleeds 
are not, (2) lobar microbleeds, unlike deep gray/infratentorial microbleeds, are associated 
with elevated CSF p-tau, although without a dose-response relationship, and (3) lobar 
microbleeds, unlike deep gray/infratentorial microbleeds, are associated with accelerated 
longitudinal cognitive decline. Taken together, our analysis suggests a differential 
association of lobar versus deep gray/infratentorial microbleeds with Alzheimer’s 
pathogenesis, suggesting the importance of lobar microbleeds in prognostication, 
independent of CSF Abeta levels.  
 
The first major finding that lobar microbleeds are associated with greater overall brain 
amyloidosis is concordant with prior studies that have shown lower CSF Abeta levels 
[3,18,19] and higher uptake on PET amyloid scans [5,6] in people with microbleeds. 
Prior papers have also suggested that microbleeds that are lobar in location are more 
suggestive of underlying amyloid angiopathy [2,7,9], which is seen concomitantly in 78–
98% of Alzheimer’s disease brains postmortem [20]. The finding that only higher 
numbers of lobar microbleeds were found to be associated with CSF Abeta suggests that 
severe amyloid angiopathy is more related to overall brain amyloidosis and may 
contribute to the disease process. On the other hand, deep gray/infratentorial microbleeds, 
which are more typically associated with hypertension, were not associated with CSF 
Abeta. Prior work has also demonstrated that deep gray, not lobar, microbleeds are 
associated with small vessel disease [21]. Taken together, hypertension may produce 
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deep gray/infratentorial microbleeds and small vessel changes, but is likely involved in 
Alzheimer’s pathogenesis from a non-amyloid pathway, such as decreased cognitive 
reserve.  
 
The second major finding is that having at least 1 lobar microbleed, unlike deep gray/ 
infratentorial microbleeds, was associated with greater odds of having an abnormal level 
of CSF p-tau, adjusting for CSF Abeta levels. A recent study in a memory clinic 
population found a similar association between microbleeds and CSF total tau, but not 
CSF p-tau, in nondemented individuals [19]. The fact that they did not find an association 
between microbleeds and p-tau may reflect technical differences in the assay or the fact 
that p-tau is more specific for neurodegeneration in a cohort with more comorbid 
vascular disease. Nonetheless, both of our studies demonstrated an association between 
microbleeds and elevated levels of forms of CSF tau. One hypothesis is that microbleeds 
could reflect damaged microvasculature, resulting in decreased blood flow to neurons, 
ischemia, neuronal degeneration, and increased tau pathology. Post-mortem, p-tau does 
appear to have increased aggregation around arteries and arterioles with Abeta in the 
vessel walls [22]. Alternatively, microbleeds could induce enough inflammation, without 
duration, to cause elevated CSF p-tau. In an animal model, microhemorrhages were seen 
to trigger inflammation and activated microglia, macrophages, lymphocytes, [9,23] rather 
than cell death or ischemia. This inflammation may be sufficient to produce neuronal 
release of tau into the extracellular space. This inflammation may also contribute to 
further Alzheimer’s pathogenesis. Finally, the presence of lobar microbleeds, reflecting 
amyloid angiopathy, may suggest that the patients are farther along in the Alzheimer’s 
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disease cascade [10]. In this case, lobar microbleeds, in addition to abnormal CSF Abeta, 
may signal more severe underlying disease.  
 
The third major finding is that having at least 1 lobar microbleed is associated with 
accelerated longitudinal cognitive decline. The literature evaluating the association 
between microbleeds and cognitive decline has been variable, depending on the cohort 
studied – community-based populations [24-27], people with a history of or suspected 
stroke [28-31], or memory clinic MCI/AD subjects [3,32-36], – and whether cognition 
was being evaluated on a cross-sectional [24,28-30,32,33] or longitudinal basis 
[25,31,34-37]. The majority of these studies demonstrated an association between 
microbleeds and either global or executive impairment [3,24,26,28-30] cross-sectionally, 
as well as increased progression of memory impairment [36], greater longitudinal change 
in MMSE [34], higher likelihood of MCI conversion to AD [25], and increased risk of 
developing incident dementia [37]. One study also found cognitive improvement after 
stroke if no microbleeds were present [31], suggesting a detrimental role of microbleeds 
on cognitive recovery. However, none of these studies adjusted for concomitant 
Alzheimer’s pathology, which may have driven the longitudinal changes in cognition. In 
our study, the association between lobar microbleeds and accelerated cognitive decline 
persisted after adjusting for CSF Abeta levels, which suggests that microbleeds alone, 
perhaps reflecting underlying amyloid angiopathy, lead to cognitive impairment. This 
mirrors a postmortem study that demonstrated that moderate-to-severe amyloid 
angiopathy is associated with perceptual speed and episodic memory, even after adjusting 
for concomitant AD pathology [38]. We also found that having 3 or more lobar 
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microbleeds were more associated with decreasing cognition, similar to prior studies that 
found greater cognitive decline with 2 or more [37] or 5 or more [26]. The finding that 
deep/ infratentorial microbleeds were not associated with cognitive decline is concordant 
with a prior study [30], although differs from another study that found mixed, not strictly 
lobar microbleeds, were associated with cognitive decline [37]. The differential effect on 
cognitive decline secondary to microbleed location, again may hint at differing etiologies 
of microbleeds.  
 
Our study has several limitations. First, the ADNI is not a community sample. The cohort 
consisted of more Caucasians, was more highly educated, and had fewer comorbidities 
than a community population at this age [39]. Furthermore, ADNI subjects were included 
if they had a low Modified Hachinski score equal or less than 4, excluding people with 
more severe comorbid vascular pathologies [40]. Therefore, although we did not find a 
significant effect on hypertension-related deep gray/infratentorial microbleeds on tau 
pathology and cognition, a significant association may be found in people with more 
significant vascular disease. As a result, generalization of these findings should be 
approached with caution and further validation in prospective population-based cohorts is 
required.  
 
5.5 METHODS 
5.5.1 Subjects 
The subjects of these analyses were ADNI participants who had 3 Tesla MRI scans and a 
lumbar puncture for cerebrospinal fluid (CSF) analysis, resulting in 626 individuals - 151 
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cognitively normal, 389 with mild cognitive impairment (MCI), and 86 with AD. The 
ADNI is a longitudinal, multicenter observational cohort study designed to identify 
imaging and biochemical biomarkers for diagnosis and monitoring of AD [12]. The study 
was approved by the Institutional Review Boards of all of the participating institutions. 
Informed written consent was obtained from all participants at each site. Subjects who 
enrolled in ADNI-2 and ADNI-grand opportunity underwent a T2* GRE sequence, which 
was used to enumerate the number of microbleeds in the brain. Subjects were between 
the ages of 55 and 90, without clinical or structural evidence of a significant neurological 
or psychiatric disease, and without systemic medical illness or laboratory abnormalities 
that would interfere with follow-up. Cognitive function was assessed using the 
Alzheimer’s Disease Assessment Scale (ADAS) [13], which is the most widely used 
measure for clinical trials.  
 
The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National 
Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies, and non-profit organizations, 
as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been 
to test whether serial magnetic resonance imaging (MRI), positron emission tomography 
(PET), other biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of mild cognitive impairment (MCI) and early 
Alzheimer’s disease (AD). Determination of sensitive and specific markers of very early 
AD progression is intended to aid researchers and clinicians to develop new treatments 
and monitor their effectiveness, as well as lessen the time and cost of clinical trials. The 
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Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center 
and University of California – San Francisco. ADNI is the result of efforts of many 
coinvestigators from a broad range of academic institutions and private corporations, and 
subjects have been recruited from over 50 sites across the U.S. and Canada. The initial 
goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and 
ADNI-2. To date these three protocols have recruited over 1500 adults to participate in 
the research, consisting of cognitively normal older individuals, people with early or late 
MCI, and people with early AD. The follow up duration of each group is specified in the 
protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 
and ADNI-GO had the option to be followed in ADNI-2. For up-to-date information, see 
www.adni-info.org.  
 
5.5.2 MR Image Acquisition  
The 3 Tesla MRI protocol included T2* GRE and T1-weighted three-dimensional 
MPRAGE sequences, which have been described previously 
(http://adni.loni.usc.edu/methods/ documents/mri-protocols/). Microbleeds were 
quantified visually by a board-certified neuroradiologist with subspecialty certification 
(GCC). Microbleeds were defined as hypointense lesions within the brain parenchyma, 
measuring less than 10mm on the GRE sequence. Only microbleeds that were considered 
definite were included in the analysis.  
 
Microbleeds were visually classified by location as (1) deep gray matter/infratentorial, if 
they involved the basal ganglia, thalami, brainstem, or cerebellum, or (2) lobar, if they 
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involved other regions of the brain parenchyma.  
 
5.5.3 CSF Biomarkers  
Subjects included in this analysis underwent lumbar puncture to obtain CSF samples for 
quantifying levels of CSF beta-amyloid (Abeta) and phosphorylated tau (p-tau) [14]. 
Briefly, lumbar puncture was performed with a 20- or 24-gauge spinal needle at the 
baseline visit after an overnight fast. The CSF samples were then transferred into 
polypropylene transfer tubes, frozen on dry ice within an hour after collection, and 
shipped on dry ice overnight to a single designated laboratory. After thawing for 1 hour at 
room temperature and gentle mixing, 0.5 ml aliquots were prepared from these samples. 
The aliquots were then stored in bar code-labeled polypropylene vials at −80°C and 
measured using the xMAP Luminex platform (Luminex Corp, Austin, TX) with 
Innogenetics (INNOBIA AlzBio3, Ghent, Belgium) immunoassay kit-based reagents. 
Monoclonal antibodies specific for Abeta and p- tau were used as reagents, which have 
been found to be useful in predicting AD [15]. CSF total tau was not included in this 
analysis because this value was not available for some of the participants. In addition, p-
tau has a higher specificity and negative predictive value in ruling out the presence of AD 
with 90% probability [16]. 
 
5.5.4 APOE Genotyping 
All participants underwent APOE genotyping at the baseline visit. Approximately 6 ml of 
blood were obtained from each participant in an EDTA tube, gently mixed by inversion, 
and shipped at ambient temperature to a single designated laboratory within 24 hours of 
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collection for analysis for genotyping.  
 
5.5.5 Statistical Analysis 
All statistical analyses were programmed in STATA version 13 (StataCorp, College 
Station, TX). Comparisons of baseline variables among groups were performed using the 
Wilcoxon rank-sum test, Fisher exact test, Kruskal Wallis test, and Chi squared test, 
depending on number of groups and type and distribution of variables.  
 
To test the hypothesis that lobar microbleeds are associated with overall brain 
amyloidosis, we used ordinary least squares regression with age, gender, years of 
education, APOE2 and APOE4 status, and diagnostic group (NL, MCI, or AD) as 
covariates. CSF Abeta values were log-transformed for normality and included as the 
outcome variable. Lobar microbleeds was first dichotomized as 0 or 1, indicating 
presence or absence, and used as the predictor. The number of lobar microbleeds was 
then categorized as an ordinal variable of 0, 1, 2, 3, or greater than 3, to determine 
whether increasing numbers of lobar microbleeds were associated with greater brain 
amyloidosis, reflected by decreased CSF Abeta. The regressions were then repeated using 
deep gray/infratentorial microbleeds, categorized as dichotomous or ordinal variables, to 
differentiate between microbleeds that may be associated with hypertension and those 
associated with amyloid angiopathy.  
 
To determine whether lobar microbleeds are associated with tau pathology, we used 
logistic regression, adjusting for age, gender, years of education, APOE2 and APOE4 
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status, and diagnostic group. CSF Abeta was also included as a covariate, dichotomized 
as normal or abnormal based on the previously published cutoff of 192 pg/ml, [17] to 
determine the effect of microbleeds independent of global brain amyloidosis. We then 
dichotomized abnormal CSF p-tau using the cutoff of 23 pg/ml, [17] which was used as 
the outcome variable. Lobar versus deep gray/infratentorial microbleeds were again 
included as the predictor, either as a dichotomous or ordinal variables.  
 
To determine whether lobar microbleeds are associated with longitudinal change in 
cognition, we used a linear mixed-effects model: ADASij = (B0 + β0) + β1 MCHii + (β2 
+ β3 MCHii) tij + covariates + ɛij. ADASij represents the ADAS score of subject i at 
timepoint j, MCHi represents the presence or absence of lobar microbleeds in each 
subject, and tij represents the time interval between ADAS tests. (B0 + β0) are the 
coefficients for the random and fixed variations in baseline ADAS scores. The coefficient 
β1 represents the fixed effects of having lobar microbleeds at baseline. Finally, (β2 + β3) 
are the coefficients for time-dependent changes in ADAS scores, irrespective (β2) and 
respective (β3) of presence of microbleeds. The error term ɛij represents random noise.  
 
5.6 CONCLUSION 
The distribution of microbleeds is clinically significant because it not only suggests 
differing underlying pathology (i.e. amyloid angiopathy versus hypertension) as 
previously reported in the pathological literature, but also is associated with different 
downstream events in Alzheimer’s pathogenesis (i.e. tau and cognitive decline). Clinical 
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reports, particularly those in older individuals who are being assessed for cognitive 
decline, should report these microbleeds separately.  
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5.8 SUPPLEMENTARY MATERIALS  
Abbreviations  
CSF cerebrospinal fluid  
p-tau phosphorylated tau-181  
Abeta beta-amyloid  
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CHAPTER 6 
USE OF TETHERED ENZYMES AS A PLATFORM TECHNOLOGY FOR 
RAPID ANALYTE DETECTION 
 
This chapter presents the design and construction of a new diagnostic platform 
(biosensor), based on enzymes tethered to nanoparticles, that is able to detect, in a rapid 
and sensitive manner, the presence of stroke biomarkers such as neuron-specific enolase 
(NSE) in blood samples. My contributions to this study was in leading the in vivo 
experiments of this project, which include: surgical and stroke model preparation (Fig 
7.3A-F), blood sample collection for enolase detection (fig 7.3C-F), histological analysis 
of stroke volumes (Fig 7.3 A and B), and contributing to the intellectual guidance of the 
study, while Roy Cohen and James Lata, researchers at Travis’s lab, completed the 
design and construction of the biosensor, the experimental data taking and analysis. 
While I am not the first author on this work and thus consider it a secondary contribution, 
I include the full manuscript for clarity and completeness. 
 
This work is published in PLoS ONE. The citation is:  
 
Cohen R., et al. (2015) Use of Tethered Enzymes as a Platform Technology for Rapid 
Analyte Detection. PLoS ONE 10(11): e0142326.  
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6.1 ABSTRACT 
Background: Rapid diagnosis for time-sensitive illnesses such as stroke, cardiac arrest, 
and septic shock is essential for successful treatment. Much attention has therefore 
focused on new strategies for rapid and objective diagnosis, such as Point-of-Care Tests 
(PoCT) for blood biomarkers. Here we use a biomimicry-based approach to demonstrate 
a new diagnostic platform, based on enzymes tethered to nanoparticles (NPs). As proof of 
principle, we use oriented immobilization of pyruvate kinase (PK) and luciferase (Luc) 
on silica NPs to achieve rapid and sensitive detection of neuron-specific enolase (NSE), a 
clinically relevant biomarker for multiple diseases ranging from acute brain injuries to 
lung cancer. We hypothesize that an approach capitalizing on the speed and catalytic 
nature of enzymatic reactions would enable fast and sensitive biomarker detection, 
suitable for PoCT devices.  
Methods and findings: We performed in-vitro, animal model, and human subject 
studies. First, the efficiency of coupled enzyme activities when tethered to NPs versus 
when in solution was tested, demonstrating a highly sensitive and rapid detection of 
physiological and pathological concentrations of NSE. Next, in rat stroke models the 
enzyme-based assay was able in minutes to show a statistically significant increase in 
NSE levels in samples taken 1 hour before and 0, 1, 3 and 6 hours after occlusion of the 
distal middle cerebral artery. Finally, using the tethered enzyme assay for detection of 
NSE in samples from 20 geriatric human patients, we show that our data match well (r = 
0.815) with the current gold standard for biomarker detection, ELISA—with a major 
difference being that we achieve detection in 10 minutes as opposed to the several hours 
required for traditional ELISA.  
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Conclusions: Oriented enzyme immobilization conferred more efficient coupled activity, 
and thus higher assay sensitivity, than non-tethered enzymes. Together, our findings 
provide proof of concept for using oriented immobilization of active enzymes on NPs as 
the basis for a highly rapid and sensitive biomarker detection platform. This addresses a 
key challenge in developing a PoCT platform for time sensitive and difficult to diagnose 
pathologies.  
 
6.2 INTRODUCTION 
There is pressing need for quick and objective diagnostic technologies for both time 
sensitive and difficult to diagnose pathologies. Much attention has therefore focused on 
the identification of disease-specific peripheral biomarkers, and use of new technologies 
to improve anti- body-based detection capabilities. This interest is well justified because 
of the enormous medical, social and economic impacts of these diseases, in both 
developed and developing countries. This manuscript presents data about an alternative 
technological approach to bio- marker detection—the use of enzymes tethered to NPs. 
For proof of principle, we’ll focus on a single biomarker, NSE, that has been suggested to 
have value for diagnosing various pathologies (particularly those involving the central 
nervous system). No single biomarker is known to be sensitive and specific enough to 
diagnose a complex neural disease state. Rather, we present these data as proof of 
principle for the underlying diagnostic platform suitable for rapid detection of biomarker 
analytes.  
 
Stroke is one of the best examples of a brain disease that is both hard to diagnose and 
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time sensitive, annually affecting over 15 million people. Of these, 5 million die and an 
additional 5 million are left permanently disabled [1]. Currently, its diagnosis relies on 
neurologists to distinguish stroke from mimics using advanced imaging tests (e.g. CT, 
MRI) in order to determine whether the stroke is ischemic or hemorrhagic. If appropriate, 
thrombolytic treatment can then be initiated, but is most effective only within a short 3–4 
hour window from onset [2]. Remarkably, due to the time constraints for initiating 
effective treatment lack of prompt diagnosis for ischemic stroke results in less than 4% of 
patients in the US receiving thrombolytic therapy [3]. In addition to rapid diagnosis of 
stroke, there is growing military and civilian need for PoCT devices that provide 
objective, biomarker-based, diagnostic and prognostic information regarding traumatic 
brain injuries (TBI/concussion), and neurodegenerative disease [e.g. Alzheimer’s disease 
(AD), Parkinson’s Disease (PD)]. For these brain injuries, an objective PoCT could lead 
to interventions beginning early upon the onset of disease as well as provide a platform to 
monitor disease progression or response to therapy. From a global perspective, the 
increasing incidence of stroke in developing countries [4], the high cost and limited 
availability of health resources associated with stroke diagnosis, significantly reduces 
favorable outcomes [5].  
 
Traditional technologies for blood biomarker diagnostics include ELISA, PCR, and mass 
spectrometry (MS). However, these technologies are limited to laboratory use because 
they require sample preparation, and use of sophisticated instruments and highly trained 
technicians. Moreover, they are time and labor intensive, and are expensive [6]. Much of 
the research on detection of blood biomarkers has focused on antibody-based methods. 
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Although there has been considerable progress in the field, such as the introduction of 
lateral flow based assays, constraints due to the speed of antibody-antigen interactions, 
low sensitivity, semi-quantitative results and the complexity of associated detection 
instrumentation have thus far prevented such antibody capture methods from becoming 
the basis for a field-capable PoCT device to detect brain injuries [6].  
 
Over the last few decades, a large number of molecules have been studied for their 
potential usefulness as blood-borne biomarkers. Although no single biomarker will likely 
provide a definitive diagnosis of any disease, the glycolytic enzyme, NSE, is released 
from damaged neurons and has been suggested to be valuable for the diagnosis of various 
brain injuries [7-9]. Evidence also supports its usefulness as a prognostic indicator in 
predicting neurological outcomes of post-cardiac arrest [10] and mild TBI [11]. NSE has 
been suggested to be useful in distinguishing stroke from mimics, an important first step 
in expediting the diagnostic process [7]. In addition, it has been suggested that changes in 
serum NSE levels may indicate changes in brain morphology in AD [12]. Overall, 
changes in plasma NSE levels are of clinical significance to several of the major brain 
injuries, making it an excellent first candidate to test a new diagnostic platform 
technology.  
 
As an alternative to antibody capture, fluid phase enzymatic reactions have been used to 
detect plasma NSE by means of its enzymatic activity [13, 14]; however, in the 30 years 
since these assays were first described, to our knowledge, no related PoCT technologies 
have been reported. Semi-solid phase bioluminescence detection of NSE through its 
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binding to immuno-beads enabled high sensitivity detection [15]. However, this method 
required long serum-bead incubation times and did not tether the downstream enzymes 
(i.e. PK and Luc). Tethering enzymes has several advantages for a PoCT, such as 
concentrating the detection reaction, spatially localizing the readout, and potentially 
improving shelf life. The principle obstacle lies in maintaining enzymatic function when 
immobilizing enzymes. Immobilization often interferes with substrate binding sites 
and/or needed conformational changes [16].  
 
To overcome this obstacle, we adopted a strategy of biomimicry, inspired by the tethering 
of glycolytic enzymes to a cytoskeletal scaffold in the sperm flagellum, where they 
provide localized energy production [17,18]. We previously showed that oriented 
immobilization via genetically-encoded binding domains conferred advantages in specific 
activity versus either random adsorption or chemically-specific binding [19,20]. Here, we 
extend our previous studies [19,20] in a novel direction to generate a PoCT platform 
based on enzymes tethered to nanoparticles via biomimetic oriented immobilization 
(Tethered Enzyme Technology, TET). Our approach couples production of ATP by PK 
with activity of firefly luciferase (Luc) to generate a highly rapid and sensitive 
bioluminescent readout for the detection of NSE. As a tethering scaffold for the PoCT 
device, we employed SiO2 nanoparticles for their many positive attributes: high 
biocompatibility, low optical absorption, dispersibility, high surface area, and the ability 
to be integrated into various devices with spatial control. We hypothesized that oriented 
immobilization of PK and Luc on SiO2 NPs could provide the basis for highly rapid, 
quantitative and sensitive detection of NSE through an enzymatic cascade reaction in a 
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form suitable for use in a PoCT.  
 
6.3 RESULTS 
6.3.1 Improving couple reaction activity by immobilization of PK and Luc on NPs  
We have previously shown that oriented immobilization of the glycolytic enzymes, TPI 
and GAPDH, enhances both their individual activities as well as the activity of their 
coupled sequential reactions in comparison to enzymes tethered via chemically-specific 
but non-oriented carboxyl-amine binding [20]. To test whether this would hold true for 
the coupled sequential reactions of PK and the non-glycolytic enzyme Luc, we generated 
mammalian PK and Luc expression plasmids, each as a fusion protein with two affinity 
tags, as described in the Materials and Methods section. Each of the constructs included 
an amino-terminal silica-binding peptide sequence (Si-tag) [21,22] for immobilization of 
proteins onto SiO2 nanoparticles (Si-NPs) and a 6xHis-tag to be used for protein 
purification (Fig 6.1A, see also 6. S1).  
 
To test our hypothesis that oriented immobilization would impart an improvement on the 
specific activity of the coupled reaction (Fig 6.1B), we measured the coupled activities of 
various combinations of tethered and free PK and Luc (Fig 6.1C and 6.S2). Analysis of 
all four possible combinations revealed a significant increase in the readout signal when 
Luc was immobilized (green triangles, 3.01±0.2 fold, p<0.001) and an even larger 
increase upon immobilization of both Luc and PK (black circles, 4.25±0.12 fold, 
p<0.001). When Luc was in solution (not tethered), the coupled activity of the PK-Luc 
reaction was reduced, regardless of whether PK was in solution or tethered, suggesting 
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that having Luc in close proximity with the source of ATP production (PK) was crucial 
for increased coupled reaction efficiency.  
 
To investigate further the source of the improvement in Luc activity when tethered, we 
com- pared Luc in-solution versus immobilized. In agreement with previous findings 
[23], our measurements revealed a 10-fold average reduction in the sensitivity to ATP of 
immobilized Luc (data not shown). However, Luc tethered on the Si-NPs exhibited 
extended photon emission dynamics, with a slower decay rate when compared to the 
soluble protein (Fig. 6.S2B). The differences in the enzymatic activity of immobilized 
Luc might result from a change in diffusion resistance and/or a slowing of kinetics due to 
conformational constraints. In terms of the PK-Luc coupled reaction, the reduction in Luc 
sensitivity was most likely compensated for by the prolonged emission kinetics. For 
example, placing Luc in closer proximity to PK (such as occurs with particle packing) 
would enhance the efficiency of ATP channeling by reducing the diffusion distance and 
effective local reaction volume, thereby increasing the effective local concentration of 
ATP, and enhancing luminescence output. Additional investigations of the impacts of 
enzyme tethering/proximity can be found as supplemental material (Figs 6.S2 and 6.S4).  
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Fig 6.1. Immobilization of PK and Luc on NPs improves coupled reaction efficiency. 
A) Schematic illustration of the 6XHis-Si tag fusion constructs for PK or Luc. B) 
Schematic representation of the PK-Luc coupled reaction as used in the experiments 
described in C. C) PK and Luc coupled activity was assayed in 4 combinations as 
indicated by the color coded schematic illustrations: black- (NP-PK) + (NP-Luc), blue- 
(NP-PK) + (soluble Luc), green- (NP-Luc) + (soluble PK) or red- (soluble PK + soluble 
Luc). All combinations included equivalent amounts of PK and Luc. Maximal coupled 
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reaction efficiency, as calculated from normalizing each time point data to t0 (indicating 
the ratio of luminescence generated at each time point relative to the luminescence at the 
beginning of the reaction) and subtraction of the negative control well (no PEP, 
corresponding to the background luminescence signal), was observed when both PK and 
Luc were immobilized on NPs (each condition was tested in triplicates; data shown 
represents 3 individual experiments; AVG±STDEV).  
 
6.3.2 Improving sensitivity of enolase detection 
We next hypothesized that the increased efficiency of the immobilized coupled reactions 
might provide a sensitive and rapid luminescence based assay for detection of the 
biomarker NSE, through a 3-step coupled reaction as follows–enolase/NSE catalyzes the 
conversion of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP), PK in turn 
converts PEP and ADP to pyruvate and ATP, with the latter being used by Luc to 
generate a photon of light. We first tested this hypothesis using the non-neuronal isoform 
α-enolase (ENO). The sensitivity of the tethered enzymes (red, PK and Luc tethered 
separately to NPs) was significantly higher than that of freely diffusing enzymes (blue) 
when detecting ENO activity (Fig 6.2A). In particular, higher sensitivity of the PK-Luc 
coupled reaction was observed at lower ENO concentrations (Fig 6.2A inset).  
 
Next, we sought to determine whether the NP-PK and NP-Luc coupled reaction could 
detect physiologically relevant concentrations of human NSE (< 8.7 ± 3.9 ng/ml [24]). 
Fig 6.2B shows a representative dose response experiment where sub-physiological 
amounts of commercial human NSE were added to the reaction mixture in the presence 
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of NP-PK and NP-Luc (tethered separately). The luminescent signal generated by Luc 
was integrated over 10 minutes, showing statistically significant differences for each 
concentration of NSE. These results indicate that using immobilized PK-Luc coupled 
reactions provides sub-physiological sensitivity for NSE, at concentrations well below 
typical pathological plasma levels, with rapid detection times.  
 
 
 
Fig 6.2. Improved sensitivity for enolase detection via its enzymatic activity when 
using tethered PK and Luc. A) Comparison of the detection sensitivity for enolase 
activity (Eno) as measured by NP-PK + NP-Luc (red) vs. PK + Luc in solution (blue). 
Increasing concentrations of Eno were added to immobilized or freely diffusing enzymes 
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in reaction buffer. Luminescence was detected and integrated over 10 minutes at RT and 
plotted against Eno final unit amount (lines were added to guide the eye). The inset 
shows the ratio of the enzymes’ activities on NPs versus in solution as a function of units 
of ENO. Data presented as AVG±STDEV. B) NSE detection via PK and Luc coupled 
activity was performed as indicated in the schematic illustration (right). His-Si-PK and 
His-Si-Luc were immobilized on 500 nm NPs and mixed with reaction buffer 
supplemented with increasing concentrations of human NSE. Luminescence readout was 
normalized to t0 (first read) values and plotted as a function of time. Then, the 
luminescent signal was integrated for first 10 minutes, and a reading from the zero NSE 
well was subtracted from the collected signal. The sensitivity of the tethered enzyme 
assay was about 5 times higher than the reported average physiological NSE blood 
concentration  (8.7 ± 3.9 ng/ml [24]). P values were calculated using student’s t-test for 
comparisons between NSE concentrations; values marked with #P were calculated for 
significance when compared against 0 ng/ml NSE.  
 
6.3.3 Detection of neurons-specific enolase on in vivo stroke model 
The improved sensitivity and kinetics of NSE detection with the tethered coupled 
enzymatic reactions encouraged us to test our biomarker detection assays in the complex 
environment of blood plasma. For these experiments, we used a rat model for stroke, in 
the form of a focal stroke that was induced by clotting the distal branches of the middle 
cerebral artery (MCA).  
 
Peripheral blood samples from experimental stroke and sham-operated control rats were 
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taken 1 hour before and 0, 1, 3 and 6 hours after occlusion of distal MCA branches. 
Luminescence output was integrated over 10 minutes from the NSE-PK-Luc coupled 
reaction (PK and Luc tethered separately to NPs), but with the active NSE originating 
from the damaged/dying neurons. Stroke-induced cell death in the rats was confirmed 
with Fluoro-Jade C staining (see details in Materials and Methods section). The volume 
of brain with damaged neurons was on average 11.25±4 mm3 (n = 4, 3A) in the stroke 
animals, and 0.002±0.001 mm3 in the sham- operated controls (3B n = 4). Integrated 
luminescence values at each time point were calculated by subtracting a negative control 
reaction (lacking the NSE substrate, 2-PG) from the test reaction (that included 2-PG). 
Fig 6.3E summarizes the data collected from 10 rats (5 stroke and 5 control), showing a 
statistically significant increase in NSE levels as soon as 1 hour post-occlusion, whereas 
control rats showed no increase in plasma NSE levels (detailed time point data for each 
rat are provided in panels 3C and 3D).  
 
Next, we compared results from our tethered enzyme technology (TET) versus 
quantification of the rat NSE as obtained from a commercial ELISA kit, which is 
currently the standard detection technology. Consistent with the results from the coupled 
enzymatic assay at that same time point, the ELISA revealed a 2-fold increase in NSE 
concentration at 6 hours post stroke (Fig 6.3F). No elevation was found in non-neuronal 
isoforms of enolase (NNE) as measured using a NNE ELISA kit (data not shown), 
demonstrating that the source of enolase activity that we measured was indeed NSE. 
Importantly, while the measurements of NSE concentration using the “gold standard” 
ELISA assays took over 3 hours, the TET based assay provided results within 10 
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minutes.  
 
 
Fig 6.3. Using NP-PK and NP-Luc for rapid detection of NSE in a rat model for 
stroke. A) Fluoro Jade-C staining for measurement of damaged brain tissue volume. The 
presence and absence of FJC-labeled degenerative neurons were imaged with 
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epifluorescence under 20x magnification using filters for FITC. (a) Region with abundant 
FJC staining (bright cells) on lesioned side. (b) Region at the edge of FJC staining. (c) 
Region that is contralateral to (a) that did not show any FJC staining. Dotted line in B and 
low magnification inset indicates manually-mapped border between FJC positive and 
negative areas. B) FJC staining in control brain section. (a) and (b) are in area of 
craniotomy. C-D) Individual rat data (C-stroke and D-control) for NSE measurements at 
each time point (grayscale lines indicate data points for individual animals, line with 
symbol indicates the mean±standard deviation) as performed by tethered PK and Luc 
assay, and normalized to time point -1 hour. Plasma samples were collected from stroke 
induced or control rats pre (-1 hr), and post occlusion (0, 1, 3 and 6 hr). The mean slope 
of the trend (dashed line) was calculated averaging individual slopes in each group 
(stroke = 0.26 with 0.95 confidence interval, control = -0.02 with 0.38 confidence 
interval). E) Summary of rat stroke model experiments showing a statistically significant 
increase in NSE plasma levels in stroke (blue bars) vs. control (red bars) rats as soon as 1 
hour post occlusion. F) Measurements of NSE in plasma from rats using ELISA showed 
elevated levels in stroke compared to control rats at the last time point (6 hr post-
occlusion). P values– 0.05<*<0.1, 0.01<**<0.05. Data from 10 rats were included in our 
analysis, with the exclusion of 3 hour and 6 hour time points for one control animal that 
died (at 2 hour mark), and a 6 hour time point for a stroke animal which died and was 
found to have a large hemorrhage at the base of the brain.  
 
6.3.4 Rapid detection of neurons-specific enolase on human samples 
Moving forward from an animal model, we next tested TET’s ability to detect NSE in the 
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even less defined environment of human plasma. Blood samples were collected from 
consenting patients seen at the Central New York Alzheimer’s Disease Assistance Center 
(ADAC) at SUNY Upstate Medical University using Na-Heparin tubes. Plasma was then 
divided with a portion of the sample tested immediately using TET and the rest frozen at 
-80°C for later confirmation via commercial ELISA. We ran this experiment using TET 
in the form of a first generation PoCT technology for human NSE testing. Namely, 
reactions were designed to work with minimal plasma volume in white 96 well plates in 
which all test and control reaction components had been lyophilized. 10 µl of freshly 
collected plasma was added into pre-loaded wells and the light output was measured with 
a conventional plate reader. TET reaction reading was completed within 10 minutes from 
the addition of plasma to the pre-loaded wells, where each test included triplicate 
negative control wells (reaction lacking 2PG), positive control wells (pre-loaded with 
enolase) and test wells, so that a total of 90 µl of plasma was used for each subject tested 
(a volume able to be obtained from less than 4 drops of blood). Importantly, using a 
positive control reaction including known amounts of spiked Eno, allowed us to 
normalize the data between experiments and minimize any variabilities that might arise 
from batch to batch differences in enzyme activity. To validate the accuracy of the TET 
results (representative data shown in Fig 6.4A), plasma samples were sent for lab testing 
(ARUP labs, Salt Lake City, UT). Using a Pearson’s correlation test, we compared TET 
and ELISA data finding a significant correlation of 0.81 between the two approaches (Fig 
6.4B).  
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Fig 6.4. Using the tethered enzyme assay for rapid detection of NSE in human 
subjects. A) Representative data as measured from a total of nine wells per subject 
(triplicate measurements of negative control with no 2PG; the test sample with 2PG; and 
positive control wells with 2PG and enolase (Eno); mean ±STDEV) For calculation of 
NSE levels, slopes of averaged curves were calculated for the first 0.5–10 minutes of the 
enzymatic reactions (indicated by the red linear fit in between the dashed lines), then test 
wells were normalized to positive and negative wells (see methods section). B) High 
correlation was found between NSE measurements by ELISA (ng/ml) vs. TET assay (AU 
represents the normalization of test reaction to the negative and positive reactions, as 
illustrated in A and described in the methods section) as of the human plasma samples. 
Line indicates best fit. Pearson’s r = 0.815, n = 20.  
 
6.4 DISCUSSION 
Our results suggest that enzymes tethered via oriented immobilization can provide a 
PoCT platform enabling simple, rapid and objective testing for biomarkers associated 
with hard to diagnose and time sensitive diseases. We focused on NSE for this proof of 
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concept because it has been shown to convey clinically relevant information for several 
brain injuries and cancers.  
 
Immobilized enzymes present several important advantages for medical applications 
including stability and spatial organization in a device, whether with a microfluidic card 
or paper chromatography. Of note, our data show that oriented enzyme immobilization 
also significantly improved the efficiency with which coupled enzymatic reactions 
occurred. This is of special importance because use of coupled enzymatic reactions 
allows signal amplification at both the stages of biomarker detection and transduction of 
signal into the luminescent readout. When combined with the inherently enhanced 
sensitivity and speed of catalytic activity, tethered enzymes provide some of the highly 
desired features expected from a PoCT diagnostic platform. Demonstrating their 
suitability for this purpose, we showed in vitro the advantages of using tethered versus 
soluble enzymes. We showed that TET-based systems could detect physiologically and 
pathologically relevant concentrations. Importantly, the immobilized enzyme-based 
detection system provided an ultra-rapid analysis (i.e. within 10 minutes) even when 
using plasma samples obtained from rat stroke models or human patients.  
 
The high correlation between ELISA and TET suggests circulating NSE enzymatic 
activity corresponds very well with the amount of protein. This comparison between TET 
and ELISA in detection of NSE raises another important finding regarding the dynamic 
range for detection provided by these two methods. Whereas the ELISA method provides 
a linear detection range, the enzyme-based assay offers close to a 2-fold larger dynamic 
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range (as defined by the difference between the smallest and largest usable signal, and 
calculated from the max to min values for each assay). Along with the increased assay 
speed (minutes for TET vs. hours for ELISA), minimal user effort (TET is a “mix and 
test” assay, while ELISA requires multiple wash steps), this finding revealing the 
increased sensitivity of TET versus antibody capture techniques pro- vides another 
feature contributing to the improvements of TET over ELISA.  
 
One potential criticism of use of tethered enzymes is that the range of biomarkers able to 
be detected through enzymatic reactions represents a limited subset of target analytes. 
However, there are numerous biomarkers with bona fide enzymatic activity (e.g. 
nucleoside diphosphate kinase A; NDKA [25], and phosphoglycerate mutase; PGM [26]), 
or are modulators of enzyme activity (e.g. calcium [27], magnesium [28]), or are 
substrates and metabolites of enzymatic reactions (e.g. glutamate and glucose [29]). 
Currently, no single biomarker, including NSE, can accurately and definitively diagnose 
any disease. Therefore, we are designing and testing TET- based approaches for multiple 
classes of target analytes, beyond enzymes. This will allow us to simultaneously quantify 
suites of biomarkers, significantly increasing the accuracy and robust- ness of the 
diagnostic test.  
 
Together, our data support further investigations of enzymes tethered to NPs via oriented 
immobilization in PoCT diagnostics. The advantages of spatial control of enzyme 
activities, and rapid and sensitive detection with signal amplification at both detection 
and transduction into luminescence output, combine to make TET a highly attractive 
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alternative to antibody- based detection. These attributes are especially attractive for 
integrating TET into a PoCT technology for use by paramedics, athletic trainers and in 
the field. In terms of lack of need for excitation, low power requirements, and potential 
telemedicine capability, this technology is potentially game-changing for health care 
management in rural areas and developing countries.  
 
6.5 METHODS 
6.5.1 Ethics Statement  
All research involving human participants (including consent forms and procedure) was 
approved by Cornell (#1410005002) and SUNY Upstate (#623458–5) IRBs. Written and 
verbal consent were obtained from participating subjects or health care surrogates and 
documented according to best practices. Samples were given de-identifying codes to 
ensure participant confidentiality. All animal procedures were reviewed and approved by 
the Cornell University Institutional Care and Use Committee (#2009–0043) and were 
conducted in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals (published by NIH).  
 
6.5.2 Experimental Design  
The aim of this study was to explore the advantages of utilizing enzymes tethered via 
oriented immobilization in the detection of NSE, a neuronal injury biomarker, towards 
development of a PoCT technology for time sensitive illnesses.  
The study was designed to follow 3 successive stages: (i) Test the enzyme-based assay in 
vitro to examine the effects of oriented enzyme immobilization on the sensitivity and 
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efficiency of the solid phase vs fluid phase reaction. (ii) Test the tethered enzyme assay in 
plasma from a rat stroke model. Here, to simulate stroke, 2 groups of rats underwent 
craniotomy under anesthesia, and branches of the MCA were cauterized in the test group. 
Peripheral blood samples were drawn over a time period of 6 hours to monitor changes in 
NSE level. Finally, the changes in NSE levels as measured with TET were compared to 
those obtained with ELISA. (iii) Use pre-filled 96 well plates in a comparative analysis of 
NSE plasma levels in samples taken from human subjects and measured by both the solid 
phase TET reaction and ELISA.  
 
6.5.3 Reagents  
Enliten ATP detection kit was purchased from Promega (Madison, WI). 2-PG, PEP, 
ADP, ATP, luciferin, PK antibody, NSE, and yeast α-enolase were from Sigma (St. 
Louis, MO). pcDNA4/HisMax TOPO TA vector was from Invitrogen (Carlsbad, CA). Si-
NPs (500 nm) were purchased from Spherotech Inc. (Lake Forest, IL).  
 
6.5.4 Construction of His-Si4 fusion proteins  
The complementary deoxyribonucleic acid (cDNA) of PK was obtained by reverse-
transcription polymerase chain reaction (RT-PCR) from mouse muscle RNA. The Luc2 
sequence was amplified from the Luciferase2 plasmid, Promega (Madison, WI). His-PK 
and His-Luc were generated by TA cloning of PK and Luc into pcDNA4/HisMax TOPO 
TA. To generate the His-Si4 vector, two complementary oligonucleotides (Integrated 
DNA Technologies, Inc. USA) encoding the Si4 sequence [22] with overhanging A were 
hybridized and cloned into the TA site of the pcDNA4/HisMax TOPO TA plasmid, 
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followed by restriction/ligation of PCR fragments of PK and Luc to make His-Si4-
plasmids. Subsequently, the Si4-PK and Si4-Luc sequences were amplified by PCR and 
inserted into pcDNA3.1 to make Si4-PK and Si4-Luc. Constructs were validated by 
sequencing and amplified in TOP10 cells and then purified.  
 
6.5.5 Protein expression and purification  
HEK293-F-FreeStyle cells (Invitrogen, Grand Island, NY) were transfected with 
plasmids encoding His, His-Si4 or Si4 fusion proteins using the Freestyle MAX reagent 
(Invitrogen, Grand Island, NY) and incubated for 24–72 hrs in 8% CO2. Cells were 
harvested and lysed by sonication (Sonifier 250, Branson, Danbury, CT). His-tag or His-
Si4 fusion proteins were purified on Ni/NTA beads as previously described [30], with the 
exception that the Si4 tag was used to immobilize PK on silica NPs directly from the cell 
lysate (Figs. 6.S1D and 6.S1E), providing a fast and simpler purification process.  
 
6.5.6 Enzymatic activity assays  
Enzyme activities for both single and coupled reactions were assessed via luminescence 
output, in sodium phosphate buffer (50 mM) supplemented with MgCl2 (5 mM) and KCl 
(20 mM). The forward reaction for PK is: PEP + ADP ! pyruvate + ATP. The forward 
reaction for Luc is: ATP + luciferin + Mg2+ ! hν. The PK and Luc coupled reaction is: 
PEP + ADP ! pyruvate + ATP + luciferin ! hν. All experiments were carried out in 96-
well black or white plates at room temperature. Purified or immobilized PK was mixed 
with Enliten luciferase/luciferin reagent in addition to ADP and PEP as indicated for 
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individual experiments. Purified or immobilized Luc was mixed with luciferin, Mg2+, 
K+ and ATP as indicated in individual experiments and activity was monitored by means 
of light emission as detected by a luminometer (GloMax, Promega, Madison, WI), where 
the luminescence signal was integrated for 3 seconds every minute for up to 50 minutes, 
as indicated per each experiment. To assess the activity of the coupled reactions, PK and 
luciferase were mixed as indicated above, with luciferin, ADP and PEP, and light 
emission was measured by luminescence. To maximize enzyme activity per NP, protein 
was added in saturating amounts to the NPs [31]. Data processing and analysis were 
carried out using Excel (Microsoft) and Origin (Origin Lab, Northampton, MA). In 
experiments with internal repetitions, data are presented as average ± standard deviation. 
Otherwise, representative experiments are shown that were repeated independently at 
least three times with similar results.  
 
6.5.7 Detection of NSE in rat stroke model  
Surgery and occlusion. Male Sprague-Dawley rats (Charles River, Wilmington, MA) 
with average weight 400 g (std. dev. 83 g, range 260–530 g) were used in these 
experiments. Only males were used, to eliminate potentially confounding effects from the 
stage of estrus cycle. Animals were anesthetized with 5% isoflurane in oxygen and were 
maintained on 1.3–2.0% isoflurane. Anesthesia was adjusted to maintain both constant 
breathing rate of ~1 Hz, measured manually, and suppression of pedal withdrawal reflex. 
Rats were free breathing. In previous work [32], we have found that with these 
parameters it is not necessary to artificially ventilate animals for consistent cortical blood 
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flow. Body temperature was maintained at 37.5°C with a feedback controlled rectal 
thermometer. Glycopyrrolate (50 mg/100 g rat) was injected intra- muscularly to suppress 
fluid buildup in the lungs. Rats were placed in a stereotaxic device and incision locations 
were shaved, cleaned and injected with bupivacaine (0.125%, s.c.) for analgesia. The 
femoral artery was catheterized with PE 50 tubing for arterial blood draws. The skin and 
muscle on the right side of the skull were retracted, and a craniotomy was drilled from 
the temporal bone to just above the zygomatic arch. The dura was reflected. In 
experimental stroke animals, branches of the MCA were cauterized at both the entry and 
exit points from the field of view so that there was no flow visible in the exposed 
branches of the MCA. In sham animals no cauterization was used. The occlusion 
procedure took approximately 15 minutes, with time 0 recorded at the end of the 
occlusion procedure. The occlusions were visually checked every 15 minutes to ensure 
that the clots remained. In a few animals, some vessels became patent within the first 
hour and were re-cauterized. Experiments were conducted in matched pairs of sham 
animals and stroke animals. Blood (0.5 ml) was drawn at 1 hour before occlusion (or 
sham), and after 0, 1, 3 and 6 hours post occlusion. In order to avoid dilution, flushing of 
the catheter was minimized. Fluids were replenished by subcutaneous injection of 0.5 ml 
of 5% glucose after every blood collection.  
 
After the last blood draw, animals were overdosed with pentobarbital. Chest cavities were 
opened before the heartbeat ceased and in some cases blood was drawn from a ventricular 
cardiac puncture. Animals were intracardially perfused with ~150 ml PBS and 300 mL 
4% paraformaldehyde in PBS. Heads were stored in paraformaldehyde. Images were 
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taken of each brain after extraction and before sectioning.  
 
Fluoro-Jade C Staining. Brains were harvested and cryoprotected in 30% sucrose and 
then 60% sucrose for at least 24 hour each. Brains were frozen and cut into coronal, 45-
µm sections on a cryotome. For Fluoro-Jade C (FJC; Millipore) staining, sections were 
washed in 80% EtOH in 1% NaOH for five minutes, 70% EtOH for 2 minutes, and 
0.06% KMnO4 for 10 minutes. Sections were then incubated in the solution of 0.00015% 
of FJC solution (1:100 stock, according to manufacturer’s instructions, dissolved in 0.1% 
of acetic acid) for 20 minutes. Sections were then washed with distilled water 3 times, for 
1 minute each, at which time the slides were dried for 5 minutes and put into xylene 
solution for 5 minutes. Last, slides were dried for an hour and coverslipped with 
Permount (Electron Microscopy Sciences). Initially, FJC staining was performed at 1 mm 
spacing throughout the brain. After the most anterior and posterior sections with FJC 
staining were identified, additional sections were stained to resolve the stroke volume 
with 200–300 µm spacing.  
 
Measurement of rat brain infarct volume and torn tissue area. Low magnification 
white light images of the entire section were photographed under a stereoscope. FJC 
staining was imaged with epifluorescence under 20x magnification using filters for FITC. 
The area labeled with FJC was manually identified by a person blinded to the treatment 
and marked on the low magnification, white light images of whole brain sections using 
ImageJ. For figures, images were normalized by calculating the mean and standard 
deviation of manually selected back- ground region and then setting the minimum 
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intensity to 4.2 x standard deviation below the mean, and maximum intensity to 7.2 x 
standard deviation above the mean. Total FJC volume was obtained by multiplying each 
section’s infarct area by the distance between sections.  
 
In some sections, a part of tissue was torn in the stroke region. To compensate for 
missing tissue volume, the torn tissue area was obtained by subtracting the area of the 
ipsilateral from the contralateral side as calculated from the low magnification images. 
The volume of torn tis- sue was obtained by multiplying each section’s missing tissue by 
the distance between sections. The torn tissue volume was then added to the FJC volume 
to calculate the total stroke volume.  
 
Measurements of NSE activity and quantification by ELISA. Plasma was separated 
from whole blood samples using CAPIJECT Micro Collection Tubes (Terumo Medical 
Corporation, Somerset NJ). 50 µl samples of plasma were added to individual wells in a 
96-well plate, and reaction mix was added just before luminescence measurements were 
initiated (GloMax, Pro- mega). Reaction mixtures included 1:1 ratio of NP-PK and NP-
Luc, with equal mass amounts of enzyme bound to the NPs, resulting in roughly a 2:1 
ratio of Luc to PK molecules. To minimize batch-to-batch differences in repeat 
experiments, the amounts of the NP-PK and the NP-Luc to be added was based on their 
individual activities. In this way, the relative activities of each enzyme were kept constant 
among experiments with different batches of protein. Luminescence signal was integrated 
for 3 seconds, every minute for 50 minutes. Control wells (-2PG) were then subtracted 
from the raw data and LU were integrated over the first 20 minutes of the measurements. 
  
 
 
 
175 
Integrated LU values of each time point were then normalized to t (-1 hour).  
 
Rat NSE was quantified using an ELISA Kit, (R&D Systems, Inc., Minneapolis, MN) 
according to the manufacturer’s directions. Non-Neuronal Enolase (NNE) was also 
detected using ELISA Kit, (antibodies-online.com, Atlanta, GA) according to 
manufacturer’s directions. Assays were read using an Infinite M200Pro microplate reader 
(Tecan Trading AG, Maennedorf, Switzerland) and Magellan software (Tecan Austria 
GmbH, Grödig/Salzburg, Austria).  
 
6.5.8 Detection of NSE in blood samples from human subjects  
Plasma sample collection. 5 ml of blood was collected from enrolled subjects into Na- 
heparin 6 ml tubes. Tubes were spun at 1000 g for 5 minutes and then plasma was 
aspirated and placed over ice. Samples were divided and aliquots frozen for later analysis 
as indicated.  
 
6.5.9 Detection of NSE in plasma samples from human subjects. 10 µl of freshly 
collected plasma was diluted with 10 µl of water and added to individual wells of a 96-
well plate pre- loaded with lyophilized TET reagent mixtures for negative, test and 
positive control wells (in triplicates). The readout luminescence signal was integrated for 
0.4 seconds, and read continuously for 25 minutes using a TECAN Safire plate reader. 
For calculation of NSE levels, the linear regression slope for the initial activity was 
calculated per each well. Then, control wells (-2PG) were subtracted from the test 
channel and normalized to the positive control well (with 2-PG and enolase). Positive 
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control reactions allowed us to normalize the results to reduce batch to batch variability. 
Plasma samples were sent for further analysis to ARUP laboratories (Salt Lake City, UT). 
Variability for PK and Luc activity between batches was addressed by preparing mixtures 
of the enzymes with equal activity rather than adding equal amounts of each protein.  
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6.7 SUPPLEMENTARY MATERIALS 
 
 
Fig. 6.S1 Construction and expression of PK-affinity tag fusion constructs. A) 
Schematic illustration of fusion PK constructs indicating location of the His and Si4 
peptide sequences. Three fusion plasmids were constructed for PK–His-PK, His-Si-PK 
and Si-PK. B) HEK-293 cells were transfected with each of the 3 plasmids. 3 days later, 
cell lysates were separated by SDS-PAGE and then immunoblotted for PK expression, 
where His-PK showed highest expression level. C) His-PK and His-Si-PK were purified 
(using the His-tag, see methods section) and tested for their specific activity when not 
tethered. Protein concentrations were determined with the Micro-BCA assay (Pierce, 
Rockford, IL), and purity of the samples was analyzed by SDS-PAGE and 
immunoblotting. D) Immunoblot (top) and quantification (bottom) of protein bound to 
500 nm SiO2 NPs following incubation with whole cell lysates of His-PK, His-Si4-PK or 
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Si4-PK expressing cells. This comparison shows that the Si tag increases >2 fold the 
amount of protein bound to SiO2 NPs. E) The activity of His-PK, His-Si4-PK or Si4-PK 
fusion proteins was measured when immobilized on SiO2 NPs following incubation of 
whole cell lysates with the 500 nm NPs. Oriented immobilization through the Si tag of 
His-Si-PK (blue squares) and Si-PK (red circles) results in comparable initial reaction 
rates, while His-PK lacking the SiO2 affinity tag reveals a slower activity rate most likely 
due to its non-specific adsorption to the NPs.  
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Fig. 6.S2 Supplementary analysis for PK-Luc coupled reaction as shown in Fig 6.1. 
A) PK and Luc coupled activity was assayed in 4 combinations: (NP-PK) + (NP-Luc), 
(NP-PK) + (soluble Luc), (NP-Luc) + (soluble PK) or (soluble PK + soluble Luc). 
Luminescence output was measured for each combination with and without PEP, as 
indicated by the colored symbols. All combinations included equivalent amounts of PK 
and Luc. Here, coupled efficiency was calculated using the analysis as used in Fig 6.5, 
calculated by subtracting the negative reaction (-PEP) from positive reactions (+PEP) 
slopes (indicated by solid lines). B) Summary of data presented in A, shows that having 
both PK and Luc on NPs (black) facilitates reaction rates compared to other 
combinations. Each condition was tested in triplicates; data shown represents 3 individual 
experiments; AVG±STDEV.  
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Fig. 6.S3 Determining the activity of His-Si4-Luc immobilized on silica NP’s. A) 
Schematic representation of experimental setup in the luciferase activity assay. B) 
Representative traces showing the activity of Luc measured when immobilized on silica 
NPs (blue dots), or in solution (square) with various ATP concentrations. For these 
experiments, the luminescent signal was normalized against LU at time point 0, and 
plotted as a function of time, demonstrating a significantly slower decay time for Luc 
when tethered.  
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Fig. 6.S4 Co-immobilization of PK and Luc on single NPs reduced reaction 
efficiency when ADP was limiting. A) To investigate the effect of enzyme proximity on 
coupled activity more directly, His-Si-PK and His-Si-Luc were immobilized on 500 nm 
silica NPs separately (black) or together (red). Luminescence signal in the presence of 
0.2, 2 or 6 mM ADP was normalized to t (0 min) and plotted against time (all other 
conditions/substrates were kept the same). B) Surprisingly, we found the activity of the 
coupled reactions to be significantly reduced when the enzymes were co-tethered on 
single particles versus tethered on separate particles. There are multiple possible 
explanations for this finding, ranging from steric hindrance between the two proteins 
when co-tethered, to interference by Luc with PK tetramers, to a competition between the 
enzymes for interaction with ADP [33, 34]. Such competition would reduce substrate 
availability for PK, resulting in overall reduced luminescence. To distinguish between 
these possibilities, we repeated the experiment with increased concentrations of ADP, 
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and found that 10-fold excess or more of ADP reversed the reduction in activity (middle 
and right panels), suggesting that competition for ADP was largely responsible.  
 
 
Fig. 6.S5 Testing various ratios of PK and Luc in coupled reactions to detect 
Enolase. A and B) Representative traces showing the luminescence output signal as 
measured for 3 ratios of PK and Luc on NPs (A) or in solution (B) in coupled reactions to 
detect Eno (PK:Luc ratios as follows- blue squares- 2:1, red triangles- 1:1, black circles 
1:2; filled markers represent reaction with Eno, empty markers represent no Eno). C and 
D) average slopes for reaction as presented in A and B (blue bars–no Eno, red bars with 
Eno, AVG±STDEV). E and F) the calculated signal to background ratio for the 3 
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different ratios of PK:Luc when tethered (E) or in solution (F). Each ratio was tested in 
triplicate; AVG±STDEV.  
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CHAPTER 7 
THE DEVELOPMENT OF A MIDDLE SCHOOL SCIENCE CURRICULUM TO 
FURTHER DEVELOP THE UNDERSTANDING OF ENGINEERING AND 
PHYSICS APPROACHES TO SOLVING BIOLOGICAL PROBLEMS 
 
This chapter presents two main parts, the first one is the design and development of a 
middle school biological science curriculum, which explain the concepts of 
inflammation, Alzheimer’s disease, plugging phenomena and blood flow in the brain of 
healthy and disease states. In the second part, this chapter presents an unpublished 
educational manuscript, which introduces the concepts of fluorescence and collateral 
transport to the students. The second part of this chapter has been coauthored with 
Amanda Bares, another graduate student, and an identical version of this chapter appears 
in her thesis. In the second part of the chapter, we had the students use an oak leaf to 
study what happens to transport when collateral pathways are and are not present after an 
injury. We then translated this idea over to the human cerebral vasculature and discussed 
some of the research that was being conducted in SN lab. The writing style in this chapter 
diverges from the rest of the chapters as it is meant to help motivate and guide middle 
school teachers to replicate this activity in their classroom.  
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PART I: Modeling of brain capillary network and leukocyte capillary plugging  
 
7.1 ABSTRACT 
We have developed a module to help middle school students apply their quantitative 
approaches and physics knowledge to solve biological questions. The specific goal of this 
activity was understand and simulate how blood flow at the normal conditions differs 
from blood flow under brain inflammation or microstrokes. In order to achieve these 
goals, we had the students construct a vascular network similar to the capillary network 
in the brain to study what happens to the flow when one or multiple components of the 
network get obstructed. We then translated this idea over to the brain capillary network 
and discussed some our research that was being conducted in our lab. An evaluation of 
the curriculum in the form of a lab report and survey, yielded an increase in 
understanding of concepts in biology and physics as well as how these two fields can be 
applied into the biomedical research. The writing style in the first part of this chapter 
diverges from the rest of the chapters as it is meant to help motivate and guide middle 
school teachers to replicate this activity in their classroom.  
 
7.2 INTRODUCTION 
The microvasculature system (the portion of the circulatory system composed of the 
smallest vessels, such as the capillaries, arterioles, and venules) (Fig. 7.1) is comprised a 
series of feeder vessels and networks with extensive redundant connections 1. Normal 
brain function is completely dependent of adequate level of blood flow, since the brain 
energy usually comes from oxygen-dependent metabolism (i.e., blood sugar). To 
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maintain the adequate blood flow, the brain has extensive inter-connections between 
capillaries to provide a high surface area for gases and nutrients exchange. In addition, if 
there is a potentially adverse event (strokes, microhemorrhages, atherosclerosis, etc.) that 
can cause miss-function in any of these vessels (i.e. a blood clot, stalls, ischemia, etc.) the 
redundancy of this microvasculature network allows blood flow to be redistributed with 
minimal damage to the brain (Fig 7.2) 2. As a result the obstruction or malfunction of one 
of the capillaries would expect a reroute of flow to the neighboring capillary, a change in 
pressure and eventually blood flow velocity across the microvasculature network. 
 
We present an inquiry-based activity that was recently taught to a seventh- grade class.  
The purpose of this lab was to develop an understanding of how engineering and physics 
is involved in science such as neurobiology and behavior. To initiate this activity, 
students will first learn about optics and how new advances in imaging allow us to 
perform in vivo experiments and study the progression of diseases at cellular level.  In 
addition student learn about the main pathological condition present in dementia and 
other neurodiseases, and finally the students were invited to perform the experiments. By 
conducting these experiments, students will strengthen their understanding of scientific 
inquiry, including further development of their ability to generate and test hypotheses.  
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Figure 7.1 Branching of a typical microvasculature showing the inter connection 
between the capillaries network. 
 
 
Figure 7.2 Loops in surface arterial network provide collateral flow. Case study 
highlighting the importance of vascular loops following a vessel occlusion. For baseline 
and post-clot examples, the left panels are magnified fluorescence images of the surface 
vasculature, with an arterial network outlined. Right panels show the network schematics 
with blood flow speeds in the vessels of interest, with arrows indicating direction of 
blood flow. Note that after optochemically inducing a clot (red X under post-clot), blood 
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flow does not stop, but is maintained through the reversal of flow in two vessels (red 
arrows and values). These redundant loops help support collateral flow and minimize the 
pathological effects associated with a blocked vessel2. 
 
7.3 LESSONS 
We split this activity into two separate lessons, with students working in groups of four or 
five. In the first section, an open- class discussion was held to explain the main concepts 
of optics and flow in biology how this lab is analogous to flow in the brain and 
physiological consequences that may arise from complications in blood flow (45 
minutes). Second, the experiment was performed, they create a vascular system to help 
flow transport network and understand the significance of collateral loops (~1 hour).  
 
7.4 LABORATTORY COMPONENTS 
The implementation of the lab took place in the biological science teaching classrom at 
Boynton Middle School in Ithaca, NY . Students were asked to build a network of serial 
and parallel connecting tubes in which bead solution can flow through. Students were 
asked to draw a schematic of the network and measure the dimensions of each segment of 
tubing for future analysis. Finally, the students were asked to hypothesize the flow 
direction of the bead solution through the network of tubing before and after a blockage 
in one of the channels in the tube. Figure 7.3 shows a schematic network and the pre-
modeling system analogous to the vasculature in the brain made during the lab.  
 
Students then connected their network of tubes to a syringe pump or peristaltic pump 
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containing bead solution. The bead solution was set to flow at a constant flow rate while 
the students measured the time it took for beads to travel a given distance, yielding 
velocity, using screen projector.  
 
Once velocity measurements were taken for all tube segments in the network, students 
were asked to block a segment to study the rearrangement and distribution of flow after 
blockage. Students blocked a segment then repeated velocity measurements as described 
above for each segment of the network.  
 
 
Figure 7.3 Schematic of vascular network. (A) Network design. (B) Pre-modeling 
system (tubing, connectors, clamps and beads). 
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7.5 MATERIALS AND METHODS 
7.5.1 Materials: 
• Flexible tygon tubing (Cat# EW-95665-09, Cole Parmer) 
• Connectors (Cat# ZW-30726-01, Cole Parmer) 
• Necklace spherical beads (local store) 
• Roller clamps (Cat# LRC001, Europlaz) 
• Peristaltic pump (Cat# 50220, Studica) 
 
7.5.2 Procedure: 
Students will design and assemble a simple network using Tygon tubing, connectors and 
roller clamp. They will predict the flow pattern/ direction of bead flow, and which 
channels have faster or slower beads. They should record their predictions. They will 
pump in a bead solution (beads + water + red colorant) at a constant flow rate and watch 
the flow profile in each tube “channel”. This will verify their predictions. 
 
They will then block a channel and predict a new flow profile and velocity of beads. 
They will measure the velocity of the beads in the blocked network.  
 
1. Draw a schematic of your network and hypothesize the network flow before and after 
a block in one of the channels. 
2.  Use the tubing, connectors and roller clamps and create your own network.  
3. Connect your model to the peristaltic pump. Set the peristaltic pump to constant flow 
rate until the solution (water + red colorant) fills the entire network.  
  
 
 
 
196 
4. Fill the main channel of the system with bead solution. Seal your system and connect 
it to the peristaltic pump. 
5. Connect the computer to the projector and put your system under the computer 
camera. 
6. Look at the projection of the channels and make sure you can visualize the beads. If 
the beads are moving too fast, decrease the flow rate. 
7. You are expected to measure the velocity of the beads in each channel; some channels 
may have similar velocities. 
8. Measure velocity by counting the number of beads that pass through a channel over a 
given amount of time. Or the time it takes for 1 bead to pass through the channel. You 
will be expected to track more than 10 particles per channel type in order to get 
statistically relevant data.  
9. When you have obtained the bead velocities for each channel, you will use the 
blocking tool to block 1 channel roller clamp). The purpose of  the blockage is to see 
a redirection of flow e.g. redistribution of the flow and a change in velocity. Block the 
channel wait a minute until the network has reached a steady state. 
10. Measure the velocity in each channel as well as note if there is redirection of flow. 
 
7.5.3 Classroom Activity: 
Engage (Time: 15 min) 
Allow students to construct the microfluidic device using the flexible tube and valves 
before they conduct any mixing experiments. Encourage them to discuss and write down 
their observations of differences in the blood flow behavior under certain conditions. 
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Explore (Time: 40 min) 
Exploration and explanation are concurrent in this lab, owing to its many parts. Move 
students through each section of the lab, encouraging them to stop and observe flows of a 
previous designed vascular network of the brain (healthy) before fully construct their 
different model of brain stroke. When doing the annular shear flow experiment, 
encourage students to draw a design of their choosing, and to look at the effect of 
distance from the stalling (occlusion) and the reduction in the blood flow down stream of 
the “stroke area.” 
 
Explain (Time: 25 min) 
At each stage, ask directed questions about their observations (Are the flows the same? 
How are they different?) The students’ observations will immediately help them learn 
many fundamental aspects of fluid mechanics. Guide these observations with additional 
explanations; in particular point out fluid deformation, shear stress, and increasing shear 
near the moving boundary. Also how the different modification in the vascular network 
affect the rate of blood flow. 
 
7.6 EVALUATION OF THE CURRICULUM 
Students were asked to complete a laboratory report on the network flow laboratory. The 
students were to answer a series of questions pertaining to the network they designed and 
to core concepts in flow and how it related to biology. The following questions were 
asked: 
  
 
 
 
198 
 
I. Observation 
a. What does blood bring to cells?  
________________________________________________________________________  
b. Why is proper blood flow critical in the brain?  
________________________________________________________________________  
 
II. State the Question  
(Hint – What are you trying to find out through this experiment?)  
________________________________________________________________________  
 
III. Form a Hypothesis 
a. Based on the question that your group will be investigating, what is the dependent 
variable?  
________________________________________________________________________ 
b. Based on the question that your group will be investigating, what is the independent 
variable?  
________________________________________________________________________ 
c. Write the hypothesis for your investigation - Remember that the formula for writing a 
hypothesis is “If (independent variable) then (dependent variable) because (logical 
explanation)”             
________________________________________________________________________  
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IV. Experiment 
 a. In our experiment, what do the tubes represent? 
________________________________________________________________________ 
b. What do the clamps represent?  
________________________________________________________________________  
c. What does the pump represent? 
________________________________________________________________________ 
d. What do the beads represent? 
________________________________________________________________________  
e. Why are we counting the number of beads that pass through?  
  
IV. Record the Data  
Baseline = No Clot  
Branch Trial 1 Trial 2 Trial 3 Average 
     
 
With Clot  
Branch Trial 1 Trial 2 Trial 3 Average 
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V. Analyze the data 
 a. Calculating percent of Blood Flow 
 % Blood Flow Compared to Baseline = (BF in Branch with Clot / Baseline) x 100 
 
Branch % Blood flow compared to baseline calculations Results 
   
   
   
   
 
b. When you graph, remember you have a TASK ahead of you!   
1. Give the graph a Title                                                2. Number the Axes  
3. Check your Scale to plot points                              4. Key – We will not need one today  
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c. Did the “clots” reduce the blood flow in all parts of the brain? Why or why not? 
________________________________________________________________________  
 
VI. Form a conclusion  
On the lines below, form a paragraph that answers the question you worked to answer in 
this lab. To write your conclusion, answer the following in this order:  
• Restate the question   
• Restate the hypothesis   
• Restate the analysis   
• State whether the data SUPPORT or DO NOT SUPPORT your hypothesis.   
• Describe which sources of error may have affected your data   
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• Explain why you think this lab simulates what happens when a clot forms in the brain 
 
7.7 CURRICULUM ASSESSMENT: 
Students were asked to fill out a series of survey questions to evaluate the activity. The 
statements they were asked to evaluate were: 
1. After conducting this experiment, I feel I understand how science can be applied to 
real-world applications  
2. After conducting this experiment, I feel I understand how different science 
 disciplines, such as physics, can be applied to other fields such as  neuroscience.   
3. I am more excited about science than before.   
4. I enjoy this research experiments more than most labs.   
5. After conducting this experiment, I feel I understand how scientists design  their own 
experiments.   
6. This experiment was more difficult than most labs.   
Students were to evaluate these statements based on a numerical score between 1 and 
5, with 5 being that the student agreed strongly with the statement and 1 being that 
the student disagreed strongly with the statement.  
 
7.8 CONCLUSIONS  
This curriculum was designed to be very dynamic and cooperative, and as a consequence 
the students really appreciated it.  We introduce the concept of using engineering and 
physics approaches to solve biological problems in a research setting. Students were 
provided with guidance from the teacher and graduate student in their laboratories and 
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were encouraged to use inquiry-based learning and rational thinking to solve the 
biological problems presented in the labs.  
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PART II: FLUORESCENCE IN LEAF VEINS: AN INQUIRY MODULE 
 
7.9 ABSTRACT 
This hour-long activity introduces students to the concept of liquid flow through leaf 
veins, and explores what occurs when the leaf is damaged. This module is designed to 
allow students to openly explore the concept of network redundancy using inquiry 
methods similar to real research labs. Students damage the veins in tree leaves, make 
prediction about how this will affect transport, and then soak the stems in fluorescent dye. 
While the leaves are taking up dye, they explore the concept of fluorescence using lights 
and colored glass filters. They then use the lights and filters to view the pathway the dye 
traveled in the leaf, and thus to test their hypotheses on how leaf damage affects liquid 
flow. Students discover that small veins in the leaf allow the dye to travel around the 
points of damage, enabling un-interrupted flow. This concept of redundancy is critical in 
a variety of networks, ranging from biological networks like blood vessels to man-made 
networks like the electrical power grid.  
 
7.10 INTRODUCTION 
Blood travels through vessels in the body and provides oxygen and nutrients to 
surrounding cells. If blood flow is disrupted, catastrophic damage can occur. There is 
substantial redundancy in these blood flow networks in many organs, especially in the 
brain, resulting in alternate routes for blood to reach the tissue if one route is blocked or 
damaged. This module describes an ~1 hour long, inquiry-based learning activity where 
students discover the concept of redundancy by following the flow of fluorescent dye 
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through small vein networks in leaves. Students damage the vein networks in some 
leaves, make predictions about how this will impact transport, and then compare the 
transport of fluorescent dye through veins in damaged and undamaged leaves.  While dye 
is being taken up by the leaves, students compare how similarly-colored fluorescent and 
non-fluorescent solutions interact with light. Through this, they discover the concept of 
fluorescence and then immediately appreciate why a fluorescent dye is being used as a 
tracer in the leaf vein networks. Students are then able to test their ideas about how vein 
damage will influence transport in the leaf and they find that redundancy in the leaf vein 
network ensures liquid from the stem can route around damaged pathways and reach the 
entire leaf. Emphasis is placed on student-lead inquiry, so students do not have a set 
series of steps to follow to reach a “correct” answer and rather are encouraged to explore 
with no written materials and only minimal verbal guidance. This module introduces 
inquiry-based learning to students in a short, manageable timeframe, allowing them to 
explore using the open-ended approach to scientific questions that is used in actual 
research labs. 
  
7.11 ENGAGE 
Begin with a brief introduction to leaf veins and the role they play in transporting liquid 
and nutrients to all cells of the leaf. Students should have freshly-collected leaves they 
can examine. Leaves with highly interconnected vein networks are necessary to illustrate 
the concept of network redundancy providing resilience to damage (we have found oak 
leaves work well). Because the concept of “networks” may be hard to grasp, relate the 
leaf vasculature to a set of water pipes. If water is flowing through pipes, and there’s a 
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hole in a pipe, where does the water go? Ask students to predict what happens if an insect 
takes a bite out of a leaf and damages a vein. Does the whole leaf die? What happens to 
liquid transport? Tell the students that they can test their ideas by damaging leaves with a 
hole punch and using a colored dye to track liquid flow.  
 
7.12 EXPLORE 
Have students form small groups and task them with damaging the leaves using a hole 
punch or other tools (Figure 7.4A). Encourage them to keep some leaves intact so they 
can compare damaged leaves with normal ones. Make sure to provide enough leaves so 
students are willing to explore their own hypotheses, like ripping part of the leaf, scoring 
it, or other creative approaches. To keep track of expected results, have students trace the 
leaves they damaged as well as control leaves onto a sheet of paper and sketch out the 
pattern of large veins, marking where they made holes or otherwise damaged the leaf. 
Students should then trim the end of the leaf stem at an angle using a pair of scissors so 
that liquid easily absorbs into the stem and insert the stems of all leaves (including 
control leaves) into the 30 mL tube of Rhodamine B dye and allow them to soak (Figure 
7.4B). Warn students that the dye can stain clothing and skin, to be careful inserting the 
leaves, and to wear gloves (lab coats and goggles are also recommended). While the 
leaves soak, ask students to predict where the dye will flow by tracing on their sketches 
of the leaf vein networks from damaged and undamaged leaves (Figure 7.4C, 7.4D, 
7.4E). Ask the student groups to generalize this prediction by writing down, in their own 
words, a hypothesis on how leaf vein disruption affects liquid flow.  
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While the students are conducting these tasks, the instructor should prepare extra 
damaged and control leaves to soak in the fluorescent solution and should also soak some 
control leaves in the non-fluorescent colored water to use as an example during the 
Extend and Elaborate phase. 
 
While the leaves are soaking point out the two vials of dye; one holding Rhodamine B 
(fluorescent) and one holding colored water (non-fluorescent, should be mixed to roughly 
match the color of the Rhodamine B), unbeknownst to the students. The fluorescence is 
best seen in a dark room, so turn out the lights and close any shutters. Ask students to 
“tell you” what is different between the two dyes, and to work in groups to discover the 
differences. Inform them that they can use all the supplies on the table to explore the dyes 
and gather clues. When the green colored light source lights up the fluorescent dye, it will 
glow orange. Looking at the fluorescence through a red colored glass filter helps separate 
this “glow” from the color of the dye itself and the color of the light (Figure 7.5). Do not 
point out to the students that they need to use the light source and filters to view 
fluorescence, but rather, let them figure it out for themselves. If students feel frustrated, 
ask them about their approach and encourage them to use some of the supplies on the 
table. If one student in the group discovers the fluorescent “glow” first, encourage them 
to describe what they found to the rest of their group. 
 
7.13 EXPLAIN 
As each group begins to piece out the difference between the fluorescent and non-
fluorescent solutions and identify one as “glowing,” engage them in a discussion of what 
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they are observing. If the term “fluorescence” doesn’t come up, define the “glow” as 
fluorescence and explain that some molecules have this property. Ask students why they 
had to use the colored light and colored glass filter to see this effect. Piece together an 
explanation based on student words and terms. Explain that fluorophores (fluorescent 
molecules) absorb energy from a light source of one color and then release that energy as 
light of another color. The color of light emitted by the dye is redder or longer 
wavelength than the color of light absorbed by it. For example, in this experiment the 
fluorescent dye Rhodamine-B is excited with green light and emits orange light. In 
contrast, the colored water only absorbs the green light and does not glow or emit orange 
light. The instructor can then shine a green laser pointer through these fluorescent and 
non-fluorescent solutions to further illustrate the difference. After a student group has 
mastered this general concept of fluorescence, ask them “Why do you think your leaves 
are soaking in the fluorescent dye?” Students will typically immediately appreciate that 
they can use the colored light and colored glass filter to see where the dye has gone and 
thus test their original hypotheses about transport in the leaf vein networks. 
 
7.14 EXTEND AND ELABORATE 
After the exploration of fluorescence, the students will extend this concept and use it as a 
tool to explore liquid transport in their damaged and control leaves (Figure 7.6). Ask the 
students to test their hypothesis of how leaf damage changes liquid transport. Once 
students realize that the dye goes “around” the holes they made in the leaf veins, ask 
them to figure out how the dye got there. They will quickly realize that there are tiny 
veins all throughout the leaf that liquid travels through, bypassing the damage to the 
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larger veins. While students are exploring their hypotheses, circulate around the room and 
ask questions to guide their thinking. Ask them about their approach, or why they are 
making their conclusions. Avoid giving answers or encouraging a “right” answer. Rather, 
guide them through the exploratory process. If students are wondering why they cannot 
simply use a colored dye to see where the liquid travels, show them the leaf that was 
soaked in colored water to demonstrate that colored water alone is not sufficiently visible 
within the leaf network to discern transport pathways. Light must be generated through 
fluorescence and “detected” by their eye with the aid of a filter. Occasionally, dye will 
not be taken up into a leaf. Allow groups to share control and damaged leaves with other 
groups if necessary, or provide your own experimental and control leaves for substitution. 
 
End the activity by asking the groups if anyone guessed the flow of dye correctly. If so, 
have them explain to the class why they made their initial prediction. Typically, most 
groups hypothesize that dye will stop at points of damage and not progress to 
downstream veins. Ask students to explain why they thought that, and why that differs 
from what actually happened. Because the leaf vasculature is a complex network 
composed of large veins and many interconnected small veins, liquid can travel through 
many routes to reach the same point. The dye travels around the damaged areas using 
smaller vein networks and continues to travel through the rest of the network. These 
smaller networks are actually visible with the fluorescent dye (Figure 7.6A), and are also 
visible to the naked eye when examined closely enough, depending on the leaf. Most 
seeding plants such as oak trees exhibit redundant vascular networks (reticulated 
venation) with a number of small interconnections between main veins (anastomosis). 
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Non-redundant leaves, such as ginkgo biloba, have a fan shape with veins extending 
radially from the leaf base, and do not exhibit vein interconnections (dichotomous 
venation) [1].  
 
End the activity by asking students about other networks like this. Some possible ideas 
are blood vessels, electrical power networks, roads, etc. Conclude with a short 
presentation describing how these networks are “redundant”. Redundancy is a key 
concept in many fields, ranging from biology to technology. In a complex network, 
repetition of certain components ensures that the whole system does not fail if one part 
fails. For example, if the power grid that supplies energy to every building does not 
contain redundancies, one fallen power line could result in widespread power outages 
(see the Wall Street Journal’s, The Short Answer: How Does The U.S. Power Grid Work 
video from February 5th, 2014 for an introduction to this concept).  
 
In biology, and specifically in this module, we examined redundancy in the circulatory 
system of leaves. If a portion of a leaf is damaged by weather or an insect, the rest of the 
leaf and the entire plant can bypass this damage and provide nutrients to cells in 
undamaged portions. The same is true in an animal or human circulatory system. If a 
small clot occurs in a tissue where the vasculature is redundant, blood can bypass the area 
and reach surrounding tissue.  
 
As an analogy, the brain and the heart are the two organs in the human body with the 
highest energy (and thus blood) demands and their continued function is essential. If the 
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vascular network in these organs is disrupted, cells may become permanently damaged 
because they no longer have the oxygen and energy they require. Tor this reason, these 
organs have evolved a high degree of anastomosis (interconnections between different 
parts of the network) to reroute blood flow in the event of vascular damage. On the other 
hand, the digestive system does not exhibit significant anastomosis, as energy demands of 
the organ can be reduced by the brain to accommodate for damage and the resulting 
decrease in blood flow. 
 
For example, if small vessels are damaged (like in a bruise), the tissue after that injury is 
not affected. However, areas of the body that are very sensitive to blood flow changes 
might be affected if blood vessel damage occurs there. One of the organs most sensitive 
to changes in blood flow is the brain. The cells of the brain, neurons, store very little 
energy and are highly dependent on blood flow for their nutrients. It is easy to see that 
blocking a blood vessel to the brain or in the brain could be disastrous. Redundancy in 
networks minimizes this effect, but even small disruptions in blood flow lead to damage 
in the brain. That is why strokes and hemorrhages can be so disastrous for patients. 
 
7.15 EVALUATE 
This activity serves as an excellent way to introduce inquiry, open-ended learning, to a 
class without the emphasis on a “right-answer” or correct protocol. However, evaluation 
for student participation and engagement can be included if needed (see Online 
Supplemental Materials). A generalized rubric emphasizing the content, process, and 
attitude of the students during this module may serve as a baseline. 
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7.16 CONCLUSIONS 
This experiment incorporates inquiry learning, or learning through discovery, in a short, 
manageable time frame. It allows students to experience how science really takes place in 
research labs by generating hypotheses and using observations to test and form new 
hypotheses. This activity also connects multiple fields of study: plant biology, anatomy 
and physiology, and fluorescent imaging, mimicking the highly interdisciplinary 
approach to modern day science. 
 
7.17 SAFETY CONCERNS 
All materials for this experiment are relatively safe. The Rhodamine-B dye is not toxic, 
but should not be ingested. All dyes can stain clothing, so warn students not to spill. 
Warn students to be careful with the glass filters and immediately clean up the glass 
shards if a filter is dropped. 
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7.18 RESULTS 
 
 
Figure 7.4. Leaf damage and dye flow predictions. (A) left: leaf without injury; center: 
leaf with an injury in a main vein; right: leaf with multiple injuries. (B) Leaves soaking in 
Rhodamine B solution. (C) Example prediction of dye flow in the control leaf (without 
injury). (D) Typical student prediction of flow distribution in a leaf with an injury in a 
main vein. (E) Typical student prediction of flow distribution in a leaf with multiple 
injuries. 
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Figure 7.5. Fluorescent versus non-fluorescent dyes. (A) Rhodamine B sample on top 
of the green light source. (B) Orange emission from  Rhodamine B solution viewed 
through the orange glass filter. (C) Red food coloring sample on top of the green light 
source. (D) Lack of emission from red food coloring sample viewed through the orange 
glass filter. 
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Figure 7.6.  Visualization of Rhodamine B dye transport in the vein network of oak 
leaves. (A) Close-up view of the small veins near a hole in a main vein of a leaf. 
Distribution of Rhodamine B in a (B) control leaf, (C) leaf with an injury on the main 
vein, and (D) leaf with multiple injuries in various locations in the leaf. 
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7.19 ONLINE SUPPLEMENTAL MATERIAL 
7.19.1 Suppliers and cost information  
Dyes 
● 25g of Rhodamine B (Cat# R6626-25G, Sigma-Aldrich) will cost approximately 
$20 and should last for more than five years in the freezer (the product is light 
sensitive). 
● Food coloring (Cat# 5465 Red-Red; Amazon) will cost approximately $10 and 
can be kept on the shelf for many years. 
 
Accessories 
● 50 mL tubes (Cat# C001-50pk, Scientific Equipment of Houston) will cost $7 for 
a rack of 25 tubes. 
● 30 mL tubes (Cat# 05-556-3, Fisher Scientific) will cost $56 for a bulk of 1000 
tubes, but smaller bulk size could be obtained via Amazon. 
● 1.5  mL tubes (Cat# L293251, Laboratory product sales) will cost $36 for a bag of 
1000 tubes. 
 
LED Light Box Components and Supplies 
● Green LED (Cat#: RL5-G13008, Super Bright LEDs Inc.) will cost $0.74 each. 
● Green LED Filters (Cat#: FES0550, Thorlabs) will cost $74.50 each. 
● Switch (Cat#: 360-1896-ND, DigiKey) will cost approximately $5 each. 
● 9V battery snap connector (Cat#: 36-232-ND, DigiKey) will cost $0.60 each. 
● Enclosure “boxes” (Cat#: L101-ND, DigiKey) will cost approximately $6 each  
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● Grommet (Cat#: 4946A1, McMaster-Carr) will cost approximately $6 for a pack 
of 25 grommets. 0.5 inch hole in the enclosure, this holds the LED in place. 
● 220 Ω resistors, 1 per light box (Cat#: 2711313, local Radio Shack) will cost 
$0.74 for a pack of 5. 
● 9 V batteries, 1 per light box (Cat #: 2302211, local Radio Shack) will cost $7.69 
for a pack of 2. 
● Soldering iron, solder (Cat#: USAE1-VTDS010AH, Amazon) will cost $15.99 
● 590nm long-pass color filter, Orange (Cat#: FGL590S, Thorlabs) will cost $71.50 
each. 
 
7.19.2 Materials per student group (max 5 students/group) 
● 1 conical tube (30 mL) containing 25 mL Rhodamine-B dye (2%) 
● 2 1.5-mL centrifuge tubes 
○ One containing water with red food coloring 
○ One containing Rhodamine-B dye 
● 1 pair of scissors 
● 1 hole punch 
● Sheets of white paper 
● Black and red markers 
● 10 Oak leaves  
● Orange glass filter  
● LED light source box 
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7.19.3 Procedure: 
1. Distribute all items listed above to each workstation. 
2. Provide background on leaf networks. 
3. Disrupt the vascular network of the leaves using the hole punch. Keep at least one 
leaf without holes as a control. 
4. Use scissors to cut the leaf stem at an angle, keep at least two inches of the stem 
intact. 
5. Place the leaf stems into the falcon tube with Rhodamine-B. 
6. Let the leaves soak in the dye for at least 30 minutes. 
7. While leaves are soaking, trace the outline of the leaves and their main veins onto 
sheets of paper. Sketch where holes were made. 
8. Predict what will happen to the dye flowing through the leaf vessels, based on 
where the holes were made for each leaf, and mark this on the leaf drawings. 
9. Write down hypothesis. 
10. Explore the concept of fluorescence using food color and the Rhodamine-B dye 
vials. 
11. Use the green light source and orange filter to see dye in the leaf veins for both 
the damaged and control leaves. 
12. Compare the flow distribution from the leaves with injuries vs the control leaf, 
and compare with the hypotheses made beforehand. 
13. Have students describe why the dye went around the holes. 
14. Relate findings to the concept of redundancy and other redundant networks. 
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7.19.4 Materials and teacher preparation 
An inventory of materials used for experiments are shown in Figure 7.7. For first time 
preparation, prepare the dye dilutions. It is recommended that a large stock solution be 
prepared and small amounts (aliquots) be removed from the stock for student activity use. 
For the Rhodamine B, dissolve 1 mg in 50 mL of water. Aliquot approximately 1.25 mL 
into the small centrifuge tubes and seal tightly. For a non-fluorescent control, dilute red 
and yellow food coloring into 50 mL of water until it’s approximately the same color as 
the Rhodamine B. Aliquot approximately 1.25 mL into small centrifuge tubes and seal 
tightly. Keep the Rhodamine B aliquots in a dark location for long term storage, as it is 
light sensitive. 
 
LED sources may be bought or built according to the schematic in Figure 7.8. To build 
the light sources, solder one end of the resistor to the positive end of the 9V battery clip 
(the red wire). Solder the other end of the resistor to the positive side of the LED (the 
longer wire lead). Solder the short wire lead of the LED to one of the switch contacts, and 
the other switch contact to the negative end of the 9V battery clip (the black wire). Drill 
two holes in the aluminum enclosure: one 0.5” hole to fit the grommet and LED through 
and another for the switch. Attach the 9V battery, test the circuit, and seal the aluminum 
box to prevent tampering. Tape the mounted green filter over the LED, limiting the 
amount of yellow light the LED emits so the students can clearly visualize the 
Rhodamine B fluorescence. 
 
Before each time the activity is implemented, pick approximately ten oak leaves per 
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student group. Other leaf types are suitable, but test dye absorption before implementing 
the activity. Try to pick leaves that have minimal damage and have a healthy, dark green 
color distribution. Ensure the stems are at least two inches long. Leaves can be picked the 
day before and their stems submerged in water to keep them alive. Set up all supplies on 
separate tables, one set per team. Try and maintain group sizes between three and five 
students. 
 
 
 
 
Figure 7.7. Layout of the material used for labeled the capillary network on oak 
leaves. (A) A set of ~6 oak leaves. (B) Hole punch. (C) 30 mL tubes with 25 mL of 2% 
Rhodamine B.  (D) 590 nm long-pass filter (E) 2 (1.5 mL) tubes with Rhodamine B and 
food coloring, respectively. (F) Green colored light source. 
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Figure 7.8. Layout of the LED circuit and construction. (A) Circuit diagram of the 
LED light source. (B) Assembly and connections between the LED and resistor. (C) Full 
enclosure and components of the LED power supply (D) LED power supply. 
The following rubric can be used to assess students during each part of the activity. The 
term “expectations” here refers to the content, process and attitudinal goals for this 
activity. Evidence for understanding may be in the form of oral as well as written 
communication, both with the teacher as well as observed communication with other 
students. Specifics are listed in the table below. 
 
1= exceeds expectations 
2= meets expectations consistently  
3= meets expectations occasionally  
4= not meeting expectations      
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  Engage Explore Explain Expand 
1 Student 
demonstrates 
interest in the 
assignment and 
helps other group 
members to craft 
theories as to the 
aspects of imaging 
they will observe. 
  
Student 
demonstrates 
interest in the 
experimentation, 
taking careful notes 
on the laboratory 
worksheet and 
completing the 
related 
calculations. 
Student was 
engaged with 
partners in 
conducting the 
measurements. 
  
Student helps 
describe 
different 
effects in the 
optics module 
that were 
witnessed and 
proposes 
hypotheses on 
why various 
effects 
occurred. 
Student is actively 
involved in 
summarizing the 
observations from the 
project. Student will 
ask questions about 
what they saw. 
Student will propose 
applications where 
various imaging 
systems can be used. 
2 Student 
participates in 
filling out the 
objectives of the 
laboratory and 
making 
assumptions to the 
imaging they will 
observe. 
Student shows 
interest in the 
laboratory, writes 
down findings on 
the laboratory 
worksheet, and 
conducts the 
experiments and 
calculations with 
partners. 
  
Student 
participates in 
discussion of 
the effects that 
were 
witnessed. 
  
Student participates in 
summarizing the 
project observations. 
Student discusses the 
imaging systems and 
their applications. 
3 Student 
participates in the 
group discussion 
Student 
demonstrates little 
interest in the 
Student 
participates in 
discussion with 
Student participates in 
the class discussion 
with little to no 
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with little interest. 
Little effort is put 
into the answers 
for the objectives 
of the assignment. 
experimentation. 
Measurements and 
calculations may be 
written down but 
without care. 
Student will assist 
partners but with 
little interest. 
  
little to no 
interest. 
  
interest. Answers from 
the student are simple 
direction observations 
with no thought 
behind them. 
  
4 Student does not 
participate in the 
group discussion, 
and little to no 
effort is put into 
filling out the 
laboratory 
objectives. 
Student shows no 
interest in the 
laboratory. Student 
fills in little to no 
information on the 
laboratory 
worksheet and does 
not assist with the 
experiments. 
  
  
Student does 
not participate 
in the 
discussion. 
Student does not 
participate in the class 
discussion. 
  
 
   
 
References 
1. Katifori, E., Szöllősi,  G. J., and Magnasco, M. O. Damage and Fluctuations Induce 
Loops in Optimal Transport Networks. Phys. Rev. Lett. 104. 2010. 
 
  
 
 
 
224 
CHAPTER 8 
CONCLUSION AND FUTURE DIRECTIONS 
 
8.1 Conclusion 
The circulatory system and the neurovascular unit are crucial component for the function 
and homeostasis of the brain. While many neurodegenerative diseases have several 
"remarkable" pathological aspects such as amyloid plaques found in AD and 
proteinaceous inclusion “Lewy bodies” in the neurons of Parkinson and dementia 
patients, recent evidence suggests that these neurodegenerative disorders may all share a 
common pathology, namely vascular dysfunction. Obstructed microcirculation due to a 
loss or alteration of vascular cells, molecular changes within the vascular cells of the 
neurovascular unit, and/or environmental and genetic factors that may predispose 
individuals to cerebral vascular abnormalities may be subjacent causes of many 
neurological disorders.  
 
Classically a "neuro-centric" view has suggested that the cause of AD must be something 
erratic with the neuronal network of the brain. However, this view fails to consider that 
the other essential cells of the neurovascular unit and the circulatory system are also 
involved during pathogenesis or maybe in the initiation of AD and other 
neurodegenerative diseases. Here we provide some of the first evidence that alteration of 
the circulatory system and the cerebral vasculature can indeed contribute to the symptoms 
of neurodegenerative diseases. Additionally, we have shown that cellular changes 
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specifically within brain vascular cells (leukocytes) may potentiate and/or initiate 
processes that exacerbate the progression of AD.  
 
We demonstrated that cellular changes in the circulatory system and in the brain vascular 
network preceded the classical hallmarks of AD. This new mechanism maybe able to 
explain the hypoperfusion seen patients with AD and could bring new insight for new 
targets to ameliorate the progression of the disease.  
 
I hope that the increasing number of studies focusing on neurovascular dysfunction will 
bridge the fields of neuroscience and vascular biology to further identify the specific 
roles of the cerebral vasculature components in maintaining a healthy central nervous 
system. Furthermore, research aiming to identify novel mechanisms to restore 
neurovascular dysfunction may have profound implications in the way patients get 
treated in the future for so many devastating neurodegenerative diseases, such as 
Alzheimer's.  
 
8.2 Future directions  
Although the findings reported here provide strong evidence for the functional 
significance of stalled neutrophils on brain hypoperfusion in AD, a number of important 
questions still remain open. Treatments with α-Ly6G significantly reduce the numbers of 
neutrophils stalls and improve cortical blood flow and cognitive performance (short-term 
and spatial memory) in APP/PS1 mice. However, similar improvements were not 
observed in tests for motor coordination or depression-like behavior other important 
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symptoms of patients with AD. As previously discussed the absence of a change in 
performance of these tests is likely the result of the short treatment period or suboptimal 
dosing in this study. Additional studies using different doses as well as a longer treatment 
period will be needed to assess the optimal dose needed to improve both rapid and 
constant effect during the desire time frame. 
 
Based on the nature and mechanism of action of α-Ly6G (mouse only and depletion), it 
will be necessary to screen for new drugs (antibodies and/or small molecules) that 
interfere with neutrophil activation and/or adhesion to the endothelium without causing 
their depletion. Additional studies are necessary to fully characterize the biochemical 
pathways that trigger these cascade events. Directly blocking leukocyte adhesion in 
patients would likely lead to a number of unacceptable side effects, so our work to 
identify potential upstream pathways that cause the vascular inflammation that likely 
modulates these stalling will help to identify more viable therapeutic targets that could 
move forward to pre-clinical studies and trials in the future. One of the putative 
candidates is the Nox2 containing NADPH oxidase pathway responsible for the 
production of vascular reactive oxygen species (ROS). One of several Nox isoforms, 
Nox2 is found in neurons, neutrophils, and, interestingly, in brain endothelial cells, and is 
a major source of ROS in the brain endothelium. In transgenic AD mice, Nox2 knockout 
rescued Aβ associated dysfunction in neurovascular coupling [1]. In human AD patients, 
Nox2 is activated in brain vessels relative to healthy subjects [2]. There is also evidence 
that statins reduce AD risk, perhaps by a pleiotropic inhibition of Nox2 [3]. Tacking these 
findings in consideration we can assume that the inflammation triggered by the ROS, 
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might increase the binding receptors in the endothelium making this capillary segments 
more susceptible to stalling formation.  Once the entire biochemical cascade has been 
elucidated and new drugs identified, additional studies will focus on changes in amyloid 
deposition or other effects on disease progression when these stalls are eliminated over 
time. 
 
Finally, these findings reported here have potentially broader implications for other 
disorders and diseases that involve vascular dysfunction independent of the underlying 
mechanism of dysfunction. Preliminary experiments in our lab have shown that mouse 
models of Alzheimer’s disease also have an increased level of stalls indicating that this 
could be a common feature shared between neurodegenerative diseases. These findings 
may provide an analog for similar conditions in humans such as Alzheimer’s, vascular 
dementia, Parkinson’s among others.  
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